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Chapter 1 
1.1 Epidermal Growth Factor Receptor 
A. EGFR discovery and identification of EGFR family of proteins 
Discovery/Structure of EGFR 
 The epidermal growth factor receptor (EGFR) was discovered as a result of the finding 
that epidermal growth factor (EGF), a potent mitogen, showed specific, rapid, and reversible 
binding to the cell surface (Hollenberg and Cuatrecasas, 1973; O'Keefe et al., 1974; 
Carpenter et al., 1978; Das et al., 1978; Linsley et al., 1979).  Sequence and structural 
analysis showed that EGFR contains three primary domains: a 621 amino acid extracellular 
EGF binding domain, a 23 amino acid transmembrane domain, and a 542 amino acid 
cytoplasmic domain (Fig. 1.1).  The ligand binding domain of EGFR was further subdivided 
into four sub-domains, domains I, II, III and IV.  Domains I and III were shown to be directly 
involved in ligand binding to the receptor (Lax et al., 1989), while domain II was necessary 
for receptor dimerization, and domain IV was required for localization to membrane 
microdomains (Heldin, 1995; Garrett et al., 2002; Ogiso et al., 2002; Yamabhai and 
Anderson, 2002).  The transmembrane domain, along with an N-terminal signal sequence, 
were responsible for directing EGFR to the plasma membrane where it becomes a type I 
integral membrane protein (Ullrich and Schlessinger, 1990).  The cytoplasmic domain of 
EGFR has been demonstrated to contain a tyrosine kinase domain and c-terminal regulatory 
region that is autophosphorylated upon kinase activation (Buhrow et al., 1982; Cohen et al., 
1982a; Cohen et al., 1982b; Buhrow et al., 1983).  Specifically, EGFR autophosphorylation 
occurs on tyrosines 992, 1068, 1086, 1148, and 1173 (Downward et al., 1984a). 
Figure 1.1: EGFR structure, dimerization, and activation.  Before activation, EGFR exists as 
an inactive dimer in the membrane.  Upon ligand binding, a conformational change occurs in 
both the extracellular and intracellular domains leading to autophosphorylation of the receptor 
complex.
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  Phosphorylation of these residues results in the recruitment and activation of downstream 
signaling molecules that participate in cell growth, survival, migration, differentiation, and 
angiogenesis [reviewed in (Jorissen et al., 2003)]. 
EGFR tyrosine kinase family members  
Further analyses of the structural and functional qualities of EGFR revealed a common 
protein family.  The EGFR tyrosine kinase family consists of four members that include 
EGFR, HER2, HER3, and HER4. 
HER2 
 Coussens and colleagues discovered a receptor tyrosine kinase with high homology to 
EGFR, human EGFR-related 2 (HER2), while other laboratories identified the same protein 
in human mammary carcinoma cells, naming it ErbB2 (Coussens et al., 1985; King et al., 
1985).  HER2 is the most homologous to EGFR in the family, and is thought to be the major 
partner for heterodimerization (Tzahar et al., 1996; Graus-Porta et al., 1997).  HER2 contains 
82% structural homology with EGFR in the kinase domain, 33% in the c-terminus, and 44% 
in the extracellular domain (Earp et al., 1995).  HER2 has no known ligand, thus is thought to 
be activated following heterodimerization, however, when HER2 is over-expressed, it may 
form active homodimers (Tzahar et al., 1996). 
HER3   
HER3 was discovered through cDNA homology screenings of EGFR in 1989 (Kraus et 
al., 1989).  HER3 possesses a 59% structural similarity to EGFR within the kinase domain, 
24% in the c-terminus and 36% in the extracellular domain (Earp et al., 1995).  This receptor 
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lacks intracellular kinase activity, and therefore, becomes phosphorylated only when 
heterodimerized (Guy et al., 1994b; Kim et al., 1998).  Neuregulins, rather than the EGFR 
ligands described later, are the ligands for HER3 (Stove and Bracke, 2004).   
HER4  
The final EGFR family member, HER4 was also discovered through cDNA homology 
screening of EGFR (Plowman et al., 1993a).  HER4 presents a 79% structural similarity to 
EGFR in the kinase domain, 28% in the c-terminus, and 48% in the ligand-binding domain 
(Earp et al., 1995).  As with HER3, neuregulins are the primary ligands for HER4 (Stove and 
Bracke, 2004).  
B. Activation of EGFR 
i. EGFR Ligands 
EGFR has six known ligands that all posses an EGF-like domain that may be sufficient to 
confer binding specificity (Beerli and Hynes, 1996).  Ligands for EGFR include EGF, 
amphiregulin, transforming growth factor alpha, betacellulin, heparin-binding EGF-like 
growth factor, and epiregulin (Marquardt et al., 1984; Shoyab et al., 1989; Higashiyama et 
al., 1991; Shing et al., 1993; Toyoda et al., 1995).  These proteins differ in sequence identity 
(with ~25% homology between each other), as well as glycosylation, presence of heparin-
binding domains, and other biochemical properties (Harris et al., 2003).  Primarily, these 
proteins all have cysteine rich EGF modules.  The restrictive spacing of these residues and 
the splicing and functional placement of this module distinguishes these ligands from other 
EGF module-containing proteins (Groenen et al., 1994; Van Zoelen et al., 2000; van der 
Woning et al., 2006).  Despite diversity in primary sequences, the tertiary structures of EGFR 
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ligands are all similar.  Specifically, orientation of two beta sheet domains, a short omega 
loop, and a leucine at the fifth position past the sixth cysteine have been shown to be similar 
or identical in all EGFR binding ligands (Harvey et al., 1991; Matsunami et al., 1991; 
Hommel et al., 1992; Barbacci et al., 1995; Chau et al., 1996; Jacobsen et al., 1996; Louie et 
al., 1997; van de Poll et al., 1997; Ballinger et al., 1998).   
Ligand binding to the receptor results in an amplification of EGFR activation such that 
occupancy of 20% of receptors by ligand results in maximal cellular proliferation 
(Hollenberg and Cuatrecasas, 1973).  However, this amplification may be contingent on the 
differential binding affinities of the ligands for EGFR, as well as their ability to recycle the 
receptor or target the receptor for degradation due to the pH stability of the ligand-receptor 
complex (French et al., 1995; Olayioye et al., 2000).  Most EGFR ligands act in an autocrine 
or paracrine fashion (Olayioye et al., 2000).  Activation of EGFR ligands requires proteases 
which release the ligand from the cell surface and remove the regulatory domains (Lee et al., 
1985; Massague and Pandiella, 1993; Harris et al., 2003).  These ligands are summarized 
below and in Table 1.1. 
EGF 
Epidermal growth factor (EGF) was discovered as a peptide growth factor purified from 
mouse salivary glands by Cohen and colleagues.  EGF treatment in newborn mice led to 
early tooth eruption and eyelid opening (Cohen, 1962).  EGF is produced in a precursor form 
that needs to be proteolytically cleaved to be functional.  The active form of EGF is a 53 
amino acid peptide that binds specifically to EGFR (Salomon et al., 1995). 
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Ligand 
Size 
(processed 
amino 
acids) 
Homology 
to EGF 
(%) 
EGFR 
receptor 
affinity 
(nM) 
Other 
EGFR 
family 
member 
binding 
Overexpression Knockout References 
EGF 53 _ 1.9 - Hyperproliferation 
of skin cells No phenotype 
Salomon et al.,1995, 
Jones et al., 1999 
AREG 78-84 38 90 - Inflammatory skin lesions 
Decreased 
ductal 
development 
in the 
mammary 
gland 
Shoyab et al., 1989, 
Brown et al., 1998, 
Adam et al., 1995, 
Thompson et al., 1996, 
Neelam et al., 1998, 
Jones et al., 1999  
TGFalpha 50 30-40 9.2 - 
Hyperproliferation 
of liver, metaplasia 
of pancreas, breast 
carcinoma 
No phenotype 
Salomon et al., 1995, 
Salomon et al., 1990, 
Massague and 
Pandiella, 1993, Jones 
et al., 1999 
BTC 80 32 1.4 HER4 
Growth retardation 
and 
pulmonary/cardiac 
distress 
No phenotype 
Sasada et al., 1993, 
Shing et al., 1993, Jones 
et al., 1999 
HB-EGF 75 43 7.1 HER4 Hyperplasia of skin 
and heart 
Lethal; 
cardiac 
abnormalities 
Higashiyama et al., 
1991, Schneider and 
Wolf, 2009, Jones et al., 
1999 
Epiregulin 46 37 2800 HER4 
Susceptibility to 
cancer causing 
intestinal damage 
No phenotype 
Toyoda et al., 1995, 
Shelly et al., 1998, 
Komurasaki et al., 2002, 
Jones et al., 1999 
 
Table 1.1: Structure, affinity, and function properties of EGFR ligands.  
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AREG 
Amphiregulin (AREG) was discovered as an EGFR ligand produced by MCF-7 breast 
adenocarcinoma cells.  It was named “amphi” due to an apparent, but yet to be validated, 
growth inhibitory effect in human neuroblastoma and adenocarcinoma cell lines, and a 
growth stimulatory effect in human fibroblast, cervical, ovarian, and other breast carcinoma 
cell lines (Shoyab et al., 1988).  AREG is also synthesized as a precursor protein that is 
cleaved from the membrane, to produce a 78-84 amino acid peptide that shares 38% 
homology with EGF (Shoyab et al., 1989; Brown et al., 1998a).  Like EGF, AREG binds 
specifically to EGFR.  The binding affinity for AREG to EGFR is less than EGF due 
potentially to a methionine substitution in a conserved region of the ligand (See Table 1.1) 
(Adam et al., 1995; Thompson et al., 1996; Neelam et al., 1998; Jones et al., 1999). 
TGFα 
Transforming growth factor alpha (TGFα) was discovered as a low molecular weight 
polypeptide able to induce transformation of normal rat kidney fibroblasts (de Larco and 
Todaro, 1978).  TGFα is a 50 amino acid peptide when fully processed with 30-40% 
sequence homology to EGF (Salomon et al., 1995).  This ligand binds specifically and with 
high affinity to EGFR (Table 1.1) (Salomon et al., 1990; Massague and Pandiella, 1993).  It 
is expressed during normal embryogenesis and in a number of adult tissues including 
regenerating populations of epithelial cells (Kudlow and Bjorge, 1990; Yasui et al., 1992).   
Betacellulin 
Betacellulin (BTC) was identified from conditioned media of pancreatic beta cell tumor 
lines, and binds to both EGFR and HER4 with high affinity (Table 1.1) (Sasada et al., 1993; 
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Jones et al., 1999).   BTC is an 80 amino acid peptide that shares 32% homology with EGF 
(Sasada et al., 1993; Shing et al., 1993).  BTC is also expressed in many mesenchymal and 
epithelial cell lines, particularly in the pancreas, liver, kidney, and small intestine, as well as 
the heart, lung, colon, testis, and ovary (Sasada et al., 1993; Seno et al., 1996; Dunbar et al., 
1999; Dunbar and Goddard, 2000). 
HB-EGF 
Heparin-binding epidermal growth factor (HB-EGF) was purified originally from 
conditioned medium of a human lymphoma cell line (Higashiyama et al., 1991).  HB-EGF is 
a 75 amino acid peptide that shares 43% homology with EGF.  HB-EGF binds to EGFR with 
high affinity (Table 1.1), and is also capable of binding HER4 and, potentially, N-arginine 
dibasic convertase (Higashiyama et al., 1991; Schneider and Wolf, 2009).  HB-EGF is highly 
controlled, both in timing and distribution, as it is induced within the uterine luminal 
epithelium at the site of blastocyst apposition approximately six hours before uterine 
implantation (Paria et al., 1999).  HB-EGF is the only EGFR ligand whose loss results in 
lethality due to defects in cardiac and lung function [reviewed in (Schneider and Wolf, 
2009)]. 
Epiregulin 
Epiregulin was purified from conditioned media of NIH 3T3/clone T7 cells in a 46 amino 
acid soluble form (Toyoda et al., 1995).  Epiregulin is 37% homologous to EGF (Toyoda et 
al., 1995).  Epiregulin is capable of binding to both EGFR and HER4, however, it may 
preferentially activate EGFR-containing heterodimers (Shelly et al., 1998).  This ligand is 
expressed primarily in placenta and peripheral blood leukocytes, and in cancers of the 
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bladder, lung, kidney, pancreas, and colon (Toyoda et al., 1997; Zhu et al., 1999).  It is a 
stronger mitogenic signal as compared to EGF, although epiregulin has a far weaker binding 
affinity for EGFR (Table 1.1) (Toyoda et al., 1995; Jones et al., 1999; Komurasaki et al., 
2002).   
Mice with disruption in EGFR ligand expression have indentified functional redundancy 
between EGFR ligands, as well as specific contributions of individual ligands to EGFR-
mediated pathways (Luetteke et al., 1999).  Loss of EGF gene expression shows no true 
phenotype alone, however over expression results in hyperproliferation of epidermal basal 
layer cells (Schneider and Wolf, 2009).  Knockout mouse models have shown that AREG 
expression is related to ductal development (Luetteke et al., 1999).  Overexpression of AREG 
results in psoriasis-like inflammatory lesions (Schneider and Wolf, 2009).  Overexpression of 
TGFα results in hyperproliferation of the liver, metaplasia of the pancreas, and breast 
carcinoma, while, in contrast to AREG, knockout models showed no developmental 
phenotype in the mammary gland (Matsui et al., 1990; Sandgren et al., 1990; Sandgren et al., 
1995).    As with EGF, no phenotype is reported due to loss of BTC alone, however, 
overexpression results in growth retardation and an abnormally large heart and lungs which 
result in pulmonary and cardiac distress  (Schneider and Wolf, 2009).  Mice lacking the 
ability to shed HB-EGF develop severe heart abnormalities (similar to HB-EGF knockout) 
while mice expressing constitutively soluble HB-EGF suffer with hyperplasia of the skin and 
heart (Yamazaki et al., 2003).  Knockout of epiregulin results in no developmental 
abnormalities, however, epiregulin knockout mice are more susceptible to cancer-
predisposing intestinal damage (Lee et al., 2004).   
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ii. Homodimerization 
 In 1987, Yarden and Schlessinger described a reversible aggregation of EGFR upon EGF 
stimulation, suggesting that EGFR may dimerize (Yarden and Schlessinger, 1987).  Early 
evidence of this possible dimerization has been described by Zidovetzki and colleagues, and 
was hypothesized to have a role in EGFR function (Zidovetzki et al., 1981; Schreiber et al., 
1983).  Initial studies utilizing covalent cross-linking reagents have suggested that EGFR 
dimers are formed upon ligand-binding to the receptor (Cochet et al., 1988; Lax et al., 1989; 
Lax et al., 1991; Tanner and Kyte, 1999).  However, more recent technologies such as 
fluorescence resonance energy transfer (FRET), single-molecule imaging of EGFR, and 
biophysical studies, have implied the existence of pre-formed dimers of EGFR on cell 
membranes (Gadella and Jovin, 1995; Sako et al., 2000; Teramura et al., 2006; Clayton et al., 
2007).  Further studies have indicated that dimerization and activation of the receptor are 
independent events (Van de Vijver et al., 1991; Yu et al., 2002).  Unfortunately, limitations 
of crystallography techniques used to analyze the membrane bound EGFR have prevented 
the analyses of an intact EGFR molecule.  However, crystallography has demonstrated that 
asymmetric orientation of the intracellular domains of the receptor pair is required before 
activation of the dimer can occur (Groenen et al., 1997; Zhang et al., 2006).  In the active 
asymmetric dimer, the c-terminal lobe of one kinase domain and the n-terminal lobe of the 
second are in contact (Fig. 1.1) (Zhang et al., 2006).  The donor kinase then promotes activity 
of the acceptor kinase (Zhang et al., 2006).  In the absence of ligand, the dimer is non-
functional due to the extracellular domain having a compact structure where the domain II 
hairpin loop is buried (Burgess et al., 2003; Ferguson et al., 2003).  Upon ligand binding to 
domains I and III of the extracellular region of the receptor, activation occurs due to a change 
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in conformation of the receptor dimer complex that brings domain II from each receptor 
molecule in contact (Heldin, 1995; Garrett et al., 2002; Ogiso et al., 2002).  This is thought to 
bring the intracellular kinase domains in closer proximity to allow autophosphorylation to 
occur (Fig. 1.1) (Zhang et al., 2006). 
iii. Regulation of EGFR via internalization and degradation of the receptor 
 The earliest notion of EGFR internalization was proposed by Carpenter and Cohen in 
1976.  Their pulse chase experiments suggested that, after approximately 10 hours, EGF 
binding to membrane receptors decreased.  New synthesis of DNA and RNA were required 
for binding efficiency to be recovered (Carpenter and Cohen, 1976).  This ten hour time point 
correlates with the discovered half life of EGFR (Stoscheck and Carpenter, 1984).  Silver 
grains with electron microscopy, fluorescence, and affinity labeling were all employed to 
analyze the loss of EGFR described by Stoscheck and Carpenter.  These analyses uncovered 
concomitant loss of EGF-binding activity or fluorescence, and loss of EGF:EGFR complex 
or staining at the cell surface with appearance of defined degradation products or increased 
EGF fluorescence in lysosomal fractions (Das and Fox, 1978; Gorden et al., 1978; Haigler et 
al., 1978; Schlessinger et al., 1978).  Internalization of the ligand-receptor complex is 
mediated via coated pits and coated vesicles (Schlessinger, 1986; Carpenter, 1987).  This 
degradation is inhibited by lyosomal inhibitors, suggesting a role of lysosomes in the 
degradation of EGFR.  Also, inhibitors of vesicular trafficking impair EGF-induced 
degradation of EGFR, suggesting that EGFR is trafficked through vesicles into the lysosomes 
(Stoscheck and Carpenter, 1984).   
 12 
While it was previously thought that EGFR is solely degraded, as no recycling of the 
receptor had been described (King et al., 1980; Krupp et al., 1982; Lyall et al., 1985), it was 
later determined by Beguinot and colleagues that the receptor has the capacity to recycle 
back to the membrane.  Essentially, internalization of the receptor does not automatically 
target the receptor for degradation.  An ubiquitin ligase, known as Cbl, is responsible for 
targeting EGFR for lysosomal degradation.  Recruitment of Cbl to the receptor in early 
endosomes promotes receptor ubiquitination and loss of Cbl results in receptors recycling to 
the plasma membrane (Levkowitz et al., 1998).  A specific EGFR tyrosine residue, 1045, is 
essential for Cbl-mediated EGFR degradation, and mutation of this site leads to extended 
EGFR signaling (Levkowitz et al., 1999). 
iv. EGFR family receptor associations 
 EGFR family members are capable of forming both homo and heterodimers.  EGF, HB-
EGF, and BTC are known to stimulate dimerization between EGFR and HER2 (Goldman et 
al., 1990; Wada et al., 1990; Graus-Porta et al., 1997).  HER2:EGFR heterodimers are more 
stable on the cell surface than other EGFR containing dimers.  They are also preferentially 
recycled rather than sent for degradation.  This is due to being less stable in the early 
endosomal environment, thus Cbl dissociates from the complex, allowing the receptors to 
recycle to the cell surface (Lenferink et al., 1998).  HER2 heterodimerization with EGFR 
also slows the rate of ligand dissociation from EGFR, prolonging and strengthening the 
activation of downstream signaling (Karunagaran et al., 1996).  Both EGF and neuregulins 
can stimulate dimerization between EGFR and HER3 (Graus-Porta et al., 1997; Pinkas-
Kramarski et al., 1998).  HER3 has been shown to effectively associate with the p85α subunit 
of phosphoinositide-3-kinase (PI3K) due to the presence of consensus motifs present in the 
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intracellular domain of the receptor (Fedi et al., 1994; Prigent and Gullick, 1994).  As such, 
EGFR heterodimerization with HER3 is thought to be a mechanism by which EGFR 
mediates PI3K activity (Soltoff et al., 1994).  HER2:HER3 heterodimers have also been 
described, and these form in the presence of neuregulins (Sliwkowski et al., 1994).  In 1996, 
Zhang and colleagues found that co-expression of EGFR and HER4 leads to phosphorylation 
of EGFR in response to heregulins, and phosphorylation of HER4 in response to EGF, 
suggesting that functional heterodimers form between these two proteins (Zhang et al., 
1996).  EGF has also been demonstrated to stimulate dimers of EGFR:HER4 in cell lines 
(Graus-Porta et al., 1997).  Functional dimers of HER4 and HER2 have been shown in 
artificial systems (Plowman et al., 1993b).  In contrast, co-expression of HER3 and HER4 
did not result in increased cellular foci in response to ligand stimulation, suggesting that 
these two proteins either do not functionally interact, or that their interaction does not result 
in increased cellular survival and proliferation (Zhang et al., 1996).  More recent evidence 
suggests a role in HER3:HER4 dimerization in the sustained activation of PI3K in colorectal 
carcinoma (Lee et al., 2009).  Together, these possible dimerization pairs can alter the 
properties of stability and functionality of the EGFR family of receptors, and as such, add 
important diversity to EGFR signaling (Riese et al., 1995; Riese et al., 1996).   
C. Interactions and Signaling  
 The EGFR family is a complex system involved in growth factor cellular signaling 
(Gullick, 2001).  Knockout studies determined that EGFR was important in normal growth 
and development of epithelial cells.  Specifically, knockout of EGFR resulted in embryonic 
lethality or failure of development of the epithelium of multiple organs including the skin, 
lungs, and gastrointestinal tract (Miettinen et al., 1995; Sibilia and Wagner, 1995; Threadgill 
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et al., 1995).  Indeed, the consequences of activation of EGFR are a number of second-
messenger cascades, which promote cell proliferation, angiogenesis, migration, 
differentiation, and survival (Fig 1.2) (Jorissen et al., 2003).  Phosphorylation of EGFR at the 
plasma membrane results in high-affinity binding sites for Src homology 2 (SH2) domain 
containing proteins (Pawson, 1995; Pawson, 1997).   
i. EGFR substrates 
Shc/Grb2 
 Shc interacts with EGFR via SH2 domains that bind to the phospho-tyrosine residues on 
EGFR (Lowenstein et al., 1992; Chardin et al., 1993; Gale et al., 1993; Li et al., 1993).  Shc 
is present in three isoforms, p52/46Shc and p66Shc, the first two of which are involved in 
EGF-induced mitogen activated protein kinase (MAPK) signaling (Migliaccio et al., 2006).  
Grb2 binds to receptor-bound Shc (via phosphorylation of residues on Shc/SH2 domain), or 
can bind directly to EGFR via tyrosines 1068 and 1086 (Batzer et al., 1994; Sasaoka et al., 
1994).  Grb2 also contains two SH3 domains, which allow for interactions with proline-rich 
sequences, including those of Son of sevenless (SOS) (Pawson, 1995).  The Grb2/Shc/EGFR 
interaction results in the recruitment of SOS to the plasma membrane.  SOS is a guanine 
nucleotide exchange factor which promotes the conversion of Ras-GDP to the active Ras-
GTP.  Ras then activates Raf, a serine-threonine protein kinase, which in turn phosphorylates 
and activates MEK1/2, which then activates ERK1/2 (MAPK) (Marshall, 1994; Pawson, 
1995; Marshall, 1996).  Shc null cells demonstrated that Shc is not required for Ras 
activation to occur, however, p52/46Shc amplifies the signal and enhances Ras activity (Lai 
and Pawson, 2000).  Induction of this pathway results in marked increases in cellular
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Figure 1.2: EGFR signaling pathways.  Phosphorylation of EGFR on tyrosine residues leads to 
recruitment of proteins involved in downstream signaling pathways.  Tyrosine 845 is involved in 
c-Src signaling.  Tyrosines 891 and 920 facilitate PI3K recruitment leading to Akt activation and 
cellular survival.  Tyrosine 992 is where PLCγ interacts leading to migration pathways.  
Tyrosine 1045 is responsible for c-Cbl binding, which leads to receptor degradation.  Tyrosine 
1068 recruits Grb2 directly, leading to cellular migration.  Finally, tyrosines 1148 and 1173 bind 
to Shc, which recruits other proteins leading to Ras activation and MAPK signaling which 
promote proliferation.
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proliferation [reviewed in (Zhang and Liu, 2002)].  Shc itself can also be detected complexed 
with other proteins including MEKK-1, linking to JNK pathway activation, as well as 
cadherins, which implies a role for this protein  in cell-cell adhesions (Xu et al., 1997b; 
Pomerance et al., 1998).  Grb2 also links EGFR to proteins such as Fak and dynamin which 
implicate a role for Grb2 in migration of cells (Schlaepfer et al., 1999).  Grb2 is also 
associated with differentiation, as Grb2 null mouse embryos contain defects in this process 
(Cheng et al., 1998).   
Signal transducers and activators of transcription (STAT) 
 Signal transducers and activators of transcription (STAT) proteins are transcription 
factors that, when activated by tyrosine phosphorylation, translocate to the nucleus [reviewed 
in (Jorissen et al., 2003)].  The STAT family of proteins consists of seven members (STAT1, 
STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6), of which, STAT1, STAT3, 
STAT5a, and STAT5b are known to play a role in cancer [reviewed in (Quesnelle et al., 
2007)].  Unlike in cytokine receptor activation of STATs, ligand-dependent phosphorylation 
of STATs by EGFR does not require Jak kinases (David et al., 1996; Leaman et al., 1996; 
Park et al., 1996).  EGFR has been noted to activate STAT1, STAT3, and STAT5 (Olayioye 
et al., 1999).  STATs may also be constitutively associated with EGFR, and their activation is 
strictly dependent on EGFR tyrosine kinase activity (David et al., 1996; Olayioye et al., 
1999; Xia et al., 2002).  Activation of STATs leads to increased transcription of proteins 
involved in mitogenesis, cell survival, and cell differentiation (Cressman et al., 1995; David 
et al., 1995; Eilers and Decker, 1995; Eilers et al., 1995; Demoulin et al., 1996; Kordula et 
al., 1996). 
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p85α 
  PI3Ks can be divided into subclasses, of which, class Ia is the only one activated by 
tyrosine kinase receptors (Jorissen et al., 2003).  The regulatory subunit of PI3K, p85α, binds 
to, and represses, the catalytic subunit of PI3K, p110α.  This complex is recruited to receptor 
tyrosine kinases by interaction between an SH2 domain of p85α and phospho-tyrosine 
residue of the receptor.  Binding of the SH2 domain of p85α to a phospho-tyrosine residue 
results in a conformational change in the p85α: p110α complex that de-represses the activity 
of p110α.  This de-repression allows p110α to catalyze the phosphorylation of the 3’ position 
of phosphatidylinositols [reviewed in (Vanhaesebroeck et al., 2010)].  p85α associates with 
EGFR either through ErbB3 heterodimerization (as HER3 is a major binding partner for 
p85α) or through c-Src phosphorylation of EGFR (Kim et al., 1994; Stover et al., 1995; Ram 
and Ethier, 1996).  Activation of PI3K in this manner leads to phosphorylation of Akt, and 
subsequent activation of cellular processes such as proliferation, survival, adhesion, and 
migration [reviewed in (Cantley, 2002)].  Akt activation also results in phosphorylation of 
Bad, a Bcl family member, that when phosphorylated cannot translocate to the mitochondria 
to inhibit the survival protein Bcl-Xl, such that, apoptosis does not occur (Zha et al., 1996; 
Datta et al., 1997).   
PLCγ 
 Phospholipase C gamma (PLCγ), is one of a family of enzymes that catalyze the 
hydrolysis of phosphatidylinositol bisphosphate (PIP2) to inositol trisphosphate and diacyl 
glycerol [reviewed in (Rhee et al., 1989)].  This family of enzymes has a common 
dependence on calcium, and substrate specificity for phosphoinositols.  PLCγ shares 
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structural homology with the Src family tyrosine kinases within the SH2 and SH3 domains 
(Pawson, 1988; Stahl et al., 1988; Suh et al., 1988).  Phosphorylated EGFR provides a 
docking site for PLCγ (Margolis et al., 1989) to induce EGFR-mediated cell motility but not 
EGF-induced mitogenesis (Chen et al., 1994a). 
Gab1 
 Gab1, or Grb2-associated protein 1, is a docking protein that binds to EGFR, is 
phosphorylated, and then acts as a docking center for protein complexes (Holgado-Madruga 
et al., 1996).  In particular, Gab1 contains three p85α PI3K binding sites (Holgado-Madruga 
et al., 1996), and association of p85α with Gab1 and subsequent activation of PI3K has been 
shown after ligand stimulation (Holgado-Madruga et al., 1997).  Rodrigues and colleagues 
have demonstrated that the PH domain of Gab1 is sufficient for binding of Gab1 to PIP3 and 
targeting of Gab1 to the plasma membrane.  They have also shown that Gab1 directly binds 
to EGFR and potentiates EGF-induced MAPK, JNK, and PI3K activity (Rodrigues et al., 
2000). 
Src Family kinases – see Section 1.2 
ii. EGFR localization 
 While EGFR signaling is well known to occur at the plasma membrane, signaling from 
EGFR also occurs at alternative localizations including the mitochondria, endosomes, and 
nucleus.  For example, EGFR is functionally active at the mitochondria, where 
phosphorylation of tyrosine 845 is required for association of EGFR with cytochrome c 
oxidase II.  This co-localization and co-association occurs after ligand-stimulation and re-
localization of EGFR to the mitochondria through clathrin mediated endocytosis (Boerner et 
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al., 2004; Demory et al., 2009). EGFR is also capable of signaling while within endosomes.  
A number of groups have shown that EGFR is autophosphorylated and catalytically active 
while in endosomes (Cohen and Fava, 1985; Kay et al., 1986; Kuruvilla et al., 2000).  Also, 
signaling molecules (specifically those that regulate Ras activity – including Grb2, SHC, and 
Cbl) are associated with EGFR localized within endosomes (Di Guglielmo et al., 1994; 
Fukazawa et al., 1996; Wang and Moran, 1996; Levkowitz et al., 1998; Clague and Urbe, 
2001).  Following these findings, Wang and colleagues were able to show that EGFR 
stimulates signal transduction pathways leading to cell survival from within endosomes 
(Wang et al., 2002; Sadowski et al., 2009).  Localization of EGFR to the nucleus has been 
shown in a number of cell types (Gusterson et al., 1985; Kamio et al., 1990; Lipponen and 
Eskelinen, 1994; Tervahauta et al., 1994; Zimmermann et al., 1995).  Specifically, Lin and 
colleagues have shown that EGFR rapidly translocates to the nucleus after ligand stimulation, 
where it acts as a transcription factor in a complex to activate gene transcription of cellular 
factors including cyclin D1 (Lin et al., 2001), thus promoting cell cycle progression.  These 
diverse localizations increase the complexity of EGFR signaling.  
D. EGFR in cancer 
 Purification and sequencing of EGFR revealed a close sequence similarity of this receptor 
to the previously characterized v-erb-B viral oncogene.  v-erb-B and EGFR are most similar 
in the transmembrane and cytoplasmic tyrosine kinase domains (Downward et al., 1984b),  
suggesting that the functional portion of EGFR may be implicated in the cancer phenotype 
(Downward et al., 1984b).  An oncogene is a gene, the product of which has the ability (via 
mutation, amplification, or overexpression) to promote transformation of normal cells.  
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EGFR can be labeled an oncogene as EGFR is over-expressed in many cancer types, and this 
overexpression has been shown to lead to increase tumorigenicity of cells (Velu et al., 1987).  
i. EGFR and hallmarks of cancer  
 The hallmarks of cancer, as described by Hanahan and Weinberg, include evading 
apoptosis, sustained angiogenesis, un-regulated cellular proliferation, and tissue invasion and 
metastasis (Hanahan and Weinberg, 2000).  EGFR has been shown to regulate each of these 
hallmarks.  Specifically, by increasing PI3K/Akt signaling, EGFR family receptors can 
modulate both the extrinsic and intrinsic apoptosis pathways.  Also, EGFR is known to 
constitutively activate Stat3 in head and neck cancer (Grandis et al., 1998), which may lead 
to sustained expression of the anti-apoptotic protein Bcl-Xl effectively allowing these cells to 
evade apoptosis (Grandis et al., 2000).  Angiogenesis, or neovascularization, is necessary to 
support growing tumors and supply the nutrients and oxygen the tumor needs for growth.  
Treatment of cells with small molecule kinase inhibitors of EGFR (which block kinase 
activity of the receptor) results in decreased vascular epithelial growth factor (VEGF) 
expression, which, in turn, decreases the ability of vascular epithelial cells to migrate towards 
tumor cells in vitro.  EGFR inhibition also leads to the death of tumor-associated vascular 
epithelial cells in orthotopic pancreatic tumor models (Bruns et al., 2000; Hirata et al., 2002).  
The ability to proliferate independently of normal growth inhibitory signals is also a trait of 
cancer cells.  EGFR activation can lead to and modulate cellular proliferation and neoplastic 
growth (Salomon et al., 1995).  Interestingly, studies have shown that inhibition of the EGFR 
family of proteins leads to proliferative block (Mendelsohn and Baselga, 2000)  Therefore, it 
can be suggested that EGFR is necessary for the limitless replicative potential of cancer cells.  
EGFR has been shown to influence the movement of a variety of cell types in a ligand-
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dependent fashion (Barrandon and Green, 1987; Chen et al., 1994b).  As mentioned earlier, 
PLCγ activation is necessary for EGFR mediated cell movement (Chen et al., 1994a).  EGFR 
has also been suggested to directly affect expression and function of integrins, which mediate 
cytoskeletal changes associated with focal adhesions and motility (Bellas et al., 1991).  
EGFR can also promote the metastatic phenotype of cancer cells [reviewed in (Khazaie et al., 
1993)].  
ii. EGFR in human cancers 
 Ullrich and colleagues showed the first evidence that EGFR itself may be closely related 
to tumor cell function, as they discovered that EGFR was amplified at the genetic level in 
A431 epidermoid carcinoma cells (Ullrich et al., 1984).  These data, along with the close 
structural relationship between EGFR and v-erb-B, suggested that EGFR may be important 
in the cancer phenotype.  Mouse models have demonstrated that overexpression of EGFR 
induces cellular transformation in the mammary gland (Brandt et al., 2000; Marozkina et al., 
2008b), ovary (Marozkina et al., 2008a), uterus (Marozkina et al., 2008a), bladder (Cheng et 
al., 2002), esophagus (Andl et al., 2003), and brain (Holland et al., 1998).  Indeed, as 
mentioned earlier, EGFR itself has been found to be over-expressed in nearly all tumors of 
epithelial origin (Earp et al., 1995)  Below is a concise review of EGFR in these tumor types. 
Gliomas 
 Over-expression of EGFR occurs in 40% of gliomas and correlates with amplification 
and mutation of the receptor (Libermann et al., 1985; Wong et al., 1987; Helseth et al., 1988; 
Yung et al., 1990; Ekstrand et al., 1991; Agosti et al., 1992; Chaffanet et al., 1992; Wikstrand 
et al., 1995).  EGFR expression is a negative prognostic marker in glioblastomas, and is 
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correlated with higher grade of tumor and reduced overall survival (Hurtt et al., 1992; 
Hiesiger et al., 1993).  While overexpression is one way EGFR is activated in gliomas, 
mutations of EGFR are also present.  The most common is a mutation that deletes part of the 
extracellular domain (vIII) and yields a constitutively active receptor (Wong et al., 1992; 
Moscatello et al., 1995).   
Prostate 
 EGFR over-expression occurs in approximately 18% of prostate cancers (Schlomm et al., 
2007).  This protein is amplified in 3-11% of prostate cancers (Edwards et al., 2003; 
Schlomm et al., 2007).  EGFR expression may serve as a prognostic marker for prostate 
cancers (Gorgoulis et al., 1992; Wong et al., 1992; Irish and Bernstein, 1993).  Di Lorenzo 
and colleagues investigated the relationship of EGFR expression with prostate cancer in 
human tumor tissue samples.  They found that EGFR expression was significantly correlated 
with higher Gleason scores and PSA levels, as well as disease relapse in patients (Di Lorenzo 
et al., 2002).  EGFR contributes to prostate cancer growth by activating the androgen 
receptor (AR) through phosphorylation, promoting further cellular growth of both androgen-
dependent and androgen-refractory prostate cancer cells without androgen stimulation 
(Bonaccorsi et al., 2004; Migliaccio et al., 2006; Bonaccorsi et al., 2007; Leotoing et al., 
2007).  In contrast to normal prostate, where androgens decrease EGFR expression, prostate 
cancer cell lines have increased EGFR expression induced by androgens leading to increased 
cellular proliferation (Liu et al., 1993b).  Hammarsten and colleagues have demonstrated that 
treatment of castrated animals with gefitinib (an inhibitor of EGFR) leads to prostate cancer 
cell growth inhibition (Hammarsten et al., 2007).   
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Pancreatic 
 EGFR overexpression occurs in ~30-50% of pancreatic carcinomas (Yamanaka et al., 
1990; Barton et al., 1991; Korc et al., 1992; Yamanaka et al., 1993).   Pancreatic cancer cell 
lines often contain overexpression of EGFR without gene amplification (Smith et al., 1987; 
Chen et al., 1990).  Treatment of cells with small molecule kinase inhibitors of EGFR results 
in decreased angiogenesis in orthotopic pancreatic tumor models (Bruns et al., 2000; Hirata 
et al., 2002). 
Lung 
 EGFR is over-expressed in 40-80% of primary non-small cell lung cancers (NSCLC); 
however, squamous cell carcinomas generally have higher levels of expression than other 
types of NSCLC (Berger et al., 1987b; Veale et al., 1987; Dazzi et al., 1989; Di Carlo et al., 
1993).  This high level of overexpression is due primarily to amplification of the gene 
encoding for EGFR (Suzuki et al., 2005).  EGFR expression has been shown as an important 
prognostic indicator for NSCLC, as stage III NSCLC was found to have higher levels of 
EGFR expression compared to stage I and II tumors (Veale et al., 1987).  Furthermore, 
overexpression of EGFR correlates with high levels of metastases, poor differentiation of the 
tumor, and elevated tumor proliferation rates (Pavelic et al., 1993).  As mentioned for 
gliomas, a mutation that deletes part of the extracellular domain (vIII) yields a constitutively 
active receptor, and has been found in NSCLC (Garcia de Palazzo et al., 1993).  Additional 
mutations in EGFR also occur in lung cancer.  Many of these, including the L858R mutation, 
result in sensitivity to EGFR inhibitors (Costa and Kobayashi, 2007).  This conferred 
sensitivity to EGFR inhibitors has led to FDA approval of the EGFR TKIs gefitinib and 
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erlotinib.  However, other mutations, such as the T790M mutation, result in acquired 
resistance to EGFR kinase inhibition (Kobayashi et al., 2005; Pao et al., 2005).  Thus, 
screening of patients for EGFR mutational status in lung cancer may allow further approval 
of EGFR-based therapies for the sub-populations of lung cancer patients who possess these 
mutations.    
Colon 
 Approximately 8% of all colorectal carcinomas over-express EGFR.  This overexpression 
is a result of genetic amplification in ~60% of cases (Ooi et al., 2004).  While no correlation 
has been observed between this expression and tumor grade, proliferative index, histological 
stage, or overall survival (Salomon et al., 1995), Mayer and colleagues have shown that 
patients whose tumors are over 50% positive for EGFR expression have worse prognosis 
compared to those with less than 50% of their tumor positive for EGFR (Mayer et al., 1993).  
Also, EGFR expression is elevated in more highly metastatic primary colon tumors than 
those with a less aggressive phenotype (Radinsky, 1993).  Cetuximab (Erbitux), an EGFR-
directed monoclonal antibody, is currently in clinical use in colorectal cancers.     
Ovarian 
 EGFR is over-expressed in 35-70% of primary ovarian carcinomas (Battaglia et al., 1989; 
Bauknecht et al., 1989a; Bauknecht et al., 1989b; Bauknecht et al., 1990; Johnson et al., 
1991; Morishige et al., 1991b; Berns et al., 1992; Henzen-Logmans et al., 1992; Owens et al., 
1992; Scambia et al., 1992; Bauknecht et al., 1993).  Such overexpression occurs without 
gene amplification (Zhang et al., 1989; Bauknecht et al., 1990; Berns et al., 1992; Kohler et 
al., 1992).  EGFR expression was found to be significantly associated with high risk of 
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ovarian carcinoma progression (Scambia et al., 1992).  As with gliomas and lung cancers, the 
vIII constitutively active mutant of EGFR is expressed in ovarian carcinomas (Wong et al., 
1992; Moscatello et al., 1995).  Proliferation of ovarian cancer cells can be significantly 
inhibited in vitro utilizing EGFR monoclonal antibodies or anti-TGFα antibodies (Morishige 
et al., 1991a; Morishige et al., 1991b; Stromberg et al., 1992).   
Liver 
 EGFR over-expression occurs in 30-60% of hepatocellular carcinomas, however little is 
known about the mechanism of this over-expression (Nonomura et al., 1988; Ito et al., 2001).  
Nevertheless, over-expression of EGFR in this cancer type correlates with high proliferation, 
advanced stage, and poor prognosis (Ito et al., 2001). Also, EGFR, as well as ErbB3, and the 
ligands HB-EGF, TGFα, BTC, and AREG are over-expressed in human hepatocellular 
carcinoma tissues (Ding et al., 2004; Avila et al., 2006; Breuhahn et al., 2006; Castillo et al., 
2006; Berasain et al., 2007).  Production of EGFR ligands has been suggested to influence 
the growth of premalignant liver epithelial cells (Drucker et al., 2006).  Activation of EGFR 
in a ligand-dependent manner in liver cancer cells has been demonstrated to potentiate the 
aggressive behavior of such cells (Lin et al., 2006).   
Bladder 
 EGFR expression is higher in malignant bladder as compared to normal bladder 
epithelium, yet EGFR is rarely genetically amplified (Neal et al., 1985; Berger et al., 1987a; 
Messing et al., 1987; Neal et al., 1989; Messing, 1990; Lonn et al., 1993).  EGFR expression 
in these tumors correlates with invasive potential, poor tumor differentiation, decreased 
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survival, increased recurrence, and increased rate of progression in bladder cancers (Neal et 
al., 1985; Neal et al., 1989; Smith et al., 1989; Neal et al., 1990).   
Esophagus 
 Approximately 35% of primary esophageal tumors express EGFR (Iihara et al., 1993) 
and EGFR is genetically amplified in primary human esophageal carcinomas (Hollstein et al., 
1988; Lu et al., 1988).  Survival rate is significantly lower in patients with tumors that over- 
express EGFR as compared to patients with no EGFR overexpression (Iihara et al., 1993).  In 
these tumors, TGFα is also highly expressed, and this expression correlates with short 
doubling time of esophageal cancer cells (Kim et al., 1991; Thornley and Jones, 1992).   
Head & Neck 
 EGFR is over-expressed in oral squamous cell carcinomas (SCC) (Todd and Wong, 
1999), and this over-expression often times occurs without gene amplification [reviewed in 
(P et al., 2002)].  Ligand-independent activation of EGFR through E-cadherin and 
subsequent MAPK phosphorylation allows adhesion-mediated survival for this cancer type 
(Shen and Kramer, 2004).  EGFR is known to constitutively activate Stat3 in head and neck 
cancer (Grandis et al., 1998).  Ligand stimulation of EGFR was shown to stimulate 
anchorage-independent growth in oral SCC cell lines (Lee et al., 1990).  Resistance of oral 
SCCs to chemotherapy and radiotherapy can be pharmacologically reversed through the 
utilization of inhibitors of EGFR function (Bonner et al., 2002; Raben et al., 2002).    
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Gastric 
 Over-expression of EGFR has been noted in approximately 33% of advanced stage 
gastric carcinomas (compared to 3.8% in early stage or non-malignant samples) (Yasui et al., 
1988).  Such over-expression is rarely due to genetic amplification in this form of cancer 
(Kim et al., 2008).  EGFR expression has been suggested as a useful prognostic indicator for 
gastric cancer (Yasui et al., 1988; Lemoine et al., 1991).  EGFR expression occurs more 
frequently in well-differentiated advanced stage adenocarcinomas; however there is no 
apparent association of EGFR expression with tumor grade or size (Yasui et al., 1988; 
Lemoine et al., 1991). 
Breast – see Section 1.4 
E. Inhibiting EGFR activity  
i. Monoclonal Antibodies  
 In 1981, John Mendelsohn and colleagues initially hypothesized that blocking the binding 
site for EGFR ligands using a monoclonal antibody (mAbs) might be an effective treatment 
strategy for cancer [reviewed in (Mendelsohn and Baselga, 2000)].  In the years following 
that hypothesis, mAbs directed toward EGFR have been developed and applied in the clinic,  
leading to treatment regimens for cancer [reviewed in (Herbst et al., 2001)].  Specifically, 
mAb 225 (later derived into C225, a humanized murine chimeric version of the mAb) was 
isolated in 1983.  This antibody was later developed into a cancer therapeutic for head and 
neck cancer.  There are currently five EGFR targeting antibodies in development including 
Cetuximab (Erbitux), Matuzumab, Nimotuzumab (TheraCIM), Panitumumab (Vectivix), and 
Zalutumumab (Wheeler et al., 2010).  These inhibitors have been introduced in clinical trials 
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both as monotherapies and as combinatorial therapy with chemo- or radio-therapies in 
colorectal, head and neck, pancreatic, and lung cancers (Mendelsohn, 2004).  EGFR-directed 
mAbs compete with ligand binding and then down-regulate receptor expression, leading to 
inhibition of cell growth by arresting cells in G1 (Wu et al., 1996; Waksal, 1999).  While 
mAbs can directly stimulate immune response in patients, leading to complement-mediated 
cytotoxicity or antibody-dependent cell-mediated cytotoxicity (Harris and Mastrangelo, 
1989), at least in the case of cetuximab, the primary mechanism of action is related to the 
disruption of EGFR-mediated signaling (Mendelsohn, 1997).  It has been suggested that 
antibodies against HER2 require endocytic sorting and Cbl to exert their antitumor effects, 
however, it has yet to be shown if antibodies specific to EGFR act in the same manner 
(Klapper et al., 2000).  To date, two EGFR targeting monoclonal antibodies have been FDA 
approved for use in cancer patients.  Specifically, cetuximab (Erbitux) was approved for use 
in combination with irinotecan or alone if the patient cannot tolerate irinotecan in metastatic 
colorectal cancer in 2004, and for head and neck cancer in 2006.  Also, panitumumab 
(Vectibix) was approved for EGFR-expressing advanced colorectal cancer with disease 
progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing 
chemotherapy regimens in 2006. 
ii. Small molecule tyrosine kinase inhibitors (TKIs)   
 TKIs target the intracellular ATP-binding pocket of the tyrosine kinase moiety of EGFR.  
In xenograft models and human tumor-derived cell lines, these inhibitors have shown dose 
dependent tumor growth inhibition alone, or in combination with drugs and/or radiation 
(Ciardiello, 2000).  Clinically, TKIs have demonstrated anti-tumor activity in head and neck 
cancer (Feng et al., 2007; Reuter et al., 2007) where approximately 10% respond to the 
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inhibitor, non-small cell lung cancer (Jubelirer et al., 2006), and glioblastomas (Mellinghoff 
et al., 2005) where again 10-20% of patients respond.  Glioblastoma patients that responded 
were vIII mutants.  Those that responded in non-small cell lung cancer have been 
demonstrated to possess the L858R EGFR mutation (Costa and Kobayashi, 2007).  
Currently, five EGFR tyrosine kinase inhibitors are in clinical trials including erlotinib 
(Tarceva), gefitinib (Iressa), vandetanib (Zactima), lapatinib (Tykerb), and pelitinib (Wheeler 
et al., 2010).  Gefitinib (Iressa), an EGFR specific TKI, was approved in 2004 for 
monotherapy treatment for advanced, chemotherapy-refractory non-small cell lung cancer 
based on an 11-18% response rate in two phase II clinical trials (Mendelsohn and Baselga, 
2000), but approval was later revoked do to failure to produce survival benefit alone or with 
chemotherapy in three phase III trials (Giaccone et al., 2004; Herbst et al., 2004; Thatcher et 
al., 2005).  Erlotinib (Tarceva) was approved for treatment of non-small cell lung cancer and 
pancreatic cancer, and recently has been approved for maintenance of locally advanced or 
metastatic NSCLC that is not progressing after four cycles of platinum based chemotherapy 
(2010).  Lapatinib, a dual EGFR/HER2 inhibitor, has also been recently approved, in 
combination with letrozole, in post menopausal women with hormone receptor positive 
metastatic breast cancers that over-express HER2 (2010).   
 Resistance to EGFR TKIs is a common occurrence in cancer.  Generally, resistance can 
occur by two mechanisms.  First, de novo or intrinsic resistance may occur.  This type of 
resistance is thought to be due to lack of tumor dependence upon EGFR (Baselga and 
Arteaga, 2005).  Also, EGFR-independent or constitutive activation of effectors downstream 
of EGFR could contribute to de novo resistance.  For example, failure to inhibit PI3K/Akt, by 
mutation or alternative activation, also prevents response to EGFR inhibitors (Bianco 2003, 
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Cheng 1992, Cheng 1996, Forgacs 1998, Lu 1999, Hoilestelle 2007).  EGFR-independent 
activation of c-Src after interaction with other tyrosine kinases or integrins may lead to 
activation of signaling pathways downstream of EGFR [reviewed in (Bianco et al., 2007)].  
Activated Ras (and thereby persistent MAPK signaling) is associated with intrinsic resistance 
to both gefitinib and cetuximab in NSCLC (Janmaat et al., 2003), and resistance to gefitinib 
in breast cancer cells (Normanno et al., 2006).  In addition, glioblastomas containing the 
EGFRvIII mutation are relatively resistant to gefitinib due to persistent Akt phosphorylation 
after PTEN loss (Kuan et al., 2001).  Acquired resistance may also occur after initial 
response to EGFR inhibitors.  This may be due to alternative activation of proangiogenic 
pathways, as EGFR inhibition can lead to subsequent down-regulation of tumor-induced, 
VEGF-mediated angiogenesis (Ciardiello et al., 1996; Petit et al., 1997; Perrotte et al., 1999).  
It has been demonstrated that altered control of these angiogenic pathways can induce 
resistance to EGFR inhibitors in vivo (Viloria-Petit et al., 2001).  Also, activation of 
alternative tyrosine kinases (such as IGF-1R or c-Met), has also been shown as a potent 
mechanism of acquired resistance to EGFR blockade (Jones et al., 2004).  While alterations 
in EGFR protein such as the L858R mutation or deletion mutants may lead to sensitivity to 
EGFR inhibitors (Lynch et al., 2004; Paez et al., 2004), secondary mutations, including the 
T790M mutation, can occur and lead to acquired resistance to EGFR inhibitors (Kobayashi et 
al., 2005; Pao et al., 2005). 
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1.2. Src Family Kinases (SFKs) 
A. Structure and Activation of SFKs 
 c-Src, the prototypical member of the Src family kinases, was discovered in 1976 as a 
mammalian homologue of the transforming agent in avian sarcoma virus, v-Src (Stehelin, 
1976; Stehelin et al., 1976).  This family of non-receptor tyrosine kinases contains nine 
members that differ based on tissue specific expression.  The first subfamily, Lck, Blk, Lyn, 
and Hck, are fairly restricted in their expression to hematopoietic cells.  The second 
subfamily, c-Src, Yes, Fyn, Yrk, and Fgr, are ubiquitously expressed (Bolen and Brugge, 
1997).  These proteins have structural homology consisting of an N- terminal sequence, 
unique domain, a SH3 domain, a SH2 domain, and a tyrosine kinase domain (Fig 1.3) 
[reviewed in (Tsygankov and Shore, 2004)].  Within the c-terminal tyrosine kinase domain 
are two phosphorylation sites that are critical to the function of the protein.  First, 
phosphorylation on tyrosine 527 negatively regulates SFK activity.  Phosphorylation of this 
site occurs via the Csk-family of protein tyrosine kinases (Okada et al., 1991; Bergman et al., 
1992; Sabe et al., 1992; Chow et al., 1993; Nada et al., 1993; Superti-Furga et al., 1993; 
Takeuchi et al., 1993; Thomas et al., 2006).  The SH2 domain of SFKs binds to tyrosine 527 
after phosphorylation on this site  (Roussel et al., 1991; Amrein et al., 1993; Liu et al., 1993a; 
Weijland et al., 1997), which induces the binding of the SH3 domain to the linker region 
between the SH2 and tyrosine kinase domains, prohibiting binding of ATP, effectively 
inactivating the protein (Fig. 1.3) (Sicheri et al., 1997; Williams et al., 1997; Xu et al., 1997a; 
Gonfloni et al., 1999; Schindler et al., 1999; Xu et al., 1999).  Dephosphorylation on tyrosine 
527 occurs by one of several protein tyrosine phosphatases including CD45, SHP-1, SHP-2,
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Figure 1.3: c-Src activation.  In the inactive conformation, tyrosine 527 on the c-terminal tail 
of c-Src is phosphorylated, which facilitates binding of the Src SH2 domain to this tail.  This 
binding positions the link region in close proximity to the SH3 domain and prevents the 
activation of the complex.  In the active conformation, tyrosine 416 is phosphorylated leading to 
opening of the substrate binding pocket and release of the SH2 domain from tyrosine 527, thus 
repositioning the SH3 and linker domains.
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PTP-α, or PTP-λ (Mustelin et al., 1989; Mustelin and Altman, 1990; Mustelin et al., 1992; 
Shiroo et al., 1992; Zheng et al., 1992; Hurley et al., 1993; Sieh et al., 1993; Biffen et al., 
1994; Fang et al., 1994; Peng and Cartwright, 1995; Somani et al., 1997; Harder et al., 
1998a; Bjorge et al., 2000).  Second, phosphorylation of tyrosine 416, must occur for the 
protein to be active.  Phosphorylation on this site results in displacement from a pocket of 
hydrophobicity formed within the catalytic domain, resulting in the repositioning of the 
region and formation of a substrate binding pocket (Fig 1.3) (Yamaguchi and Hendrickson, 
1996; Sicheri et al., 1997; Williams et al., 1997; Xu et al., 1997a; Schindler et al., 1999; Xu 
et al., 1999).  Tyrosine 416 is phosphorylated by many proteins, including PDGFR, focal 
adhesion kinase (FAK), and EGFR (discussed later) (Kypta et al., 1990; Cobb et al., 1994; 
Schaller et al., 1994; Alonso et al., 1995; Eide et al., 1995; Alexandropoulos and Baltimore, 
1996; Moarefi et al., 1997; Chiang and Sefton, 2000).  Phosphorylation on tyrosine 416 is 
sufficient to activate c-Src, even when tyrosine phosphorylation of 527 is present (Sun et al., 
1998; Boerner et al., 2004).  Thus, dephosphorylation of tyrosine 416 is critical to the 
inactivation of SFKs.    PTP-α and PTP-λ are known to de-phosphorylate tyrosine 416 of c-
Src (Zheng et al., 1992; Fang et al., 1994). 
 SFKs are localized to the plasma membrane, perinuclear regions and endosomal 
membranes (Silverman et al., 1993; Ley et al., 1994; Resh, 1994).  As SFKs contain no 
transmembrane domain, membrane localization is due, in part, to myristoylation and 
palmitoylation on N-terminal fatty acid modification sites (Marchildon et al., 1984; Pellman 
et al., 1985; Peters et al., 1990; Paige et al., 1993; Shenoy-Scaria et al., 1993; Koegl et al., 
1994).  Localization may also be dependent on the specific protein interactions between 
 34 
SFKs and cytoskeletal components, cytokines, and growth factor receptors including EGFR 
(Kaplan et al., 1992; Sandilands et al., 2004; Donepudi and Resh, 2008).   
 Like the EGFR ligands, SFKs have a high level of functional redundancy.  However, loss 
of c-Src results in the onset of osteoporosis due to defective osteoclast function (Soriano et 
al., 1991; Boyce et al., 1992).  Loss of Lck results in hematopoetic deficiencies (Molina et 
al., 1992; Molina et al., 1993; Wen et al., 1995) and severe nervous system defects are seen 
in models where Fyn is knocked out (Grant et al., 1992; Beggs et al., 1994; Miyakawa et al., 
1994; Umemori et al., 1994).  Yes, Hck, Fgr, and Blk have also been knocked out in mice, 
however, no distinct phenotypes are seen, suggesting, again, that a high degree of 
redundancy exists within the family [reviewed in (Lowell and Soriano, 1996)]. 
B. Function of c-Src  
For the purposes of this dissertation, we will focus the remainder of this section the 
prototypical membrane of the Src family, c-Src.  c-Src is involved in a  number of cellular 
processes including membrane trafficking, cellular motility and migration, cell cycle 
progression, apoptosis, and differentiation (Fig. 1.4).  First, c-Src has been shown to play a 
role in the regulation of membrane trafficking.  Specifically, c-Src phosphorylates ASAP1, 
an ADP-ribosylation factor GTPase-activating protein, and association of this protein with 
Arfs and PIP2 has been shown to be important in actin cyoskeletal remodeling (Brown et al., 
1998b; Randazzo et al., 2000).  Src also associates with synapsin I, dynamin, synaptophysin, 
snaptogyrin, and cellugyrin which are all involved in vesicle transport (Barnekow et al., 
1990; Onofri et al., 1997; Foster-Barber and Bishop, 1998; Janz and Sudhof, 1998).  Second, 
cellular motility is a process that has also shown a dependence on c-Src.  c-Src localizes to 
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Figure 1.4: c-Src signaling pathways.  c-Src is activated through interaction with 
transmembrane proteins including receptor tyrosine kinases (RTK).  Activation of c-Src 
mediates the Ras/MAPK pathway, leading to proliferation, PI3K/Akt pathway leading to 
survival, FAK signaling leading to migration and invastion, and STAT pathway leading to 
proliferation, survival, and angiogenesis.
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focal adhesions, where it associates with FAK, a protein tyrosine kinase that is active 
following the engagement of integrins (Schaller et al., 1993; Cobb et al., 1994; Schaller et al., 
1994).  This co-association activates Src, which in turn phosphorylates FAK.  Subsequently, 
there is an accumulation of phosphorylated proteins critical to cell motility and migration 
including p130cas, paxillin, and PI3K (Hildebrand et al., 1993; Schaller et al., 1994; Chen et 
al., 1995; Polte and Hanks, 1995; Altun-Gultekin and Wagner, 1996; Burnham et al., 1996; 
Hall et al., 1996; Harte et al., 1996; Vuori et al., 1996; Yokote et al., 1996; Schlaepfer et al., 
1997; Schlaepfer and Hunter, 1997).  Third, c-Src has been shown to be involved in cell 
cycle progression.  Specifically, c-Src activates Shc and PI3K to modulate DNA synthesis 
and c-Src phosphorylates SAM68 to regulate mitosis (Augustine et al., 1991; Yamanashi et 
al., 1992; Pleiman et al., 1993; Taylor and Shalloway, 1993; Fumagalli et al., 1994; Ptasznik 
et al., 1995; Broome and Hunter, 1996; Luttrell et al., 1996; Pillay et al., 1996; Taylor and 
Shalloway, 1996).  Through these interactions, c-Src may also regulate apoptosis.  
Specifically, constitutive activation of c-Src leads to rescue of apoptosis induced by cytokine 
removal, irradiation, chemotherapeutics, or disruption of extracellular matrix interactions 
(Anderson et al., 1990; Frisch and Francis, 1994; Basu and Cline, 1995; Canman et al., 
1995).  Lastly, differentiation has also been described to involve c-Src.  Constitutive 
activation of c-Src is sufficient to block differentiation in myoblasts, retinoblasts, and 
chondroblasts, allowing a self renewal phenotype to persist (Muto et al., 1977; Yoshimura et 
al., 1981; Alema and Tato, 1987). 
C. The interaction between c-Src and EGFR  
c-Src interacts with a number of receptor tyrosine kinases including PDGFR, FGFR, 
CSF-1R, NGF-R, HGF-R, IGF-R, HER2, and EGFR (Luttrell et al., 1988; Kozma and 
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Weber, 1990; Kypta et al., 1990; Kremer et al., 1991; Courtneidge et al., 1993; Faletto et al., 
1993; Zhan et al., 1994; Muthuswamy and Muller, 1995).  Interaction between EGFR and c-
Src enhances many EGFR-dependent cellular functions including DNA synthesis, protein 
tyrosine phosphorylation, transformation of mouse fibroblasts and human mammary 
epithelial cell lines, and tumor formation in nude mice (Luttrell et al., 1988; Wilson et al., 
1989; Wilson and Parsons, 1990; Chang et al., 1995; Maa et al., 1995; Boerner et al., 2005; 
Dimri et al., 2007).  Activation of EGFR increases c-Src catalytic activity (Sato et al., 1995a; 
Sato et al., 1995b; Weernink and Rijksen, 1995).  c-Src, in turn, phosphorylates novel sites 
on EGFR, including tyrosine 1101, 891, 920, and 845 (Maa et al., 1995; Tice et al., 1999).  c-
Src-dependent phosphorylation on these sites promotes EGFR signaling.  Specifically, 
phosphorylation of tyrosine 845 has been shown to be critical to EGFR-induced mitogenesis 
(Biscardi et al., 1999a; Tice et al., 1999), while phosphorylation of tyrosines 891 and 920 
mediates the binding of PI3K to EGFR (Stover et al., 1995).  c-Src may also be important in 
EGFR crosstalk.  c-Src expression mediates crosstalk between estrogen receptor and EGFR 
(Castoria et al., 1999), as well as between EGFR and the HGF receptor, c-Met (Mueller et al., 
2008).  Thus, c-Src is an important regulator of EGFR signaling. 
D. c-Src in cancer 
 As c-Src was discovered due to its homology to viral v-Src, a potent oncogene, it was 
widely believed that c-Src would be involved in the cancer phenotype (Fung et al., 1983).  
Overexpression of c-Src alone is insufficient to transform mouse fibroblasts in culture, and 
cannot sustain tumor growth in vivo (Shalloway et al., 1984; Luttrell et al., 1988; Maa et al., 
1995).  However, other findings have suggested a role for c-Src in tumorigenesis.  c-Src is 
necessary for induction of mammary tumors produced by the polyoma middle T oncogene 
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(Guy et al., 1994a).  Also, expression levels of c-Src are elevated in lung, skin, colon, breast, 
cervical, parotid, esophageal, gastric, and brain cancers [reviewed in (Biscardi et al., 2000; 
Irby and Yeatman, 2000)].  While mutations of c-Src are rare in cancer, a mutant form of c-
Src that is truncated before the inhibitory phosphorylation site was identified in 1999 by Irby 
and colleagues in highly metastatic colon carcinoma (Irby et al., 1999).  
E. c-Src tyrosine kinase inhibition   
 Two classes of c-Src inhibitors have been identified and tested in clinical trials: those that 
alter the interactions of c-Src with other proteins (SH3 and SH2 inhibitors) and those that 
inhibit the intrinsic tyrosine kinase activity of Src itself [reviewed in (Sawyer et al., 2001)].  
The SH3 and SH2 inhibitors are small molecules that mimic the specific structure of SFK 
SH3 and SH2 domains thereby blocking association of substrates with c-Src.  The first active 
SH3 inhibitor of c-Src was reported in 1999 (Cussac et al., 1999), however, SH3 domains 
found in various proteins contain common protein sequences, thus specificity might be an 
issue.  The same is true for c-Src SH2 inhibitors, of which, only one has been shown 
effective in vivo [reviewed in (Sawyer et al., 2001)].  Small molecule c-Src tyrosine kinase 
inhibitors, such as PP1, PP2, SU6656, and dasatinib have also been developed [reviewed in 
(Sawyer et al., 2001)].  While PP1 and PP2 were found to inhibit Src family tyrosine kinase 
inhibitors effectively, they also showed efficacy for the PDGF receptor (Hanke et al., 1996).  
To overcome this, Blake and colleagues at SUGEN Inc., developed SU6656, which more 
selectively inhibited Src family tyrosine kinases (Blake et al., 2000).  These inhibitors have 
shown to be useful tools in the study of the effects of c-Src kinase in cell models.  Most 
clinically relevant, and important to this dissertation, is the small molecule c-Src tyrosine 
kinase inhibitor dasatinib.  Dasatinib, or BMS-354825, was originally described as an 
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inhibitor of the oncogenic tyrosine kinase Bcr-Abl (Lombardo et al., 2004).  Lombardo and 
colleagues suggested that dasatinib also could act as a potent inhibitor of SFKs.  The IC50s for 
dasatinib inhibition of SFKs were in the picomolar range, whereas the IC50 for Bcr-Abl was 
closer to 1 nanomolar.  Preclinically, dasatinib was found to have antitumor activity in mouse 
xenograft models of leukemia (Lombardo et al., 2004)  which led to the development of 
clinical trials and the  approval of dasatinib for the treatment of Bcr-Abl expressing acute 
lymphoblastic leukemia in 2006 (Brave et al., 2008).  Due to the elevated c-Src expression 
levels in many solid tumor types and preclinical evidence for an effect of c-Src TKIs on solid 
tumor growth, dasatinib has gone forward into clinical trials alone, and in combination with 
other therapeutics, in breast, skin, pancreatic, brain, colorectal, head and neck, ovarian, 
gastrointestinal, and prostate cancers (Laird et al., 2003; Kim et al., 2010).   
1.3. Lipid Rafts 
A. Discovery of lipid rafts 
 Early on, scientists held a two dimensional view of the lipid bilayer.  This view was that 
the plasma membrane was a "fluid mosaic" (Singer, 1972) containing "Icebergs in the sea" 
(i.e. proteins in a fluid surrounding of lipid).  This idea was further perpetuated by the finding 
that the membrane contained areas that were loosely packed and demonstrated rapid lateral 
diffusion (Lee, 1977).  However, in the early 1950s, flask-shaped invaginations in the plasma 
membrane were discovered by electron microscopy (Palade, 1953).  These invaginations 
were termed “little caves” or caveolae (Yamada, 1955) and were found to contain the protein 
caveolin (Glenney, 1992; Rothberg et al., 1992; Scherer et al., 1995; Tang et al., 1996).  The 
identification of caveolin-1 led to the development of biochemical techniques that resulted in 
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the isolation of low density detergent resistant microdomains (DRMs) (Brown and Rose, 
1992; Lisanti et al., 1995).  These DRMS are rich in flotillin protein (Smart et al., 1999) as 
well as glycosphingolipids, gangliosides (including GM-1), cholesterol, and other proteins; 
however, some DRMs lack caveolin and invagination structure (Mirre et al., 1996; Wu et al., 
1997).  Simons and Ilkonen coined the term “lipid raft” for the DRMs that do not contain 
caveolin protein (Simons and Ikonen, 1997).  These rafts range in size from 10 to 200 nm in 
diameter (Varma and Mayor, 1998; Sharma, 2004; Pike, 2006).  Because of their high lipid 
content, lipid rafts float to low densities during gradient centrifugation (Brown and Rose, 
1992).  However, localization within buoyant fractions after isolation does not constitute co-
association or co-localization specifically with plasma membrane lipid rafts as most isolation 
techniques also result in the isolation of caveolae, as well as lipid rafts from organelles 
[reviewed in (Simons and Ikonen, 1997)].  As recently as 2006, a consensus definition of 
what a lipid raft is was developed at the Keystone Symposium of Lipid Rafts and Cell 
Function, stating that “Lipid rafts are small (10-200nm) heterogeneous, highly dynamic, 
sterol- and sphingolipid-enriched domains that compartmentalize cellular processes.  Small 
rafts can sometimes be stabilized to form larger platforms through protein-protein and 
protein-lipid interactions” (Fig 1.5) (Pike, 2006).  Lipid rafts have been isolated from many 
cell types including epithelial cells, fibroblasts, hematopoietic cells, endothelial cells, 
adipocytes, muscle cells, neurons, and even yeast [reviewed in (Brown and London, 1997)].   
B. The controversy of lipid rafts 
 It was suggested originally by Simons and colleagues that the presence of 
glycosphingolipid rich lipid rafts may be an artificial finding.  Their hypothesis was that 
rather than the lipids interacting to form rafts in intact cells, the lipids may interact during the  
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Figure 1.5: The structure of lipid raft membrane microdomains.  Lipid rafts contain 
elevated levels of cholesterol, glycosphingolipids, and gangliosides (including GM-1).  
Transmembrane proteins, as well as various lipid modified proteins (including GPI-anchored 
proteins) have the ability to associate with lipid rafts.  A commonly used method of detection for 
lipid rafts takes advantage of the ability of cholera toxin subunit B (CTXB) to bind GM-1.
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extraction process (Simons and van Meer, 1988; Simons and Wandinger-Ness, 1990).  
Further indication that lipid rafts may not be present as structures within the plasma 
membrane is the finding that detergents themselves can cause redistribution of proteins on 
the cell surface.  For example, Triton X-100 extraction results in GPI-anchored proteins 
enriched in biochemically isolated DRMs, while other proteins, such as the transferrin 
receptor, are readily solubilized (Hooper and Turner, 1988; Hooper and Bashir, 1991; 
Sargiacomo et al., 1993; Mayor and Maxfield, 1995).  However, Mayor and Maxfield 
performed immunofluorescent staining and electron microscopy of GPI-anchored proteins in 
the absence and presence of detergent.  They found that treatment of cells with Triton X-100 
was sufficient to induce clustering of GPI-anchored proteins, suggesting that membrane 
domains enriched in GPI-anchored proteins are an artificial product of detergent treatment 
(Mayor and Maxfield, 1995).  However, in 1998, Schroeder and colleagues found that DRMs 
were not formed spontaneously during Triton X-100 treatment, as exogenously applied 
radiolabelled sphingomyelin (a main component of DRMs) is not incorporated into 
membranes previously identified as detergent soluble  (Schroeder et al., 1998).  In summary, 
detergent extraction did not spontaneously produce DRMs where there were none previously.  
A number of groups utilized single particle tracking of GM-1, chemical cross-linking of GM-
1 to other proteins, FRET between GM-1 and these proteins, and immunofluorescent 
microscopy, to show that lipid rafts exist in living cells (Sheets et al., 1997; Friedrichson and 
Kurzchalia, 1998; Harder et al., 1998b; Simson et al., 1998; Varma and Mayor, 1998).  More 
recently, non-detergent methods have addressed concerns over detergent "artifacts.”  These 
methods isolate lipid rafts from the cell by mechanical lysis in detergent free buffers 
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followed by ultracentrifugation.  These findings, along with the studies using microscopy 
techniques, support the presence of lipid rafts (Macdonald and Pike, 2005). 
C. Rafts in cellular functions  
Rafts are thought to first assemble within the golgi, where sphingolipids are synthesized (van 
Meer, 1989).  From there, these domains travel through vesicles to the plasma membrane and 
other cellular organelles.  At the membrane, lipid rafts participate in many cellular functions, 
including endocytosis and cellular signaling.   
 The endocytotic pathway has been proposed to involve lipid rafts.  Both clathrin 
dependent and independent mechanisms of endocytosis have been shown to involve lipid 
rafts (Puri et al., 1999) as evidenced by the fact that lipid rafts are themselves are found in 
early endosomes that are recycled back to the cell surface or Golgi apparatus (Puri et al., 
1999; Mukherjee and Maxfield, 2000).  Lipid rafts are also involved in the cellular 
internalization of toxins.  For example, cholera toxin, the infectious agent of vibrio cholerae, 
requires lipid rafts for entry into human cells (Orlandi and Fishman, 1998).  Specifically, 
GM-1, a lipid raft specific ganglioside, is the target binding partner for cholera toxin subunit 
B (Fig 1.5), and the cellular function of cholera toxin is solely triggered when GM-1 is 
present in lipid rafts (Wolf et al., 1998).   
 Lipid rafts contain high concentrations of signaling molecules (Chang et al., 1994; Lisanti 
et al., 1994; Hope and Pike, 1996; Wu et al., 1997).  Different classes of signaling proteins 
localize within lipid rafts including GPI-anchored proteins, transmembrane proteins, receptor 
tyrosine kinases, G-protein coupled receptors, and Src family kinases (Skibbens et al., 1989; 
Sargiacomo et al., 1993; Danielsen and van Deurs, 1995).  These rafts may facilitate 
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signaling through localizing components of a signaling pathway together or localizing 
distinct signaling pathways within the same raft to facilitate crosstalk.  Lipid rafts also 
negatively regulate signaling by sequestering molecules and preventing their association with 
molecules required to activate the proteins [reviewed in (Zajchowski and Robbins, 2002)].  
The B cell receptor (BCR) is an excellent example of the capability of lipid rafts to regulate 
the signaling abilities of proteins.  Specifically, in immature B cells, BCR does not 
translocate to lipid rafts after activation, and signaling pathways activated downstream lead 
to apoptosis rather than activation of the cell (Sproul et al., 2000).  However, in mature B-
cells, BCR rapidly translocates into lipid rafts, where it interacts with the Src family kinase 
member Lyn to promote signaling (Cheng et al., 1999; Petrie et al., 2000).  Interestingly, in 
mature B cells infected with Epstein-Barr virus, this movement into lipid rafts is impaired, 
preventing BCR signaling activation (Dykstra et al., 2001). 
D. The effect of lipid rafts on EGFR and c-Src signaling 
 Of the many proteins that are capable of localizing to lipid rafts, EGFR and c-Src are the 
most relevant to this dissertation.  EGFR has been demonstrated to localize within lipid rafts 
in a variety of human cancer cell lines (Ringerike et al., 2002; Sun et al., 2002; Abulrob et 
al., 2004; Macdonald and Pike, 2005; Oh et al., 2007; Schley et al., 2007), monkey kidney 
cells (Peres et al., 2003), vascular smooth muscle cells (Zuo et al., 2004), and Chinese 
hamster ovary cells (Macdonald and Pike, 2005).  The localization of EGFR to lipid rafts was 
difficult to detect initially, as the biochemical techniques used to isolate lipid rafts initially 
involved detergent extraction.  EGFR is lost from lipid raft fractions when Triton X-100 is 
the detergent used for biochemical fractionation (Pike and Casey, 1996; Gustavsson et al., 
1999).  When other, less stringent, detergents are utilized in lipid raft isolations, EGFR 
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remains associated with lipid rafts (Roepstorff et al., 2002).  The advent of detergent-free 
methodologies of biochemical raft isolation, as well as fluorescent and EM based techniques, 
have since confirmed the localization of EGFR to lipid rafts (Couet et al., 1997b; Waugh et 
al., 1999). Most recently, Hofman and colleagues utilized fluorescence resonance energy 
transfer (FRET) microscopy to show co-localization of EGFR with lipid raft specific 
gangliosides (Hofman et al., 2008).  Mineo and colleagues have demonstrated that 
approximately 60% of EGFR is contained within low density caveolae and non-caveolae raft 
fractions (lipid rafts) in human fibroblasts (Mineo et al., 1999).  Unlike localization to the 
nucleus (Kalderon et al., 1984; Lanford and Butel, 1984), mitochondria (Omura, 1998), 
endoplasmic reticulum (Munro and Pelham, 1987), peroxisome (Gould et al., 1989), or 
caveolae (Couet et al., 1997a), there is no conserved signaling motif present in all lipid raft 
localized proteins [reviewed in (Brown, 2006)].  However, Yamabhai and Anderson utilized 
deletion and chimera constructs to map the region of EGFR that is responsible for 
localization to lipid rafts.  Their results have suggested that the second cysteine-rich region of 
EGFR is responsible for localization of this protein to lipid rafts, however, the mechanisms 
by which this region promote such localization have yet to be determined (Yamabhai and 
Anderson, 2002).   
 There is evidence that lipid rafts play both negative and positive roles in EGFR signaling.  
First, lipid rafts are inhibitory to EGFR signaling functions in that lipid raft localization of 
EGFR inhibits EGF binding (Pike and Casey, 2002; Ringerike et al., 2002; Roepstorff et al., 
2002), decreases receptor autophosphorylation (Pike and Casey, 2002; Ringerike et al., 2002; 
Westover et al., 2003), and reduces the activation of PLCγ, Gab1 and Ras (Chen and Resh, 
2002).  Subsequently, activation of MAPK and p38 MAPK is abrogated (Liu et al., 1996; 
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Anderson, 1998; Furuchi and Anderson, 1998; Schley et al., 2007).  In contrast, increased 
EGFR signaling as a result of lipid raft localization of EGFR has also been demonstrated.  
Specifically, EGFR localization to lipid rafts recruits Shc and Grb2 after EGF binding (Biedi 
et al., 2003; Ridyard and Robbins, 2003; Yang et al., 2004), activates PI3Kinase activity 
(Pike and Casey, 1996; Pike and Miller, 1998), and mediates Akt signaling (Oh et al., 2007).  
For example, in Vero cells (non-transformed monkey kidney cells), using cholesterol 
depletion via methyl-beta cyclodextrin (MBCD), Peres and colleagues found that lipid rafts 
provide a platform to bring together EGFR, PI3K, and PIP2, creating an environment 
favorable for PI3K activation, and thereby leading to Akt activation (Peres et al., 2003).  
Thus, while lipid rafts inhibit EGFR signaling to the MAPK pathway, they also facilitate 
EGFR signaling via the PI3K/Akt pathway. 
 As mentioned earlier, Src family kinases contain lipid modifications on the N-terminus.  
In the case of Fyn and Yes, this is a double modification with both myristate and palmitate, 
whereas c-Src is singly modified with myristate (Paige et al., 1993; Koegl et al., 1994; 
Shenoy-Scaria et al., 1994; Robbins et al., 1995; Yurchak and Sefton, 1995).  Src family 
kinases are capable of localizing to lipid rafts (Liu et al., 1997; Furuchi and Anderson, 1998; 
Davy et al., 2000).  While other family members are likely to associate preferentially to lipid 
rafts through their double lipid modification, c-Src contains basic residues in the unique 
domain that, in combination with the single lipid modification on c-Src, promotes interaction 
with lipid rafts (Sigal et al., 1994).  In particular, c-Src has been shown to localize to lipid 
rafts in neuronal (Mukherjee et al., 2003; Kasai et al., 2005), hematopoietic (Stoddart et al., 
2002), and madin-darby canin kidney cells (Shenoy-Scaria et al., 1994), as well as skeletal 
myoblasts (Smythe et al., 2003), murine fibroblasts (Robbins et al., 1995), and cervical and 
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lung cancer cell lines (Shenoy-Scaria et al., 1994; Arcaro et al., 2007).  Lipid rafts also play a 
dual role in Src family kinase signaling.  While lipid rafts are important in mediation of the c-
Src dependent activation of PI3K/Akt signaling in human SCLC cell lines (Arcaro et al., 
2007) and in the co-localization FAK to promote early contact signaling in cells (Baillat et 
al., 2008), lipid rafts also provide a platform for Csk binding protien (Cbp) to bring Csk, an 
endogenous inhibitor of c-Src, in close proximity to its substrate to down regulate SFK 
activity (Torgersen et al., 2001). 
E. Lipid rafts in cancer 
 In the early 1900s, long before the discovery of lipid rafts, deposition of cholesterol was 
detected in various tumor types [reviewed in (Patra, 2008)].  It has been postulated that 
increased membrane cholesterol, and thereby lipid rafts, contributes to oncogenic pathways 
of cell signaling [reviewed in (Patra, 2008)].  Neuroblastoma and melanoma cell lines have 
specifically shown the presence of lipid rafts in cancer cells (Brown and London, 1997)).  
Levels of lipid rafts have also been shown to be elevated in prostate and breast cancer cell 
lines as compared to normal cell lines(Hazarika et al., 2004; Li et al., 2006).   
 There is evidence to suggest that lipid rafts may be essential in anti-cancer therapeutics.  
Lipid rafts cluster apoptosis-inducing death receptors for anti-cancer therapeutics (Sun, 
2005).  Specifically, lipid rafts mediate the response of colon adenocarcinoma cells to the 
chemotherapeutic cisplatin, as treatment of cells with the cholesterol-sequestering reagent 
nystatin prevents Fas clustering in these cells which is necessary for the induction of 
cisplatin-induced apoptosis (Lacour et al., 2004).  Also, edelfosine, an anti-leukemic drug, 
induces apoptosis quickly in leukemia cells where activation of Fas death receptor and 
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ligand-independent recruitment of Fas into lipid rafts occurs (Gajate et al., 2000; Gajate and 
Mollinedo, 2001; Gajate et al., 2004; Gajate and Mollinedo, 2007).  Other anti-tumor drugs, 
including resveratrol (Delmas et al., 2003), aplidin (Gajate and Mollinedo, 2005), perifosine 
(Gajate and Mollinedo, 2007), and anandamide (DeMorrow et al., 2007), work via a similar 
mechanism.  Lipid rafts also facilitate the entry of chemotherapeutics into cancer cells.  For 
example, the anti-cancer drug class of alkylphospholipids have toxic effects against many 
tumor types (Unger et al., 1989; Munder and Westphal, 1990; Mollinedo et al., 1997; Ruiter 
et al., 1999) and, in 2007, van der Luit and colleagues demonstrated that all 
alkyphospholipids utilize lipid rafts for entry into cancer cells, specifically lymphoma cells, 
where they induce apoptosis (van der Luit et al., 2007).   
 While lipid rafts may be useful in targeting cancer cells with anti-cancer therapeutics, 
they also play a role in oncogenesis.  First, proliferative signaling and migration are increased 
due to the presence of lipid rafts.  In cervical cells, the known oncogenic virus HPV-16 E5 is 
found at increased levels within lipid rafts, leading to enhanced activation of oncogenic 
signaling and proliferation (Suprynowicz et al., 2008).  In breast cancer, knockdown of lipid 
raft specific Src family kinases impairs cell adhesion and cell cycle progression (Hitosugi et 
al., 2007).  Also, in migrating cells, establishment of polarity between the front and rear of 
the cell is of vital importance for cellular motility.  Manes and colleagues have demonstrated 
that lipid rafts help to establish this polarity through re- localization of proteins including 
chemokine receptors, (Manes et al., 1999).  Lipid rafts also regulate survival in cancer cells.  
Li and colleagues found that breast and prostate cancers are more sensitive to apoptotic 
stimuli after cholesterol depletion, due, in part, to decreased lipid raft content and a decrease 
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in Akt activity following that depletion of lipid rafts (Li et al., 2006).  Thus, lipid rafts 
mediate an escape from apoptosis in cancer cells.   
F. Depletion of lipid rafts 
 Both lipid rafts and caveolae require cholesterol for structure (Rothberg et al., 1990), thus 
pharmacological depletion of cholesterol has become an important tool in the study of these 
domains.  Methods commonly used to alter cholesterol levels within cells include lipid-free 
lipoprotein-mediated cellular lipid efflux (which also removes phospholipids from the 
membrane) [reviewed in (Oram and Yokoyama, 1996)], cholesterol extraction (Ohtani et al., 
1989; Kilsdonk et al., 1995; Neufeld et al., 1996), and inhibition of cholesterol biosynthesis 
(Kandutsch and Chen, 1974; Endo et al., 1976a; Alberts et al., 1980; Berkhout et al., 1996; 
Brown et al., 1998a).  Of these methodologies, cholesterol extraction and inhibition of 
cholesterol biosynthesis are important to this dissertation. 
i.  Cyclodextrins   
 The main methodology to extract cholesterol from cellular membranes is the use of 
cyclodextrins.  The first reported isolation of a cyclodextrin substance was in 1891 when 
Villivers isolated a product from Bacillus amylobacter [reviewed in (Szejtli, 1998)].  There 
are three well known cyclodextrins, alpha, beta, and gamma, as well as several less 
characterized larger cyclodextrins, which are cyclic oligosaccharides that differ in the 
number of glucopyranose units (alpha with six, beta with seven, and gamma with eight) 
[reviewed in(Szejtli, 1998)].  Cyclodextrins have a barrel like structure with hydrophillic 
sites on the outside, and a hydrophobic core.  Water molecules present in the core of 
cyclodextrins create an energetically unfavorable environment, and thus a reactive complex.  
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Molecules that are less polar than water, such as cholesterol, will be readily substituted 
within the core of the cyclodextrin molecule [reviewed in (Szejtli, 1998)].  Cyclodextrins can 
be useful to aid in drug delivery through complex formation of a drug with the molecule, or 
in research as discussed below.  While toxicities of cyclodextrins were originally reported, 
further studies have not found in vivo toxicity in most models, however, beta cyclodextrin is 
relatively unused for in vivo applications due to its high affinity toward membrane lipid 
components which could result in hemolysis [reviewed in (Szejtli, 1998)].  However, this 
high affinity for membrane lipids can be exploited for research use in vitro.  For example, the 
methyl derivative of beta-cyclodextrin (MBCD) effectively removes cholesterol from the 
plasma membrane (Kilsdonk et al., 1995; Klein et al., 1995; Yancey et al., 1996; Furuchi and 
Anderson, 1998; Hao et al., 2001; Parpal et al., 2001; Kanzaki and Pessin, 2002) thereby 
reducing the main structural component of lipid rafts and caveolae. 
ii.  Statins   
 The inhibition of cholesterol biosynthesis with statin-type drugs is another effective 
means of reducing levels of lipid rafts in cells.  Statins were originally discovered for their 
function of reducing activity of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase, 
which, in turn, abrogated cholesterol biosynthesis.  Therefore, Endo and colleagues spent two 
years and searched over 6,000 microbes for one that would inhibit this enzyme.  Penicillium 
citrinum produces an inhibitor to lipid synthesis that was a new compound, mevastatin (Endo 
et al., 1976b), which inhibited HMG CoA reductase at nanomolar concentrations (Endo et al., 
1976b).  In 1980, mevastatin was utilized in a Japanese clinical study in heterozygous 
patients with familial hypercholesterolemia.  In this study, the HMG CoA reductase inhibitor 
showed the largest reduction in plasma cholesterol of these patients ever seen (Yamamoto et 
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al., 1980).  In 1976, Merck & Co. isolated a molecule similar to mevastatin from Aspergillus 
terreus.  Lovastatin was more effective than mevastatin (Tobert et al., 1982), and was FDA 
approved in 1987 (Stossel, 2008).  However, the landmark discovery that cholesterol 
reduction via statins was associated with inhibition of cardiovascular events was not 
established until 1994 (Stossel, 2008).  This, is turn, lead to the development of other statin-
type drugs, many of which are approved and in clinical use.  Indeed, statins are one of the 
most widely prescribed drugs in America (Collisson et al., 2003) and are well tolerated in 
patients (Law et al., 2003). 
 Statins inhibit cholesterol biosynthesis by competitive inhibition of the committed step of 
isoprenoid and sterol synthesis (Fig 1.6) (Endo et al., 1976a; Corsini et al., 1995).  
Specifically, statins inhibit HMG-CoA reductase by binding to the active site, sterically 
hindering the binding of substrate to the enzyme (Istvan and Deisenhofer, 2001).  There are 
two groups of statins, including type I (lovastatin, pravastatin, simvastatin) which are all 
similar in structure to the originally isolated mevastatin, and type II (fluvastatin, cerivastatin, 
atorvastatin, and rosuvastatin) which are fully synthetic inhibitors (Istvan and Deisenhofer, 
2001).  These drugs can be ranked according to their hydrophobicity.  The most lipohilic 
statin is cerivastatin, followed by lovastatin, simvastatin, fluvastatin, atorvastatin, 
rosuvastatin, and finally pravastatin (McTaggart et al., 2001).  Only highly lipophilic statins 
are capable of permeating the cell membrane directly to affect cellular signaling (Katz, 
2005).  In addition to inhibiting the production of cholesterol, statins also promote the growth 
of new blood vessels (Kureishi et al., 2000), stimulate bone formation (Mundy et al., 1999), 
decrease oxidative modification of LDL, and have anti-inflammatory effects (Davignon and 
Laaksonen, 1999).  While there is evidence that statins may have clinical benefit in other  
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diseases including Alzheimer's, multiple sclerosis, bacteremia, and HIV (Vaughan, 2003; 
Almog et al., 2004; del Real et al., 2004; Vollmer et al., 2004), the information pertinent to 
this dissertation is the benefit of statins in cancer.  Interestingly, cancer cells, as compared to 
normal cells, generally express elevated levels of HMG-CoA reductase and low-density lipid 
receptor (LDL), making them more sensitive than normal cells to depletion of HMG-CoA 
reductase activity (He et al., 1997; Liao, 2002).   
 As a single agent, statins have shown anti-cancer effects in vitro.  Specifically, in 
preclinical models, statins have anti-cancer effects as single agents in breast (Campbell et al., 
2006; Kotamraju et al., 2007), melanoma (Depasquale and Wheatley, 2006; Glynn et al., 
2008), lung (Glynn et al., 2008), lymphoma (Cafforio et al., 2005), myeloma (van de Donk et 
al., 2003), brain (Jones et al., 1994; Girgert et al., 1999; Macaulay et al., 1999), prostate 
(Sivaprasad et al., 2006), renal (Woodard et al., 2008) and pediatric leukemia, 
rhabomyosarcoma  and medulloblastoma (Dimitroulakos et al., 2001).  However, the 
epidemiological data on the use of statins as a singular agent in cancer prevention are mixed 
(Olsen et al., 1999; Blais et al., 2000; Coogan et al., 2002; Kaye et al., 2002; Beck et al., 
2003; Cauley et al., 2003; Boudreau et al., 2004; Graaf et al., 2004; Katz, 2005).  These 
results are confounded by the lack of information on the type of statin used or by the 
reporting of the use of pravastatin, a hydrophilic statin that has no known anti-cancer activity 
in vitro (Campbell et al., 2006).  When the hydrophobicity of the statin drug is taken into 
account, there is a 47% reduction in the relative risk of colorectal cancer (Poynter et al., 
2005) and an 18% reduction in breast cancer incidence (Cauley et al., 2006).  Also, 
hydrophobic statins may act to prevent cancer recurrence.  For example, post-diagnosis statin 
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use is associated with decreased risk of both breast and prostate cancer recurrence (Kwan et 
al., 2008; Gutt et al., 2010; Hamilton et al., 2010).    
In combination therapy, there is more hope for statins as anti-cancer drugs.  In preclinical 
in vivo studies, lovastatin enhances the response to chemotherapy in a mouse model of 
melanoma (Feleszko et al., 1998; Feleszko et al., 2002).  Also, clinical studies have 
suggested that statin drugs may increase sensitivity to chemotherapy or radiotherapy at 
therapeutic doses in prostate, rectal, and hepatocellular carcinomas (Kawata et al., 2001; Katz 
et al., 2005).  Statins also improve the efficacy of small molecule tyrosine kinase inhibitors in 
glioblastoma cells (Cemeus et al., 2008).  In addition, Mantha and colleagues have shown 
that the effects of gefitinib, an EGFR TKI, can be potentiated by large doses of statins in 
head and neck squamous cell carcinoma, non-small cell lung carcinoma, and cervical 
carcinomas (Mantha et al., 2005).  However, the doses used in this study were far above 
selective concentrations for these inhibitors, and, as such, may be inhibiting a myriad of other 
proteins.   
 Statins are a widely used research tool for the reduction of lipid rafts.  As mentioned 
earlier, lipid rafts and caveolae depend on cholesterol for structure.  Thus, the inhibition of 
cholesterol biosynthesis by statins can reduce the amount of membrane cholesterol, thereby 
reducing lipid rafts (Endo et al., 1976a; Alberts et al., 1980).  However, statins are not 
necessarily specific for cholesterol.  As seen in figure 1.6, statins may also inhibit isoprenoid 
synthesis.  Thus, while statins may have a primary effect on cholesterol, they may also inhibit 
protein prenylation leading to other cellular effects.  Generally speaking cholesterol content 
is unaffected when statin treatment decreases protein prenylation (Ghittoni et al., 2005; 
Paintlia et al., 2008), and effects deemed to be related to protein prenylation are typically 
 55 
seen after short duration (under 24 hour) statin treatment, whereas effects requiring longer 
treatment times are generally indicated as cholesterol based effects (deCathelineau and 
Bokoch, 2009).  Therefore, the use of drugs, such as NB-598, that inhibit downstream 
effectors in the cholesterol biosynthesis pathway (Fig. 1.6), should be utilized to tease out the 
effects of statins that are based on depletion of prenylation versus cholesterol (Horie et al., 
1990).  
1.4. Breast Cancer 
 Breast cancer is currently one of the leading causes of cancer death in American women 
[reviewed in (Maughan et al., 2010)].  Approximately one in eight women will be afflicted 
with breast cancer in her lifetime [reviewed in (Maughan et al., 2010)].  As such, an 
understanding of the molecular mechanisms of breast cancer, and research on how to 
effectively treat these cancers, is of vital importance.  In 2000 and 2001, Perou and Sorlie 
and colleagues established distinctive molecular sub-types of breast cancers (Perou et al., 
2000; Sorlie et al., 2001).  These genetic classifications were found to correlate well with 
clinical implications of these diseases (Sorlie et al., 2001). 
A. Molecular sub-types of breast cancer   
 The first sub-type, normal-like, contained tumor samples as well as normal breast 
specimens that are typified by expression of genes that are "normally" expressed in basal 
epithelial cells and adipose cells (Perou et al., 2000).  
 The second sub-type, luminal breast cancers, can be further stratified into two groups, 
luminal A and luminal B (Sorlie et al., 2001).  Luminal A breast cancers are approximately 
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45% positive for the estrogen receptor (ER) alpha and express high levels of luminal cell 
keratins 8/18 (Perou et al., 2000), but have low or no expression of HER2.  Luminal A breast 
cancers have the best prognosis (Sorlie et al., 2001).  Luminal B breast cancers express many 
of the same components as luminal A (including ER), and have expression of HER2 (Sorlie 
et al., 2001).  As such, luminal B-type breast cancers have a less favorable outcome than 
luminal A-type breast cancers (Sorlie et al., 2001).  While chemotherapeutics and surgery 
with radiation are standards of care in the breast cancer world, targeted therapeutics have 
become more commonly utilized [reviewed in (Maughan et al., 2010)].  Indeed, after 
approval of selective estrogen receptor modulators (SERMs), which are utilized for treatment 
of ER positive luminal breast cancers, the mortality rates of US women with breast cancer 
have declined significantly (Altekruse SF, 1975-2007) suggesting that targeted therapeutics 
may be more beneficial than previous therapies.  Specifically, tamoxifen, an estrogen 
receptor antagonist, was the first SERM to be approved for use clinically.  Currently, 
tamoxifen is used either alone or in sequence with an aromatase inhibitor for the treatment of 
ER positive breast cancers [reviewed in (Maughan et al., 2010)].  Aromatase inhibitors have 
also shown clinical efficacy in luminal breast cancers, and three have been approved for use 
alone or in sequence with tamoxifen including anastrozole, exemestane, and letrozole (Baum 
et al., 2003; Coombes et al., 2004; Thurlimann et al., 2005).   
 The third sub-type, HER2 positive breast cancer, is characterized by expression of the 
EGFR family member HER2, and GRB7, with low or no estrogen receptor expression (Perou 
et al., 2000).  These cancers have a worse prognosis than luminal breast cancers, however, a 
better prognosis than basal-type breast cancers (described below) (Sorlie et al., 2001). 
Trastuzumab (Trastuzumab), a monoclonal antibody inhibitor of the HER2 receptor, has 
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been clinically approved for the treatment of HER2+ breast cancer.  Trastuzumab targets 
HER2 by binding to domain IV of the extracellular domain of the receptor and activates 
immune effecter cells to the ErbB2-overexpressing tumor (Sliwkowski et al., 1999; Clynes et 
al., 2000; Cho et al., 2003)  The use of trastuzumab has significantly improved the disease-
free and overall survival rates for women with HER2+ breast cancer (Romond et al., 2005; 
Smith et al., 2007).  Recently, a dual HER2/EGFR inhibitor, lapatinib, was approved for the 
treatment of HER2+ breast cancer (Ryan et al., 2008).  
 The final breast cancer sub-type is basal-type.  These tumors represent approximately 15-
20% of all breast cancers and are defined by elevated expression of cytokeratin 5 and 17, 
laminin, and fatty acid-binding protein 7, and lack of estrogen receptor expression (Perou et 
al., 2000; Millikan et al., 2008).  Although basal-type breast cancers do have a high 
chemotherapy response rate (45%), they remain associated with the worst patient prognosis 
(Sorlie et al., 2001; van de Rijn and Rubin, 2002; Rouzier et al., 2005; Fulford et al., 2006; 
Laakso et al., 2006).  Basal-type breast cancers tend to be triple-negative, in that they do not 
express ER, progesterone receptor (PR), or HER2 [reviewed in (Seal and Chia, 2010)].  As 
such, no targeted therapeutic has been approved for the treatment of this type of breast 
cancer.  Thus, the current standard of care for basal-type breast cancers is surgery with 
radiation and/or chemotherapy [reviewed in (Chen and Russo, 2009)].  Taking into account 
the decreased mortality rates after approval of targeted therapeutics for luminal and HER2 
positive breast cancers, it would be advantageous to develop targeted therapeutics for basal-
type breast cancers, which, as mentioned before, are the worst breast cancers in terms of 
prognosis. 
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B. EGFR in breast cancer 
 HER2 is probably the most widely known EGFR family member to be implicated in 
breast cancer.  Initially, HER2 was found to be closely related to the transforming oncogenes 
neu and c-erb-B2 (Shih et al., 1981; Schechter et al., 1984; Coussens et al., 1985; Schechter 
et al., 1985).  Much like these oncogenes, over-expression of HER2 in transgenic mouse 
models induces transformation in the mammary gland (Pierce et al., 1991; Guy et al., 1994b; 
Eccles, 2001).  It was later discovered that the HER2/neu oncogene was amplified in breast 
cancer cell lines and tissue samples (King et al., 1985; Slamon et al., 1987).  Specifically, 
amplification of HER2 is seen in 20-30% of all breast cancers and over-expression of HER2 
correlates with poor clinical outcome (Slamon et al., 1987; Ross et al., 1998; Menard et al., 
2001).    More recently, Perou and colleagues discovered that HER2-positive breast cancers 
share a similar genetic profile (Perou et al., 2000).  Due, in part, to the high level of HER2 
expression, inhibitors to HER2, such as trastuzumab and lapatinib, have been developed.  
These inhibitors increase patient survival by increasing the time to progression of HER2 
positive breast cancers (Slamon and Pegram, 2001). 
EGFR is expressed in 14-91% of all breast cancers (Sainsbury et al., 1987; Klijn et al., 
1992; Ferrero et al., 2001; Tsutsui et al., 2002).  This wide range is most likely due to the 
myriad of techniques utilized to analyze breast cancer specimens for EGFR, including 
autoradiography, immunohistochemistry, immunoezymatic assay, and gene transcript 
analyses.  There are conflicting data on the quality of EGFR expression as a prognostic 
indicator in breast cancer (Rampaul et al., 2005).  These conflicts are due to studies being 
restricted based on small cohort size, short follow-up times, variable adjuvant therapies, and 
differing detection methodologies.  For example, in a study performed by Fox and colleagues 
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370 patients were examined over a period of eighteen months.  Utilizing a ligand-binding 
assay to detect EGFR, no correlation was reported between EGFR expression and size, stage, 
or grade of tumor.  However, multivariate analysis of their data revealed EGFR as a 
prognostic indicator for relapse-free survival (Fox and Das, 1979).  A more recent study by 
Tsuitsu and colleagues utilized immunohistochemistry to detect EGFR in 1029 cases of 
breast cancer over forty-six months and found that EGFR was an independent prognostic 
factor (Tsutsui et al., 2002).  This study, as well as several other large studies, has shown that 
EGFR over-expression is a negative prognostic variable in breast cancer (Bolla et al., 1990; 
Toi et al., 1991; Jardines et al., 1993).  More specifically, EGFR is over-expressed in 60% of 
basal-type breast cancers (Livasy et al., 2006; Siziopikou and Cobleigh, 2007).   
 EGFR contributes to the normal development of the mammary gland and deregulation of 
EGFR is a contributing factor for breast cancer (Hanahan and Weinberg, 2000; Harari et al., 
2007).  Unlike brain and lung cancers (as described earlier), deregulation of EGFR through 
activating mutations is rare in breast cancer (Rae et al., 2004; Weber et al., 2005).  Genetic 
amplification of EGFR occurs in approximately 6% of breast cancers (Kersting et al., 2004; 
Bhargava et al., 2005; Milanezi et al., 2008), however; over-expression at the protein level 
seems to be the primary mechanism by which EGFR becomes deregulated.  Such over-
expression is controlled through transcriptional up-regulation and/or protein stabilization 
(Fox and Harris, 1997). 
Other mechanisms that result in deregulated EGFR signaling include increased ligand 
expression and receptor crosstalk (Arteaga, 2002; Goswami et al., 2005; Milanezi et al., 
2008). Elevated ligand expression is one mechanism by which EGFR is deregulated in breast 
cancer leading to the transformed phenotype.  Specifically, over-expression of TGFα, an 
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EGFR ligand, in transgenic mouse models leads to a hyperplastic phenotype, as well as 
tumor formation in the mammary gland (Matsui et al., 1990; Sandgren et al., 1990; Sandgren 
et al., 1995).  TGFα promotes the growth of breast cancer cell lines, and is expressed at 
higher levels in estrogen receptor negative breast cancers (Perroteau et al., 1986; Bates et al., 
1988; Salomon et al., 1990). Cross-breeding between TGFα and HER2 over-expressing mice 
results in synergistic tumorigenesis due to increased EGFR transactivation of HER2 (Muller 
et al., 1996).  This particular EGFR ligand is expressed in 40-70% of primary and metastatic 
breast tumors (Bates et al., 1988; Dublin et al., 1993; Murray et al., 1993; Ciardiello et al., 
1996).  AREG is also expressed in breast cancer cell lines, although there is evidence that 
ER-positive breast cancers express increased levels of AREG as compared to ER-negative 
cell lines (Plowman et al., 1990).  EGF is also upregulated in breast cancer cell lines where it 
induces PI3K activity resulting in proliferation (Harris, 1989; Atalay et al., 2003).  Receptor 
crosstalk is also capable of inducing EGFR deregulation.  G-protein coupled receptors 
activate EGFR-dependent signaling.  Specifically, Andreev and colleagues have utilized 
genetic knockout models to show that c-Src and Pyk2 (another protein tyrosine kinase) 
mediate activation of EGFR by G-protein coupled receptors leading to activation of MAPK 
signaling (Andreev et al., 2001).  c-Met-dependent activation of EGFR has also been noted in 
breast cancer (Mueller et al., 2008; Mueller et al., 2010).  In particular, c-Met is responsible 
for EGFR-kinase independent phosphorylation of EGFR in breast cancer cells.  Co-treatment 
of these cells with EGFR and c-Met inhibitors resulted in abrogation of EGFR 
phosphorylation and inhibition of breast cancer cell growth (Mueller et al., 2008). 
EGFR expression is twice as frequent in ER/PR negative breast cancer than positive 
(Klijn et al., 1992), and, in fact, cellular proliferation in estrogen receptor negative breast 
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cancers is dependent on EGFR signaling (Biswas et al., 2001). When EGFR and estrogen 
receptor are co-expressed, it is thought that the signaling pathways of these two molecules 
may be intertwined.  For example, EGFR activation results in phosphorylation and activation 
of nuclear estrogen receptor.  Also, plasma-membrane localized estrogen receptor is able to 
hijack the EGFR signaling cascade for signal transduction (Levin, 2003).  EGFR may also be 
involved as a mechanism of resistance to endocrine therapy (Yarden et al., 1996; Yarden et 
al., 2001).  Specifically, estrogen-receptor positive breast cancer cell lines with acquired 
resistance to tamoxifen, an estrogen receptor antagonist, have increased levels of EGFR and 
HER2 expression as compared to the parental cell line (McClelland et al., 2001; Knowlden et 
al., 2003).  Also, treatment naive breast cancers that have elevated EGFR and/or HER2 
expression are more likely to be resistant to estrogen directed therapeutics as compared to 
low expressing cells (Gee et al., 2001).  As EGFR and HER2 are increased on tamoxifen 
resistant breast cancers, lapatinib, a dual EGFR/HER2 inhibitor (described earlier), has been 
used in preclinical studies in an effort to overcome such resistance (Chu et al., 2005).   
 As described previously, both monoclonal antibodies and small molecule tyrosine kinase 
inhibitors directed against EGFR have been designed and tested in clinical trials.  In breast 
cancer, however, the results have been less than hopeful.  While lapatinib, a small molecule 
was approved in 2007 in HER2 positive breast cancer in patients that have failed trastuzumab 
therapy (Ciardiello et al., 1996; Geyer et al., 2006), lapatinib has failed to show efficacy in 
HER2 negative breast cancers, including those of the basal sub-type (Finn et al., 2007; Di 
Leo et al., 2008).  The monoclonal antibody cetuximab has shown promise in vitro, however, 
clinical trials combining cetuximab with chemotherapeutics have shown negative results 
(Modi et al., 2006; Shiu et al., 2008; Burness et al., 2010).  Other small molecule EGFR TKIs 
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have been tested in clinical trial, however, most ER-negative breast cancers fail to respond to 
EGFR-specific tyrosine kinase inhibitors [reviewed in (Atalay et al., 2003)]. 
C. c-Src in breast cancer 
 c-Src expression and activity are elevated in breast tumor tissue and cell lines as 
compared to matched non-tumor tissue (Ottenhoff-Kalff et al., 1992; Verbeek et al., 1996; 
Belsches-Jablonski et al., 2001; Reissig et al., 2001).  Furthermore, inhibition of Src kinase 
activity results in decreased proliferation, adhesion, and invasion of breast cancer cells in 
vitro (Finn et al., 2007; Green et al., 2009).  c-Src expression correlates with breast cancer 
recurrence, and with poor clinical outcome (Aligayer et al., 2002; Wilson et al., 2006).  c-Src 
effectively promotes the mitogenic effects of estrogen (Shupnik, 2004), and as such, has been 
implicated in the tumorigenic phenotype of estrogen receptor positive breast cancers (Herynk 
et al., 2006).  c-Src kinase activity is elevated in in vitro models of tamoxifen resistant breast 
cancers, independent of its gene or protein level (Hiscox et al., 2006).  In these tamoxifen 
resistant cells, inhibition of c-Src kinase activity with a small molecule tyrosine kinase 
inhibitor is sufficient to abrogate invasion and migration (Hiscox et al., 2006), suggesting a 
role for c-Src in resistance to estrogen targeted therapies.  c-Src has also been implicated in 
the metastatic process in breast cancer.  Kinase activity of c-Src is implicated in the highly 
metastatic phenotype of HER2-type breast cancer [reviewed in (Kim et al., 2010)].  Also, 
there is an established association between c-Src and metastases to the bone and other sites 
(Myoui et al., 2003; Rucci et al., 2006; Jallal et al., 2007).   
 The interaction between EGFR and c-Src is apparent in breast cancer.  As mentioned 
earlier, co-overexpression of EGFR and c-Src occurs in a subset of human breast cancer cell 
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lines and tumor tissues (Maa et al., 1995).  The interaction between EGFR and c-Src induces 
oncogenesis through increased EGFR signaling (Luttrell et al., 1988; Wilson et al., 1989; 
Maa et al., 1995; Biscardi et al., 1998; Olayioye et al., 1999).  Inhibition of c-Src kinase 
activity reduces EGFR-mediated proliferation of breast cancer cells (Wilson et al., 1989; 
Roche et al., 1995).  c-Src also plays a role in transactivation of EGFR in breast cancer.  For 
example, activation of EGFR by urokinase-type plasminogen activator (uPA) is c-Src-
dependent, and leads to breast cancer invasion (Guerrero et al., 2004). 
 Due to the apparent role of c-Src in breast cancer growth, drug resistance, and metastasis, 
tyrosine kinase inhibitors of c-Src are currently in clinical trial.  Dasatinib, one such c-Src 
tyrosine kinase inhibitor, is undergoing trials for basal-type breast cancers, as it is efficacious 
in preclinical models (Finn et al., 2007; Huang et al., 2007).  Also, as c-Src expression alone 
is insufficient to cause transformation (Shalloway et al., 1984), c-Src inhibitors are also being 
explored in combination therapies with HER family inhibitors, VEGF inhibitors, PDGFR 
inhibitors, and chemotherapeutics (Boudny and Nakano, 2003; Griffiths et al., 2004; Hatake 
et al., 2007). 
D. Lipid rafts and breast cancer 
Lipid rafts play a role in the growth and survival of breast cancer cells.  Findings 
from multiple studies have indicated a role for lipid rafts in the growth of estrogen receptor 
positive breast cancer (Auricchio et al., 1996; Chambliss et al., 2000; Kelly and Levin, 2001; 
Marquez et al., 2001; Razandi et al., 2002; Li et al., 2003; Song et al., 2004; Marquez et al., 
2006).  Also, disruption of lipid rafts by cholesterol depletion results in increased sensitivity 
to apoptotic stimuli due to a decrease in Akt signaling in breast cancer cells, as well as 
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epidermoid carcinoma and prostate cancer cells (Li et al., 2006).  Lipid rafts also play a role 
in migration and metastasis in breast cancer.  Manes and colleagues have shown a role for 
lipid rafts in migration of breast adenocarcinoma cell lines.  Specifically, the establishment of 
front-rear polarity after growth factor stimulation, which is required for chemotaxis of cancer 
cells, is dependent on lipid rafts (Manes et al., 1999).  Furthermore, EGF-induced chemotaxis 
(Liu et al., 2007), the formation of invadopodia, and extracellular matrix degradation by 
breast cancer cell lines are lipid raft dependent (Yamaguchi et al., 2009).  Together, these 
results suggest a role for lipid rafts in metastasis of breast cancer.   
 Epidemiological data regarding the use of statins (reviewed earlier in this chapter) as 
singular agents in breast cancer prevention or treatment are mixed (Beck et al., 2003; Cauley 
et al., 2003; Kwan et al., 2008).  However, in regards to breast cancer recurrence, the data on 
post-diagnosis statin use are positive.  Specifically, a 2007 study by Kwan and colleagues 
found that starting lipophilic statin treatment after diagnosis resulted in a significant decrease 
in the risk of breast cancer recurrence (Kwan et al., 2008).   
Preclinical data for the use of statins as part of combinatorial therapies in breast cancer 
has also gained support (Katz, 2005).  For example, HER2, a member of the EGFR family of 
receptor tyrosine kinases, is expressed in approximately 30% of breast cancer, and as such, 
HER2 has been an attractive therapeutic target in breast cancer (Slamon et al., 1987; Pierce et 
al., 1991).  However, the response rate for trastuzumab, a clinically approved HER2 
inhibitor, is only 34%, indicating de novo resistance to the therapeutic (Cardoso et al., 2002; 
Vogel et al., 2002).  HER2 has been demonstrated to localize to lipid rafts (Harder et al., 
1998b; Nagy et al., 1998; Nagy et al., 2002), and modulation of lipid rafts through fatty acid 
synthase inhibition has been shown to act synergistically with trastuzumab in breast cancer 
 65 
cells (Menzo et al., 1993).  These data suggest that statins may be an effective therapeutic 
agent in breast cancer. 
1.5 Significance 
 Breast cancer is currently one of the leading causes of cancer death amongst American 
women.  As described, breast cancer is subdivided into molecular sub-types by the genetic 
signature of the tumor.  Of those, basal-type breast cancers have the fewest treatment options.  
Unlike luminal and HER2+ breast cancers, there are  no currently approved targeted 
therapeutics for basal-type breast cancers, therefore, cytotoxic chemotherapy regimens, along 
with surgery and radiation, remains the standard of care.  After the approvals of tamoxifen 
and trastuzumab, the mortality rates of American women with breast cancer declined, 
suggesting that approval of targeted therapeutics may be the key to lowering the rate of death 
from breast cancer.  Identification of a targeted therapy for basal-type breast cancers is 
therefore of the utmost importance.  Nearly 60% of basal-type breast cancers express the 
EGFR.  As such, EGFR may be an attractive therapeutic target in this cancer sub-type.  
However, these breast cancers fail to respond to EGFR tyrosine kinase inhibition.  Thus, the 
work herein seeks to discover mechanisms of resistance to EGFR tyrosine kinase inhibition.  
Levels of cholesterol rich lipid rafts are up-regulated in breast cancer cells as compared to 
normal mammary epithelial cells.  Depletion of cholesterol in breast cancer cells results in 
increased sensitivity to apoptotic stimuli, suggesting that, due to this elevation breast cancer 
cells are dependent on signaling within lipid rafts.  In support of this idea, retrospective 
studies of women with breast cancer found that women who took statins to lower cholesterol 
saw a decrease in the recurrence of their cancer compared to women who did not take statins.  
c-Src, a non-receptor tyrosine kinase, also localizes to these lipid rafts to promote signaling 
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pathways.  c-Src and EGFR interact in breast cancer, and their interaction has been 
implicated in transformation and tumorigenesis.  c-Src is capable of phosphorylating EGFR 
on novel sites, which lead to increased association of signaling molecules with the receptor.  
Thus, we hypothesized that the interaction of these two proteins within lipid rafts may 
mediate resistance to EGFR tyrosine kinase inhibition in breast cancer cells. 
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Chapter 2 
2. Materials and Methods 
2.1 Reagents - Gefitinib was provided by AstraZeneca (Wilmington, DE).  All other reagents 
were purchased from Sigma or VWR unless otherwise noted. 
2.2 Cell lines - The SUM series of cell lines were obtained from Dr. Stephen Ethier (Wayne 
State University/Karmanos Cancer Institute, Detroit, MI).  The remaining cell lines were 
purchased from ATCC (Manassas, VA).  The growth conditions for each cell line are as 
follows.  SUM 52, SUM 149, SUM 159, SUM 185, SUM 225, and SUM 229 cells are grown 
in 5%IH media (Ham’s F-12 media, supplemented with 5% FBS, 1µg/ml hydrocortisone, and 
5µg/ml insulin).  SUM 1315 cells are grown in 5%IE media (Ham’s F-12 media, 
supplemented with 5% FBS, 10ng/ml EGF, and 5µg/ml insulin).  SUM 44 and SUM 190 
cells are grown in SFIH media (Ham’s F-12 media, supplemented with 1µg/ml 
hydrocortisone, 5µg/ml insulin, 5mM ethanolamine, 10mM HEPES, 5µg/ml transferrin, 
10nM triiodo-thyronine, 50µM sodium selenite, and 5% BSA).  SUM 102 and MCF10A cells 
are grown in SFIHE media (Ham’s F-12 media, supplemented with 1µg/ml hydrocortisone, 
5µg/ml insulin, 10ng/ml EGF, 5mM ethanolamine, 10mM HEPES, 5µg/ml transferrin, 10nM 
triiodo-thyronine, 50µM sodium selenite, and 5% BSA).  MCF7, SKBr3, T47D, MDA-MB-
231 and MDA-MB-468 cells are grown in DMEM+10%FBS media (DMEM media, 
supplemented with 10% FBS).  BT-20 cells are grown in Eagles+NEAA media (Eagle’s 
MEM with 2mM L-glutamine and Earle’s BSS adjusted to contain 1.5g/L sodium 
bicarbonate, 0.1mM non-essential amino acids, 1mM sodium pyruvate, and 10% FBS).  BT-
549 cells are grown in RPMI+L-GLUT(2mM) media (RPMI-1640, supplemented to contain 
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1.5g/L sodium bicarbonate, 4.5g/L glucose, 10mM HEPES, 1mM sodium pyruvate, 0.023 
IU/ml insulin, and 10% FBS).  HCC 1937 and HCC 1954 cells are grown in RPMI+L-GLUT 
media (RPMI-1640 media with 2mM L-glutamine adjusted to contain 1.5g/L sodium 
bicarbonate, 4.5g/L glucose, 10mM HEPES, 1mM sodium pyruvate, and 10% FBS).  The 
SUM and HCC cells are cultured in 10% CO2 and the remaining cells are cultured in 5% 
CO2.  All media are supplemented with 2.5 µg/ml amphotericin B and 25 µg/ml genatimycin.  
Information regarding the isolation and estrogen or HER2 receptor status of these cell lines 
can be found in Table 2.1. 
2. 3 Immunoblotting – Breast cancer cell lines were plated at a density of 1X106 cells per 
100-mm dish and grown for 48 h. Cells were treated with indicated reagents (1.0 µM 
gefitinib for 30 min in serum free media, and/or 1 µM lovastatin 72 h, and/or 1.0 µM 
dasatinib 2 h in serum free media).  Media was aspirated, and then cells were washed in 1X 
PBS containing 1 µM sodium orthovanadate.  One milliliter of 1X PBS containing sodium 
orthovanadate was again added, and cells were scrapped and placed into a conical.  Cells 
were pelleted by centrifugation, and then lysed in CHAPs lysis buffer [10 mM CHAPs, 50 
mM Tris (pH 8.0), 150 mM NaCl, and 2 mM EDTA with 10 µM sodium orthovanadate and 
1x protease inhibitor cocktail].  Lysates were then centrifuged for 10 min at a speed of 
18,000Xg at 4 degrees Celsius.  Bradford protein assay was then performed.  For 
immunoblotting, 10 to 100 µg of protein lysate were separated by SDS-PAGE (200 V for 30 
min) and transferred to Immobilon P. Membranes were blocked in either 5% nonfat dry milk 
for 1 h at 25°C or overnight at 4°C (phospho-MAPK), or 5% BSA overnight at 4°C 
(phospho-SrcY416).   Membranes were probed with EGFR (Cell Signaling Technology, 
Danvers, MA, 1:1000), Akt (Cell Signaling Technology, Danvers, MA, 1:1000), MAPK 
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Cell Line Isolation ER Status HER2 Status References 
HMEC Primary    
MCF10A 
Immortalized 
normal mammary 
cell line 
  
(Soule et al., 1990) 
SUM 44 Pleural effusion + + (Forozan et al., 1999) 
SUM 52 Pleural effusion - + (Turner et al., 1993; Forozan et al., 1999) 
SUM 102 Intraductal 
carcinoma - - 
(Forozan et al., 1999; Bertucci et al., 2005; 
Anders and Carey, 2008) 
SUM 149 
Invasive ductal 
carcinoma 
(inflammatory) 
- - 
(Forozan et al., 1999; Bertucci et al., 2005) 
SUM 159 Anaplastic 
carcinoma - - (Forozan et al., 1999) 
SUM 185 Pleural effusion - + (Forozan et al., 1999; Zhou et al., 2004) 
SUM 190 
Invasive ductal 
Carcinoma 
(inflammatory) 
+ + (Forozan et al., 1999) 
SUM 225 
Chest wall 
recurrence of 
ductal carcinoma 
in situ 
- + (Forozan et al., 1999) 
SUM 229 Pleural effusion - - (Forozan et al., 1999) 
SUM 1315 
Skin metastasis 
of infiltrating 
ductal carcinoma 
- + (Forozan et al., 1999) 
MCF7 Pleural effusion + - (Soule et al., 1973; Levenson and Jordan, 
1997; Ross and Fletcher, 1998) 
T47D Pleural effusion + - (Keydar et al., 1979; Judge and 
Chatterton, 1983) 
BT 20 Carcinoma - - (Keyomarsi and Pardee, 1993) 
BT 474 Invasive ductal 
carcinoma + + (Lasfargues et al., 1978) 
BT 549 Invasive ductal 
carcinoma 
- 
- 
(Lasfargues et al., 1978) 
SKBR3 Pleural effusion - + (Trempe, 1976) 
HCC 1937 Primary ductal 
carcinoma 
- 
- 
(Gazdar et al., 1998; Tomlinson et al., 
1998) 
HCC 1954 Invasive ductal 
carcinoma 
- + (Gazdar et al., 1998) 
MDA-MB 231 Pleural effusion - - (Cruciger et al., 1976) 
MDA-MB 468 Pleural effusion - - (Cailleau et al., 1978) 
Table 2.1: Isolation properties and estrogen receptor/HER2 receptor status of cell lines 
used.  
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 (Cell Signaling Technology Danvers, MA, 1:500), phospho-Akt (Ser473; Cell Signaling 
Technology, Danvers, MA, 1:2000), phospho-ERK1/2 (MAPK) (Invitrogen, Carlsbad, CA, 
1:500), phospho-SrcY416 (Cell Signaling Technology, Danvers, MA, 1:1000), c-Src (Cell 
Signaling Technology, Danvers, MA, 1:500),  transferrin receptor (Invitrogen, Carlsbad, CA, 
1:2000), or flotillin (BD Biosciences, San Jose, CA, 1:1000) antibodies. All antibodies were 
incubated overnight at 4°C, except for phospho-MAPK and phospho-SrcY416 (2 h at room 
temperature). Membranes were washed with TBS + 0.1% Tween 20 three times for 10 min, 
followed by incubation with corresponding secondary antibody and another series of three 
washes. Incubation with enhanced chemiluminescence (GE Healthcare Buckinghamshire, 
UK) was followed by exposure to film. Experiments were repeated at least three times and 
quantified using densitometry (NIH Image).  
2.4 In vitro kinase assays – Under normal growth conditions, 1 million cells were grown for 
48 h. Cells were washed in 2X in PBS and lysed in solubilization buffer (50 mM HEPES, pH 
7.5, 10% glycerol, 0.5% Triton X-100, 1.5 mM MgCl2, 1 mM EGTA, 1 mM PMSF, 50 
µg/ml aprotinin, and 400 nM vanadate).  Lysates were cleared by centrifugation, quantified, 
and 0.5 mg of protein was immunoprecipitated using EGFR antibodies (mab108, M. Weber, 
University of Virginia, Charlottesville, VA).  Antibody bound proteins were collected using 
40 µl protein A beads (Upstate Biotechnology, Lake Placid, NY) and washed three times in 
HTG buffer (20 mM HEPES, pH 7.5, 0.1% Triton X-100, and 10% glycerol).  For the kinase 
assay, 40 µl HTG buffer, 4 µl MnCl2 (of 100 mM stock), and 10 µCi 32P-γATP were 
incubated with the immunoprecipitates for 10 min at 30ºC.  The beads were pelleted and the 
supernatant removed and discarded.  The beads were washed twice with solubilization buffer 
and once with PBS.  40 µl of sample buffer was added to the pellets, the samples were boiled, 
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and proteins were separated using 7.5% SDS-PAGE.  The gels were dried and exposed to 
film.  Each experiment was repeated at least three times. 
2.5 ShRNA downregulation of EGFR - To downregulate EGFR expression we utilized 21 
EGFR-directed shRNA lentiviral constructs from OpenBiosystems (TRCN0000039633, 
TRCN0000039634, TRCN0000039635, TRCN0000039636, TRCN0000039637, 
TRCN0000010329, TRCN0000121067, TRCN0000121068, TRCN0000121069, 
TRCN0000121070, TRCN0000121071, TRCN0000121202, TRCN0000121203, 
TRCN0000121204, TRCN0000121205, TRCN0000121206, TRCN0000121327, 
TRCN0000121328, TRCN0000121329, TRCN0000121330, TRCN0000121331  ). Three 
constructs were chosen based on their specific reduction in EGFR expression in our cell 
models. Specifically, EGFR shRNA #1 = TRCN0000121071 
(CCGGCCGTGGCTTGCATTGATAGAACTCGAGTTCTATCAATGCAAGCCACGGTT
TTTG), EGFR shRNA #2 = TRCN0000121329 
(CCGGCAGCATGTCAAGATCACAGATCTCGAGATCTGTGATCTTGACATGCTGTT
TTTG), and EGFR shRNA #3 = TRCN0000121204 
(CCGGCCTCCAGAGGATGTTCAATAACTCGAGTTATTGAACATCCTCTGGAGGTT
TTTG) showed pertinent effects in our model system.  The lentiviruses were packaged using 
a third generation lentiviral packaging system developed by Didier Trono and colleagues 
(Lausanne, Switzerland) and purchased from Addgene (Dull et al., 1998).  Specifically, 
Addgene plasmids pMLDg/pRRE (12251), pRSV-Rev (12253), and pMD2.G (12259) were 
transfected into HEK293T cells with the lentiviral vectors containing the shRNAs using 
FUGENE6 (Roche).  Cellular supernatant was collected on days 2 and 3 after transfection, 
pooled, and filtered.  The lentivirus was titered using HEK293T cells in a 24-well plate, 
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incubated with increasing volumes (10 to 100 µl) of virus with 8 µg/ml polybrene and 
selected for via the puromycin selection on the lentiviral vector (1 µg/ml puromycin).  
Colonies were visualized and used to compare viral preps and between viruses for consistent 
titers used in experiments.  To determine the efficacy of EGFR downregulation in breast 
cancer cells, equal multiplicity of infection (MOI) of EGFR shRNA virus (or a non-silencing 
control) was added to the indicated cells in the presence of 8 µg/mL polybrene.  Four days 
later, cell lysates were prepared, separated by SDS-PAGE, and immunoblotted using EGFR 
antibodies as described above.  EGFR was considered knocked down if the densitometric 
values of at least three experiments demonstrated at least a 50% reduction of EGFR protein 
expression.  
 To determine if EGFR downregulation affects cell proliferation in breast cancer cells, the 
indicated cells were incubated with equal MOI of virus and allowed to proliferate for three 
days.  1 µg/ml of puromycin was then added to media to select for cells that contain the 
lentivirus and cells were allowed to proliferate for an additional eight days.  The number of 
cells was quantified using a Beckman Coulter Counter.  Briefly, media was aspirated and 
plates were washed with 1 ml 1X PBS.  Cells were then incubated with 500 µL 
Hepes:MgCl2 solution (0.01 M Hepes, 0.015 M MgCl2 for five minutes, followed by 75 µL 
ZAP (Ethyl hexadecyldimethylammonium bromide) for 10 min.  This solution was then 
added to 9.5 mL of isoton solution and counted using a coulter counter.  Each experiment 
was repeated at least three times with the following control conditions: no puromycin added 
to the cells, no viral infection with puromycin selection, and non-silencing control with 
puromycin selection.  The percent of cell growth was determined by using the non-silencing 
control with puromycin selection as 100% cell growth.   
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2.6 Immunostaining - Anti-EGFR (mab108) was labeled with Alexa-fluor-488 (Invitrogen, 
Carlsbad, CA) and Anti-Src (2-17, S. Parsons, University of Virginia, Charlottesville, VA) 
was labeled with Alexa-flour-594 (Invitrogen, Carlsbad, CA) utilizing Alexa-fluor labeling 
kits.  Cells were plated onto coverslips at a density of 1.5X105 cells per 35mm dish and 
grown for 48 h.  For lipid raft staining, media was aspirated, cells were washed with 1X PBS 
once, and then incubated with Alexa-fluor-594 labeled cholera toxin subunit B (Invitrogen, 
Carlsbad, CA) at 1 µg/ml for 10 min on ice prior to fixation (Roepstorff et al., 2002; Liu et 
al., 2007).  Cells were then washed three times in 1X PBS (washed), fixed with formalin for 
20 min at room temperature, washed, permeabilized with 0.1 % Triton-x 100 (if applicable) 
for 2 min on ice, washed, blocked in 20% goat serum for 1 h at room temperature, then 
incubated with EGFR (Alexa-fluor labeled) or c-Src (2-17 unlabeled for lipid raft staining, 
594 labeled for EGFR co-staining) antibody for 1 h (followed by corresponding Alexa-fluor 
594 secondary antibody if necessary), washed, quickly washed once in deionized water, and 
then mounted onto slides with Prolong Gold containing DAPI (Invitrogen, Carlsbad, CA).  
Imaging was performed via confocal microscopy using a Zeiss Axioplan2 apotome 
microscope fitted with a 63X 1.25 oil immersion lens at the Microscopy and Imaging 
Resources Laboratory (Wayne State University, Detroit, MI).  
2.7 Biochemical Raft Isolation - Biochemical lipid raft isolation was adapted from 
established protocols (Macdonald and Pike, 2005).  Briefly, cells were plated at a density of 
0.5X106 cells in six-100 mm plates for 72 h.  Media was aspirated, and then cells were 
scraped in base buffer [20 mM Tris, pH 7.8, 250 mM Sucrose, 1 mM MgCl2, 1 mM CaCl2, 
100 µM sodium orthovanadate], centrifuged at 250Xg at four degrees to pellet cells and lysed 
in base buffer containing 1X protease inhibitor cocktail (EMD Biosciences, Gibbstown, NJ) 
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by passing through a 22 gauge X 1.5” needle 40 times.  Lysates were centrifuged for 10 min 
at four degrees and 1000Xg, and the first and second post-nuclear supernatants were 
combined and frozen at -20°C.  This freezing step was required for reproducibility of results, 
as without it the isolation was never repeatable.  Samples were thawed and combined with 
equal volume of 50% Opti-Prep (Greiner Bio One, Monroe, NC) and 0-20% Opti-Prep 
gradient was applied.  Gradients were centrifuged for 90 min at 52,000Xg and then 
fractionated into 16 - 0.56 mL fractions from the top of the tube.  Fractions were separated 
via SDS-PAGE, transferred to Immobolin-P (Millipore, Billerica, MA), and immunoblotted 
utilizing antibodies described above.  Fractions were dot blotted with Cholera Toxin Subunit 
B-HRP (Invitrogen, Carlsbad, CA) to determine GM-1 expression.  Incubation with 
enhanced chemiluminescence (GE Healthcare, Buckinghamshire, UK) was followed by 
exposure to film. Experiments were repeated at least three times and quantified using 
densitometry (NIH Image). 
2.8 Immunoprecipitation – Five hundred micrograms of whole cell lysates (as collected for 
immunoblotting) or two hundred microliters of each lipid raft fractionation (1-7) were pooled 
and immunoprecipitated with 10 µg of EGFR antibody (mab108) or 10 µg c-Src antibody (2-
17) for 1 h at 4°C.  Forty microliters of a 50% slurry of protein A agarose beads were added 
for 30 min.  Samples were then pelleted and washed three times in CHAPs lysis buffer, then 
25 µL 2X Lamelli buffer was added, and samples were boiled for 5 min.  Samples were 
subjected to SDS-PAGE followed by immunoblotting for EGFR and c-Src.  Whole cell 
lysates were utilized as a migration control.  Immunoprecipitation with 10 µg mouse IgG 
antibody served as a negative control. 
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2.9 Cholesterol Assay – SUM159 breast cancer cells were plated at a density of 0.5X104 cells 
per well of a 6-well plate then treated with  1 mM methyl-beta cyclodextrin (MBCD 1 h), 1 
µM gefitinib (72 h), 1 µM lovastatin (72 h), 1 µM atorvastatin (LC Laboratories, Woburn, 
MA; 72 h), or 0.5 µM NB-598 (72 h).  Cells were then lysed in CHAPS lysis buffer [10 mM 
CHAPs, 50 mM Tris (pH 8.0), 150 mM NaCl, and 2 mM EDTA with 10 µM sodium 
orthovanadate and 1x protease inhibitor cocktail] and Bradford protein assay (Bio-Rad, 
Hercules, CA)  was performed.  Cholesterol was measured utilizing the Amplex Red 
cholesterol assay kit (Invitrogen, Carlsbad, CA).  Briefly, 5 µl of sample was diluted into 45 
µl 1X reaction buffer and 50 µl Amplex Red buffer [2 U/mL horse radish peroxidase, 2 
U/mL cholesterol oxidase and 0.2 U/mL cholesterol esterase] was added in a 96-well plate.  
Reactions were incubated at 37°C for 30 min to allow for production of hydrogen peroxide 
due to the reaction of cholesterol esterase and oxidase with cholesterol in the samples.  The 
Amplex Red buffer changes fluorescent color upon exposure to hydrogen peroxide, thus 
excitation was performed at 540/525nm and emission measured at 620/640nm utilizing filters 
of a Synergy 2 Multi-Mode Microplate Reader (BioTek, Winooski, VT) to measure the 
amount of hydrogen peroxide produced in the samples.  Emission readings were averaged 
and compared to a cholesterol standard curve, then normalized for protein content. 
2.10 Growth Assays – Cells were plated at a density of 3.5X104cells per well in 6-well plates 
on day 0.  Every other day starting on day 1, cells were treated with 1 µM gefitinib, 1 µM 
lovastatin (EMD Biosciences, Gibbstown, NJ), or increasing doses of dasatinib alone or in 
combination.  On days 1, 4 and 8, cells were counted with a Coulter counter (Beckman 
Coulter, Brea, CA).  Briefly, media was aspirated and plates were washed with 1 ml 1X PBS.  
Cells were then incubated with 500 µL Hepes:MgCl2 solution (0.01 M Hepes, 0.015 M 
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MgCl2 for five minutes, followed by 75 µL ZAP (Ethyl hexadecyldimethylammonium 
bromide) for 10 min.  This solution was then added to 9.5 mL of isoton solution and counted 
using a coulter counter.  Graphs represent the mean of three individual experiments 
performed in triplicate. 
2.11 MTS Assays – Breast cancer cells were plated at a density of 1-2X103 in 96-well plates, 
incubated overnight, and then treated with 0.001-100 µM lovastatin, NB-598, dasatinib, 
and/or gefitinib for 72 h.  Twenty microliters of CellTiter 96 Aqueous One Solution Cell 
Proliferation Assay reagent (Promega, Madison, WI) were added to each well and allowed to 
incubate at 37°C.  Absorbance at 490nm was detected at 2 h using a OpsysMR microplate 
reader (Dynex, Chantilly, VA).  Absorbance units were normalized to the mean of a single 
dose to compare between experiments.  Dose response curves were generated using non-
linear sigmoidal dose response curve analyses in GraphPad Prism 4.  IC50 values were 
calculated and plotted on isobolograms.  The IC50 of the primary drug alone was plotted on 
the y-axis and the IC50 of the secondary drug was plotted on the x-axis.  The line of additivity 
was drawn between them.  IC50 values of the primary drug were calculated at various doses 
of the secondary drug and plotted on the graph.  Points in the graph represent a mean of three 
independent experiments performed in triplicate.  Data points below the line of additivity 
were considered synergistic. 
2.12 Statistics – Student’s t-test was performed utilizing the statistical software in GraphPad 
Prism 4.  P-values of <0.05 were considered statistically significant.  To perform synergy 
analyses, the IC50 gefitinib was calculated for each dose of lovastatin.  The combination 
index (CI-value) was calculated as follows: (IC50 gefitinib at X dose lovastatin)/(IC50 
gefitinib alone) + (dose of lovastatin)/(IC50 lovastatin alone).  
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Chapter 3 
3.1 Introduction 
Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase whose function 
has been implicated in many biological processes.  When activated, EGFR stimulates 
signaling pathways involved in cell growth, survival, and migration.  While EGFR contains 
activating mutations in glioblastomas and lung cancer, overexpression is the primary 
mechanism by which EGFR contributes to breast cancer growth and progression (Wong et 
al., 1992; Paez et al., 2004).  EGFR overexpression occurs in approximately 30% of all breast 
cancers and correlates with poor clinical prognosis (Sainsbury et al., 1987; Bolla et al., 1990; 
Toi et al., 1991).  Several small molecule tyrosine kinase inhibitors (TKIs) targeting EGFR 
have been tested in clinical trials with some success in lung and colon cancers.  While EGFR 
TKIs have shown some clinical efficacy in hormone receptor-positive breast cancer 
(Polychronis et al., 2005; Guix et al., 2008; Cristofanilli et al., 2010), EGFR TKIs lack 
efficacy in hormone receptor-negative breast cancer (Blagosklonny and Darzynkiewicz, 
2003).  
The sub-cellular localization of EGFR determines the signaling pathways stimulated by 
EGFR activation.  In fact, EGFR promotes differential signaling depending on receptor 
localization to endosomes, at the mitochondria, within the nucleus, or on the plasma 
membrane.  Specifically, EGFR localization to endosomes results in ligand-dependent 
activation of extracellular signal-regulated kinase (ERK) and p38 mitogen-activated protein 
kinase (MAPK) pathways (Sadowski et al., 2009), while mitochondrial localization of EGFR 
has been implicated in modification of cytochrome c oxidase subunit II activity (Boerner et 
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al., 2004).  Also, EGFR localizes to the nucleus where it may act as a transcription factor 
(Lin et al., 2001).  Perhaps the most well known localization of EGFR is to the plasma 
membrane, where it modulates both MAPK and Akt signaling pathways [reviewed in 
(Bianco et al., 2007)]. 
The plasma membrane contains discrete heterogeneous microdomains (Maa et al., 1995).  
These microdomains are less fluid than the surrounding bulk plasma membrane, and are 
enriched in cholesterol, sphingolipids, and gangliosides.  They have been termed lipid rafts, 
and act as platforms for cellular signaling (Simons and Ikonen, 1997).  Levels of lipid rafts 
are increased in melanomas, prostate, and breast cancer cell lines as compared to normal cell 
lines, which suggests that these structures play a functional role during tumorigenesis 
(Hazarika et al., 2004; Li et al., 2006).  EGFR is one of many proteins shown to exist within 
lipid rafts, but the effect of EGFR localization to lipid rafts is not well understood.  While it 
has been noted that lipid raft localization of EGFR inhibits ligand binding and subsequent 
signaling downstream (Chen and Resh, 2002; Roepstorff et al., 2002), other studies have 
shown that lipid rafts promote EGFR signaling (Zhuang et al., 2002; Peres et al., 2003). 
In this chapter, we have found that lipid raft localization of EGFR plays a role in the 
response of breast cancer cell lines to EGFR TKI-induced growth inhibition.  Specifically, 
EGFR localization to lipid rafts correlated with EGFR TKI resistance.  In addition, reduction 
of cholesterol from lipid rafts sensitized resistant breast cancer cells to the EGFR TKI 
gefitinib.  Significantly, the effects of cholesterol biosynthesis inhibitors and gefitinib were 
synergistic.  Interestingly, while gefitinib abrogated both Akt and MAPK phosphorylation in 
EGFR TKI sensitive cells, Akt remained phosphorylated in EGFR TKI resistant cell lines.  
Lovastatin was sufficient to diminish this phosphorylation.  Thus, our data suggest that lipid 
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rafts provide a platform for EGFR-kinase independent activation of Akt in EGFR TKI 
resistant cell lines. 
3.2 Results 
A. Resistance of EGFR expressing breast cancer cell lines to EGFR TKIs 
The lack of clinical response of breast cancers to EGFR TKIs prevents the use of an 
excellent targeted agent for the treatment of this disease.  To study mechanisms of resistance 
to EGFR TKIs in breast cancer, we characterized a panel of twenty breast cancer cell lines 
for EGFR protein expression (Fig. 3.1A).  Thirteen of the cell lines analyzed expressed 
EGFR protein.  Interestingly, in twelve of the thirteen EGFR expressing cell lines, EGFR 
was kinase active under normal growth conditions (Fig. 3.1B).  To determine the response of 
these twelve cell lines to the EGFR TKI gefitinib, we treated the cells with increasing doses 
of gefitinib, an EGFR TKI, and measured cellular proliferation over time (Table 3.1, Fig. 
3.2).  These experiments identified seven EGFR TKI resistant cell lines: SUM159, SUM229, 
BT20, BT549, HCC1937, MDA-MB231, and MDA-MB468 (Fig 3.2B).  Breast cancer cells 
resistant to gefitinib-induced growth inhibition were also shown to be resistant to other 
EGFR selective TKIs, including the irreversible inhibitor CI-1033 (data not shown).   Others 
have found similar patterns of sensitivity and resistance to EGFR inhibitors in breast cancer 
cell lines (Helfrich et al., 2006).   
In order to determine if gefitinib effectively inhibits EGFR kinase activity in these breast 
cancer cells in vitro kinase assays were performed.  We have previously published that 0.1 
µM gefitinib completely abrogates EGFR kinase activity as measured by 32P incorporation 
into EGFR via autophosphorylation  (Mueller et al., 2008).  Interestingly, we found that in  
Figure 3.1 EGFR is expressed and kinase active in breast cancer.  Breast cancer cell lines were grown 
under normal growth conditions. (A) Cells were lysed and 100 µg of lysate was separated by SDS-PAGE, 
transferred to PVDF, and immunoblotted with EGFR or β-actin antibodies.  Immunoblots were repeated at 
least three times.  (B) Cells were lysed in kinase-buffer and immunoprecipitated with EGFR antibodies.  
Kinase assays were performed with 32P-γATP incorporated into EGFR as the substrate for EGFR kinase 
activity. (C) Kinase assays were performed as described after indicated treatment times and doses of 
gefitinib in SUM 229 cells. {These experiments were performed by Julie Boerner, PhD}
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Figure 3.2 Seven of thirteen EGFR expressing breast cancer cell lines are resistant to EGFR TKI 
induced growth inhibition.  Cellular proliferation assays were performed in the presence of increasing 
doses of gefitinib for eight days.  Cell counts were taken on days 1, 4, and 8.  Error bars represent the 
standard error of the mean.  Proliferation assays were performed in triplicate and repeated at least three 
times. (A) Sensitive cells (B) Resistant cells.  {These experiments were performed by Julie Boerner, PhD}
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Cell Line Gefitinib Sensitivity 
SUM 102 Sensitive 
SUM 149 Sensitive 
SUM 159 Resistant 
SUM 229 Resistant 
SUM 1315 Sensitive 
BT20 Resistant 
BT549 Resistant 
SKBR3 Sensitive 
HCC1937 Resistant 
HCC 1954 Sensitive 
MDA-MB 231 Resistant 
MDA-MB 468 Resistant 
H3255 Sensitive 
H1650 Resistant 
 
Table 3.1: Breast cancer cell lines differ in their sensitivity to EGFR TKIs.  
Proliferation of breast cancer cell lines in the presence of increasing doses of gefitinib 
was determined as described for Figure 3.2.  Sensitive cell lines are those where less 
than 1 µM inhibited proliferation, while resistant (bold) cells lines are those that 
continued proliferation in the presence of 1 µM gefitinib. 
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five of the seven EGFR TKI resistant breast cancer cells, tyrosine phosphorylation was 
maintained in the absence of EGFR kinase activity which we have evidence to support occurs 
via transphosphorylation by other activated tyrosine kinases (Mueller et al., 2008).  Here, we 
added to these findings by determining the minimal dose and time of gefitinib required to 
completely inhibit EGFR kinase activity (Fig. 3.1C).    We found that as little as 10 nM 
gefitinib for five minutes was sufficient to deplete EGFR kinase activity in these cells.  
Therefore, EGFR kinase activity was successfully inhibited by the doses of gefitinib utilized 
in these studies in both EGFR TKI sensitive and resistant cell lines. 
Although EGFR kinase activity is not required for the growth of EGFR TKI resistant cell 
lines, the previously described maintenance of EGFR phosphorylation in the absence of 
kinase activity (Mueller et al., 2008) suggests that the protein itself may still be required for 
proliferation.  Thus, to directly determine if proliferation of EGFR TKI resistant cells 
requires EGFR protein expression, we used EGFR-targeting shRNA lentiviral infection to 
down-regulate EGFR protein expression.  Twenty-one EGFR shRNA constructs were 
screened for efficiency of knocking down EGFR expression, as measured by 
immunoblotting.  Three EGFR shRNA constructs consistently decreased EGFR protein 
expression (Fig. 3.3A). Construct three gave the best knockdown, as there was at least a 50% 
reduction in EGFR protein of all cell lines tested when compared to the non-silencing shRNA 
control.  In order to determine if knockdown of EGFR was sustained over the period utilized 
to conduct growth assays, SUM159 and SUM229 cells were infected with EGFR shRNA, 
and grown with puromycin selection for two weeks.  As seen in Figure 3.3B, EGFR protein 
expression remained reduced at two weeks in both cell lines, demonstrating that EGFR #3 
shRNA sufficiently knocks down EGFR expression over the time period necessary for  
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Figure 3.3: EGFR protein expression is required for growth in four of seven EGFR TKI 
resistant breast cancer cell lines. (A) Cells were incubated with equal MOI of virus for four 
days, lysed, separated by SDS-PAGE, and immunoblotted for EGFR and β-actin.  (B) SUM 159 
and SUM 229 cells were grown under selection pressure for two weeks post-infection, then lysed, 
separated by SDS-PAGE, and immunoblotted for EGFR (C) Cells were plated at 1,000 cells/well 
of a 6-well plate and inoculated with EGFR shRNA #3 lentivirus or non-silencing control 
lentivirus.  Three days later, the media was changed to puromycin containing media for eight days.  
Cells were then counted using a Beckman Coulter Counter.  Experiments were performed at least 
three times with the error bars representing the standard error of the mean.  Statistical analyses 
were performed utilizing Student’s t-test, * = p>0.05. {These experiments were performed by Julie 
Boerner, PhD}
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growth assays to be performed.  Additionally, SUM44 cells, which do not express EGFR 
(Fig. 3.1A) were utilized as a negative control, and HCC1954 cells which are sensitive to 
EGFR TKIs (Table 3.1, Figure 3.2A) were utilized as a positive control.  Notably, BT549, 
MDA-MB231, and MDA-MB468  cells continued to grow after a decrease in EGFR protein 
expression (Fig. 3.3C).  This non-dependence on EGFR protein expression in these three 
cells lines may be a result of genetic alterations in signaling proteins downstream of EGFR.  
For example, MDA-MB-468 and BT549 cells have lost PTEN expression and MDA-MB-231 
cells contain an activating K-Ras mutation (Hollestelle et al., 2007).  Conversely, in 
SUM159, HCC1937, SUM229, and BT20 breast cancer cell lines, knocking down EGFR 
expression significantly decreased proliferation, suggesting that EGFR protein expression is 
at least in part required for the growth of these cell lines (Fig. 3.3C, * = p<0.05).   
Previous studies have shown that EGFR localization can modulate EGFR signaling (Lin 
et al., 2001; Chen and Resh, 2002; Zhuang et al., 2002; Boerner et al., 2004; Li et al., 2006).  
Thus, to determine if the localization of EGFR was mediating the response of cells to EGFR 
TKIs, immunostaining and confocal microscopy were performed.  Cells were stained with 
Alexa-Fluor 488-labeled EGFR antibodies (Fig. 3.4; green) and DAPI as a nuclear dye 
(blue).  In two EGFR TKI sensitive cell lines (SKBr3 and SUM1315), EGFR localized 
entirely within intracellular compartments and the cytosol.   However, in two other EGFR 
TKI sensitive cell lines (SUM149 and HCC1954), as well as all four EGFR TKI resistant cell 
lines, EGFR localized both within intracellular regions and at the plasma membrane.  
Interestingly, EGFR staining was not always contiguous around the membrane.  The patchy 
nature of the staining, most prominent in SUM159 cells (Fig. 3.4; arrows), suggested that 
EGFR may localize to lipid rafts (Harder et al., 1998b; Grossmann et al., 2006).  EGFR has  
Figure 3.4: EGFR is localized to the plasma membrane in breast cancer cell lines.  For each cell line, 
two hundred thousand cells were plated onto coverslips and cultured under normal growth conditions for 48 
h.  Cells were fixed, permeabilized, and blocked with 20% goat serum.  EGFR was detected with Alexa-
fluor 488 labeled EGFR antibody (green) and nuclei were identified with DAPI (blue).  Imaging was 
performed using Zeiss Axioplan2 apotome microscope fitted with a 63X 1.25 oil immersion lens at the 
Microscopy and Imaging Resources Laboratory (Wayne State University, Detroit, MI).  Arrows indicate 
patchy EGFR staining.  Scale bars represent a distance of 50 µm.   
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SUM 1315
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been shown to localize within lipid rafts in Hela and CHO cells (Macdonald and Pike, 2005; 
Pike, 2005).  In order to determine if EGFR was localized to lipid rafts in breast cancer cells, 
we used two methods of identifying these structures: biochemical raft isolation and confocal 
microscopy.  First, a detergent-free Opti-Prep gradient was used to isolate lipid rafts (adapted 
from (Macdonald and Pike, 2005)).  Flotillin, a membrane protein found both within and 
outside of lipid rafts, was used to show presence of membrane components within all 
fractions, while transferrin receptor was used as a marker for non-raft containing fractions.  
These markers, along with dot blotting for the lipid raft specific glycosphingolipid GM-1 
(Fig. 3.5A) indicated fractions 1-7 as lipid raft fractions.  When these fractions were 
immunoblotted using EGFR antibodies, EGFR localization to the lipid raft fractions was 
most prominent in the EGFR TKI resistant cell lines (Fig. 3.5A).  As SKBR3 and SUM1315 
cell lines showed solely intracellular EGFR staining, these cell lines were excluded from 
lipid raft analyses.  Quantification of the percent of total EGFR that was present in the lipid 
raft fractions found that the four EGFR TKI resistant breast cancer cell lines contained 
significantly more EGFR within lipid rafts as compared to the average EGFR content within 
lipid rafts of two EGFR TKI sensitive cell lines, SUM149 and HCC1954 (Fig. 3.5B, * = p < 
0.05).  Taken together, these data suggest that elevated EGFR localization to lipid rafts may 
correlate with resistance to EGFR TKI-induced growth inhibition. 
While lipid rafts are predominately found within the plasma membrane, there is evidence 
that they are also present in endosomes, lysosomes, and mitochondria (Galbiati et al., 2001).  
To determine if EGFR localized specifically within plasma membrane lipid rafts, we used 
immunofluorescent staining under non-permeabilizing conditions.  Cholera toxin subunit B 
binds specifically to GM-1 and was used to detect localization of lipid rafts and EGFR was  
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Figure 3.5: EGFR localization to lipid rafts correlates with EGFR TKI resistance (A) One half 
million cells were plated, cultured 72 h, detergent-free lysis was performed and lipid rafts were 
separated by ultracentrifugation [23].  Western blotting was performed with EGFR, transferrin 
receptor, and flotillin antibodies.  Fractions were dot blotted for GM-1 utilizing cholera toxin 
subunit B-HRP.  Fractions 1-7 indicate lipid raft fractions. # indicates that the blots are 
representative. (B) Densitometry was performed on western blots from A.  Bars represent the 
percent of EGFR in lipid raft fractions (1-7) as compared to the total amount of EGFR present (1-
14) from at least three independent experiments.  Statistical analyses were performed utilizing a 
student's t-test, * = p<0.05 compared to SUM149 and HCC1954 cells. (C) Two hundred thousand 
cells were plated onto coverslips and cultured for 48 h.  Coverslips containing cells were then 
incubated with Alexa-fluor 594 labeled cholera toxin subunit B (red) for 10 min on ice.  Following 
incubation, cells were fixed, blocked in 20% goat serum, and incubated with immunofluorescent 
EGFR antibodies (extracellular domain epitope, green) and nuclei were stained with DAPI (blue).  
Imaging was performed using Zeiss Axioplan2 apotome microscope fitted with a 63X 1.25 oil 
immersion lens at the Microscopy and Imaging Resources Laboratory (Wayne State University, 
Detroit, MI).  Arrows indicate areas of co-localization.  Scale bars represent a distance of 50 µm.
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detected as described above.  In the EGFR TKI resistant cell lines (SUM159, HCC1937, 
SUM229, and BT20), EGFR (green) co-localized (yellow/orange) with GM-1 (red) at the 
plasma membrane (Fig. 3.5C; arrows).  In contrast, in the EGFR TKI sensitive cell lines 
(SUM149 and HCC1954), EGFR and GM-1 did not co-localize (Fig. 3.5C).   These data 
suggested that EGFR localizes within plasma membrane lipid rafts in breast cancer cells that 
are resistant to EGFR TKI-induced growth inhibition. 
B.  Disruption of lipid rafts sensitizes breast cancer cells to EGFR inhibitors 
Cholesterol is the primary structural component of lipid rafts [reviewed in (Barenholz, 
2002)], thus, to determine if the presence of EGFR in lipid rafts mediates cellular response to 
EGFR TKIs, we pharmacologically depleted cholesterol from the cells.  HMG CoA-
reductase inhibitors lovastatin and atorvastatin were used to reduce lipid raft cholesterol 
content [reviewed in (Simons and Toomre, 2000)].  The Amplex Red cholesterol assay, 
which determines total cellular cholesterol content by measuring the amount of H2O2 
produced by the reaction of cholesterol in the sample with cholesterol oxidase and 
cholesterol esterase enzymes, was utilized to determine the ability of these drugs to reduce 
cellular cholesterol (Fig. 3.6).  Methyl-beta cyclodextrin (MBCD), a cytotoxic cholesterol 
sequestering agent, reduced cholesterol by 41.5% +/- 8.1%, and was therefore used as a 
positive control for these experiments.  Seventy-two hours of treatment with the HMG CoA 
reductase inhibitors lovastatin and atorvastatin resulted in depletion of cholesterol content, 
with a reduction of 59.0% +/-12.4% at 1.0 µM lovastatin and a reduction of 49.6% +/-10.3% 
at 1.0 µM atorvastatin (Fig. 3.6).  Importantly, gefitinib treatment had no effect on 
cholesterol content of these cells, and did not alter the ability of lovastatin to reduce total  
Figure 3.6: MBCD, lovastatin, atorvastatin, and NB-598 reduce cholesterol in breast cancer 
cells.  Fifty thousand cells were plated into 6-well plates and treated with 1 mM MBCD (1 h), 1 
µM lovastatin (72 h), 1 µM atorvastatin (72 h), 1.0 µM NB-598 (72 h), 1 µM gefitinib (1 h), or a 
combination of 1 µM gefitinib (1 h) and 1 µM lovastatin (72 h).  Lysis was followed by protein 
quantification and cholesterol was measured using the Amplex Red cholesterol assay kit.  
Absorbance was converted to µg cholesterol/mL utilizing a cholesterol standard curve, and then 
samples were normalized to protein concentration for a final value in µg cholesterol/µg protein.  
Bars represent fraction of cholesterol with untreated samples as 1 (µg cholesterol/µg protein 
sample)/(µg cholesterol/µg protein untreated).  Experiments were repeated at least three times.  
Error bars represent the standard error of the mean. Statistical analyses were performed utilizing 
Student’s t-test, * = p < 0.05 compared to untreated.
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cellular cholesterol (Fig. 3.6).  The levels of cholesterol reduction produced by the statins are 
comparable with published results (Sethy-Coraci et al., 2005; Ehehalt et al., 2008). 
To determine if lovastatin has the ability to sensitize breast cancer cells to gefitinib, cell 
counting assays were used to measure proliferation. Cells were treated every other day with 
the drugs and counted on days 1, 4, and 8 (Fig. 3.7).  As described previously, the four EGFR 
TKI resistant cell lines continued to proliferate in the presence of gefitinib.  Interestingly, 
lovastatin was able to significantly reduce proliferation in the presence of gefitinib when 
compared to gefitinib or lovastatin treatment alone (Fig. 3.7; * = p<0.0001, ♦).  Taken 
together, these data suggested that treatment with lovastatin sensitizes EGFR TKI resistant 
cell lines to gefitinib. 
In order to determine if the effects of lovastatin and gefitinib were synergistic in EGFR 
TKI resistant breast cancer cells, cell viability assays were performed. Briefly, cells were 
treated for 72 h with the combination of lovastatin and gefitinib prior to performing 
tetrazolium-based cell viability assays.  It can be noted that the IC50 values for cell viability 
analyses were much higher than doses found to be effective in cellular proliferation assays.  
While proliferation assays allow for the measurement of the number of cells over time, cell 
viability assays indicate the metabolic activity of the cell population.   The IC50 of gefitinib 
was calculated at various doses of lovastatin, and then isobolograms were generated (Fig. 
3.8).  An additive interaction in SUM149 and HCC1954 cells was calculated from these 
assays (Fig. 3.7, points on the line).  In contrast, synergistic effects were seen in all four 
EGFR TKI resistant cell lines (Fig. 3.8, points below the line).  Combination index (CI) 
values were calculated based on the IC50 values (Table 3.2).  These values were significantly 
lower than one in all of the EGFR TKI resistant cell lines.  These results suggested that the 
Figure 3.7: Lovastatin sensitizes EGFR TKI resistant breast cancer cells to gefitinib.  Thirty 
five thousand cells were plated into 6-well plates and treated for eight days with lovastatin and/or 
gefitinib (HCC1954, SUM149 and SUM159 cell lines were treated with 1 µM of both lovastatin 
and gefitinib, while HCC1937, SUM229, and BT20 cells were treated with 5 µM lovastatin and 1 
µM gefitinib).  Cell number was determined on days 1, 4, and 8 using a coulter counter.  
Experiments were repeated at least three times and counts were averaged.  Error bars represent the 
standard error of the mean. Statistical analyses were performed utilizing Student’s t-test, * = p < 
0.0001.
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Figure 3.8: Lovastatin and gefitinib act synergistically to reduce breast cancer cell 
viability. Two thousand cells were plated onto 96-well plates and treated for 72 h with varying 
doses of gefitinib and lovastatin alone and in combination.  Values were normalized and then 
plotted.  Non-linear regression (sigmoidal-dose response) curves were generated and  IC50s 
were calculated and plotted on isobolograms.  Experiments were repeated at least three times.
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Cell Line Lovastatin Dose 
Combination Index 
(CI-value) 
p-value 
(compared to 1) 
SUM159 0.25 µM 0.659 
+/-0.066 0.0262 
HCC1937 1.0 µM 0.554 
+/-0.069 0.0124 
SUM229 1.0 µM 0.331 
+/- 0.164 0.0269 
BT20 5.0 µM 0.695 
+/- 0.065 0.0348 
 
Table 3.2: Effects of lovastatin and gefitinib are synergistic in EGFR TKI resistant 
cell lines.  The combination index (CI-value) was calculated as follows: (IC50 gefitinib at 
X dose of lovastatin)/(IC50 gefitinib alone) + (dose of lovastatin)/(IC50 lovastatin alone).  
p-values were calculated as a difference between CI-value and one.  p-values, calculated 
by student’s t-test, less than 0.05 were considered significant. 
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combinatorial inhibition of lipid raft structure and EGFR-kinase activity resulted in a 
synergistic decrease in cell viability when EGFR is localized to lipid rafts.  Therefore, the use 
of lovastatin and gefitinib in combination may effectively decrease viability and proliferation 
of breast cancers that contain EGFR within lipid rafts. 
Statin drugs work by inhibiting HMG-CoA reductase.  In addition to cholesterol 
biosynthesis, this enzyme also regulates isoprenoid synthesis.  Therefore, in order to 
determine if the synergistic effect between lovastatin and gefitinib is mediated by cholesterol 
depletion, the drug NB-598 was used.  NB-598 is a squalene monooxygenase inhibitor 
(Horie et al., 1990), and therefore inhibits cholesterol biosynthesis but not isoprenoid 
synthesis.  First, to determine if NB-598 effectively inhibited cholesterol biosynthesis, 
SUM159 cells were treated with NB-598 for 72 h prior to assaying cholesterol esterase 
activity  (Fig. 3.6).  NB-598 treatment reduced cholesterol by 37.1% +/- 0.59%, suggesting 
that NB-598 depleted cholesterol to a comparable level as lovastatin.  Therefore, we utilized 
NB-598 to determine if inhibiting cholesterol biosynthesis in the absence of altering 
isoprenoid synthesis has the ability to sensitize cells to gefitinib.  EGFR TKI resistant breast 
cancer cells were treated with variable doses of NB-598 alone, or in combination with 
gefitinib.  Cell viability assays were used to determine the IC50 of gefitinib at variable doses 
of NB-598. As shown in Figure 3.9, the effects of gefitinib and NB-598 were synergistic.  
These data suggest that cholesterol depletion is sufficient to sensitize EGFR TKI resistant 
cells to gefitinib.   
Figure 3.9: The effects of NB-598 and gefitinib are synergistic. Two thousand cells were plated 
onto 96-well plates and treated for 72 h with varying doses of gefitinib and NB-598 alone and in 
combination.  Values were normalized and then plotted.  Non-linear regression (sigmoidal-dose 
response) curves were generated, and IC50s were calculated and plotted on an isobologram.  
Experiments were repeated at least three times.
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C.  Akt phosphorylation is abrogated with lipid raft disruption 
Resistance to EGFR TKIs suggests that inhibiting the EGFR kinase activity is insufficient 
to turn off growth and survival signaling in these cells.  Localization of EGFR to lipid rafts 
has variable effects on signaling pathways downstream of EGFR (Chen and Resh, 2002; Li et 
al., 2006), thus we determined what effect depletion of cholesterol had on EGFR signaling in 
EGFR TKI resistant cells as compared to EGFR TKI sensitive cells.  As discussed further 
below, BT20 cells contain a PIK3CA mutation, and the HCC1937 cell line has loss of PTEN 
expression, therefore, and lovastatin does not effect the phosphorylation of Akt in these cell 
lines (data not shown).  Thus, two EGFR TKI resistant cell lines (SUM159 and SUM229) 
and one EGFR TKI sensitive cell line (SUM149) were treated with lovastatin and gefitinib 
alone or in combination and immunoblotting was performed to determine the 
phosphorylation of Akt and MAPK.  Gefitinib treatment resulted in a reduction of MAPK 
phosphorylation in both the sensitive SUM149 cell line and two gefitinib resistant cell lines 
(SUM159 and SUM229).  In contrast, Akt phosphorylation was inhibited in the EGFR TKI 
sensitive cell line yet persisted in the presence of gefitinib in EGFR TKI resistant cell lines 
(Fig. 3.10, lane 3).  This phosphorylation persisted even after 72 h treatment with gefitinib 
(data not shown).  When treated with lovastatin, alone or in combination with gefitinib, Akt 
phosphorylation was abrogated (Fig. 3.10, lanes 2 and 4).  These data suggested that, co-
treatment of cells with lovastatin and gefitinib was able to inhibit two major EGFR signaling 
pathways.  Thus, we propose that lipid rafts may provide a platform whereby EGFR may 
functionally interact with other proteins to activate Akt and modulate the response to EGFR 
TKIs.  
pMAPK
EGFR
pAKT
SUM 159SUM 149
UN Lov G Lov+G
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UN Lov G Lov+GUN Lov G Lov+G
MAPK
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Figure 3.10: Lovastatin inhibits Akt phosphorylation in EGFR TKI resistant cell lines.  One million 
cells were plated and allowed to grow for 48 h.  Cells were then treated with 1 µM (SUM 149 and SUM 
159) or 5 µM lovastatin (SUM 229) for 72 h (LOV) and/or 1 µM gefitinib (G) for 1 h.  Lysates were 
prepared and separated by SDS-PAGE.  Immunoblotting using EGFR, Akt, MAPK, phospho-Akt, and 
phospho-MAPK antibodies was performed as described. 
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3.3 Discussion 
We have provided evidence describing a role for lipid rafts in resistance to EGFR TKI-
induced growth inhibition using four EGFR expressing breast cancer cell lines which 
continue to proliferate in the presence of gefitinib, an EGFR TKI.  We have shown that seven 
of thirteen EGFR-expressing breast cancer cell lines are resistant to EGFR TKI-induced 
growth inhibition, and that four of those cell lines retain the requirement of EGFR protein 
expression for growth.  Also, we have provided evidence that EGFR localization to lipid rafts 
correlates with EGFR TKI resistance.  Further, lovastatin, a HMG CoA reductase inhibitor, 
as well as NB-598, a squalene monooxygenase inhibitor, reduced cholesterol biosynthesis in 
the EGFR TKI resistant breast cancer cells.  In addition, lovastatin sensitized EGFR TKI 
resistant breast cancer cells to gefitinib-induced growth inhibition.  Importantly, this 
sensitization of EGFR TKI growth resistant cells to gefitinib was determined to be 
synergistic for both lovastatin and NB-598.  Our data suggests that Akt phosphorylation 
persists in the presence of EGFR kinase inhibition, and that lovastatin abrogated this 
phosphorylation, thus sensitizing the cells to EGFR kinase inhibition.   
Overexpression of EGFR is one mechanism by which EGFR contributes to cancer 
progression.  In fact, overexpression of EGFR occurs in glioblastomas, breast, prostate, 
ovary, liver, bladder, esophagus, larynx, stomach, colon, and lung cancers (Khazaie et al., 
1993).  This fairly ubiquitous overexpression suggests that EGFR may be an attractive target 
for cancer therapeutics.  Inhibitors of EGFR kinase activity show clinical efficacy in lung, 
pancreatic, colorectal, and head and neck cancers (Baker, 2004; Cohen et al., 2005; Giusti et 
al., 2008; Sobrero et al., 2008), however they have proven ineffective in the treatment of 
breast cancers (Blagosklonny and Darzynkiewicz, 2003; Twombly, 2005).  Herein, we have 
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provided evidence that breast cancer cell lines differ in their responses to these EGFR TKIs 
(Table 3.1).  Seven of thirteen breast cancer cell lines were found to be resistant to EGFR 
TKI-induced growth inhibition using cellular proliferation assays (Table 3.1).  Specifically, 
SUM159, SUM229, BT20, BT549, HCC1937, MDA-MB231, and MDA-MB468 cell lines 
continued to proliferate in the presence of 1 µM gefitinib (Table 3.1). 
A number of mechanisms have been suggested for resistance to EGFR TKI-induced 
growth inhibition including EGFR independence, mutations in EGFR and alterations in 
downstream signaling pathways.  We have shown that three of seven EGFR TKI resistant 
breast cancer cell lines grow independently of EGFR protein expression, while four retain the 
requirement of EGFR expression for their proliferation (Fig. 3.3A-C).  Mutations of EGFR, 
such as the VIII or T790M, have been implicated in glioblastomas and non-small cell lung 
cancers; however, these mutations are rare in breast tumors (Bianco et al., 2005).  We have 
sequenced EGFR in the cell lines we used for our studies and no EGFR mutations were 
present (R. Haddad, personal communication).   
Failure to inhibit Akt signaling, due to mutation or loss of PTEN, constitutive activation 
of PI3K, or overexpression of Akt, has also been shown to be a mechanism of resistance to 
EGFR TKI-induced growth inhibition (Cheng et al., 1992; Lu et al., 1999; Hollestelle et al., 
2007).  Of the cell lines that retain the requirement of EGFR protein expression for growth, 
but are EGFR TKI resistant, one has a PIK3CA mutation (BT20), and one has loss of PTEN 
expression (HCC1937) suggesting that the PI3K/Akt pathway may be important in the 
tumorigenicity of these cell lines (Hollestelle et al., 2007).   Indeed, Akt phosphorylation 
persists in the absence of EGFR kinase activity in these two cell lines and lovastatin had no 
effect on Akt phosphorylation (data not shown).  The two other EGFR TKI resistant cell lines 
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(SUM159 and SUM229) do not contain genetic mutations in the Akt pathway, yet retain Akt 
phosphorylation in the presence of gefitinib (Fig. 3.10, lane 3).  Lovastatin treatment was 
sufficient to abrogate this phosphorylation, suggesting that lipid rafts play a role in the 
regulation of Akt phosphorylation in EGFR TKI resistant cells (Fig. 3.10, lanes 2 and 4).  
Specifically, we suggest that lipid rafts provide a platform for EGFR protein-dependent, 
EGFR kinase-independent activation of Akt signaling.  However, as EGFR signaling is 
mediated by many more proteins than addressed here, it is possible that other pathways may 
also be downstream of EGFR-kinase independent, lipid raft-dependent activation.  
Nevertheless, localization of EGFR to lipid rafts is an important factor in the resistance of 
breast cancer cells to EGFR TKI-induced growth inhibition.   
Lipid rafts have been suggested to play a functional role in cancer cell drug resistance.  
Depletion of lipid rafts through inhibition of fatty acid synthase (FAS) has been found to 
overcome trastuzumab resistance in breast cancer (Menendez et al., 2005).  Specifically 
Her2/Neu co-localizes with lipid rafts in breast cancer cells, and the lipid environment of 
Her2/Neu-overexpressing cells influences the dimerization properties and signaling functions 
of Her2/Neu (Menendez et al., 2005).  Furthermore, preclinical data suggest that lipid raft 
depletion via statins can decrease cell growth and sensitize cells to apoptotic stimuli in a 
number of cancer models including melanoma, prostate, and HER2-overexpressing breast 
cancers (Li et al., 2006; Glynn et al., 2008; Herrero-Martin and Lopez-Rivas, 2008).  
Epidemiologic data regarding the use of statins as singular agents in breast cancer are mixed 
(Beck et al., 2003; Cauley et al., 2003; Kwan et al., 2008).  The apparent in vitro benefit of 
combining statins with other therapies suggests that statins may have a greater clinical 
benefit when utilized as a part of combinatorial therapies (Katz, 2005).  In that regard, we 
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have shown that cholesterol depletion synergizes with gefitinib in four EGFR TKI resistant 
breast cancer cell lines (Fig. 3.8 and 3.9, Table 3.2).  Specifically, co-treatment of these cell 
lines with lovastatin and gefitinib significantly reduces cell proliferation compared to either 
drug alone (Fig. 3.7).  Also, when CI-values were determined for the combination of 
lovastatin and gefitinib, all four cell lines resistant to EGFR TKI-induced growth inhibition 
showed synergy (Table 3.2).  Thus, in breast cancer cells resistant to EGFR TKI-induced 
growth inhibition, EGFR is commonly localized to lipid rafts, and our data indicate that this 
localization plays a functional role in such resistance. 
Our data suggest that the synergistic mechanism between lovastatin and gefitinib in 
breast cancer cells is due to depletion of cholesterol and thereby depletion of lipid rafts.  
However, it is important to note that while statin use has been a common method to deplete 
cells of lipid raft structure for many years, the mechanism of action of statin drugs is not 
solely through the reduction of cholesterol.  Statin treatment and consequent reduction of 
HMG-CoA reductase activity also inhibits protein prenylation.  Indeed, previous studies have 
demonstrated that lovastatin can potentiate the effects of gefitinib (and vice versa) in 
squamous cell carcinoma, non-small cell lung cancer, colon carcinoma, and glioblastoma cell 
lines due to decreased protein prenylation (Mantha et al., 2003; Mantha et al., 2005; Cemeus 
et al., 2008; Park et al., 2009; Zhao et al., 2010).  Specifically, in 2003 Mantha and 
colleagues combined gefitinib and lovastatin in head and neck cancer cell lines and found a 
synergistic interaction between these drugs due, at least in part, to protein prenylation 
(Mantha et al., 2003).  This group later showed a synergistic interaction with this drug 
pairing in cervical and non-small cell lung cancers in addition to recapitulating their findings 
in head and neck cancer.  In that manuscript, the effects of lovastatin are completely 
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attributed to protein prenylation (Mantha et al., 2005).  Further, researchers have described 
such an interaction between lovastatin and gefitinib in glioblastoma and non-small cell lung 
cancer, again attributing their effect to protein prenylation (Cemeus et al., 2008; Park et al., 
2009).  Most recently, Zhao and colleagues have proposed that EGFR dimerization is 
inhibited by treatment with lovastatin, an effect dependent on aberrant prenylation of RhoA 
(Zhao et al., 2010).  While all of these groups show a functional interaction between 
lovastatin and gefitinib, they do not link EGFR localization to lipid rafts as a mechanism of 
this effect.  We cannot completely eliminate the possibility that protein prenylation may play 
a role in the synergistic effect between lovastatin and gefitinib; however, we have clearly 
shown a role for the cholesterol lowering effect of lovastatin in such synergy, as the squalene 
monooxygenase inhibitor, NB-598 (which inhibits cholesterol biosynthesis downstream of 
the prenylation branches) was sufficient to sensitize EGFR TKI resistant breast cancer cells 
to gefitinib (Figs. 3.8 and 3.9).  Taken together, these results suggest that the effects of 
lovastatin treatment in our study are due to cholesterol modulation and subsequent lipid raft 
impairment rather than decreased protein prenylation. 
Here, we have shown that EGFR localizes to lipid rafts in EGFR expressing, EGFR TKI 
resistant, breast cancer cell lines.  We have provided evidence that reducing cholesterol 
biosynthesis sensitizes these EGFR TKI resistant cells to the EGFR TKI gefitinib.  We have 
demonstrated that cholesterol reducing drugs and gefitinib act synergistically to decrease cell 
viability in breast cancer cells that are resistant to EGFR TKI-induced growth inhibition.  We 
have also shown evidence to suggest that cholesterol depletion, not protein prenylation, 
results in a synergistic effect with gefitinib in these cells.  Mechanistically, while gefitinib 
effectively reduced MAPK phosphorylation in EGFR TKI resistant cell lines, Akt 
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phosphorylation persisted.  Lovastatin was sufficient to abrogate this phosphorylation of Akt.  
As EGFR kinase activity is completely inhibited by gefitinib treatment in these cells (Mueller 
et al., 2008), we hypothesize that lipid rafts provide a platform by which EGFR interacts with 
other proteins to activate EGFR kinase-independent signaling pathways including the Akt 
pathway.  Thus, as both statin drugs and gefitinib are well tolerated and approved for use in 
patients, the work herein provides rationale for further exploration of the combination of 
these drugs in breast cancers that are resistant to EGFR TKI-induced growth inhibition. 
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Chapter 4 
4.1 Introduction 
Breast cancer is divided into molecular sub-types that are defined by distinct genetic 
signatures (Perou et al., 2000; Sorlie et al., 2001).  While targeted therapeutics have been 
approved for two of these sub-types (ER+ and HER2+ breast cancers), the basal-type of 
breast cancer has no currently approved targeted therapeutic.  Epidermal growth factor 
receptor (EGFR) is a receptor tyrosine kinase that is over-expressed in 60% of basal-type 
breast cancers (Livasy et al., 2006; Siziopikou and Cobleigh, 2007).  Such over-expression 
correlates with poor clinical outcome [reviewed in (Jardines et al., 1993)].  As such, EGFR is 
an attractive therapeutic target in breast cancer.  Unfortunately, while EGFR-targeted 
therapeutics have shown efficacy in estrogen-receptor positive breast cancers (Polychronis et 
al., 2005; Guix et al., 2008; Cristofanilli et al., 2010), basal-type breast cancers, which are 
estrogen receptor-negative, fail to respond to EGFR inhibitors (Blagosklonny and 
Darzynkiewicz, 2003).   
Our lab has recently described a mechanism of intrinsic resistance of breast cancer cells 
to EGFR tyrosine kinase inhibition (chapter 3), where EGFR localization to lipid rafts 
promotes EGFR-kinase independent survival signaling.  To further characterize the 
mechanism by which lipid rafts mediate EGFR TKI resistance, we sought to identify other 
proteins that associate with EGFR within lipid rafts.  c-Src, a non-receptor tyrosine kinase, is 
over-expressed in many cancer types, including breast cancer (Biscardi et al., 2000; Irby and 
Yeatman, 2000), where it enhances EGFR-dependent cellular functions, including DNA 
synthesis, protein tyrosine phosphorylation, cellular transformation, and tumor formation in 
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nude mice (Luttrell et al., 1988; Wilson et al., 1989; Wilson and Parsons, 1990; Chang et al., 
1995; Maa et al., 1995; Boerner et al., 2005; Dimri et al., 2007).  Recent data from our 
laboratory has described a role for c-Src in c-Met-dependent intrinsic resistance of a basal-
type breast cancer cell line to EGFR inhibitors (Mueller et al., 2008).  c-Src is over-expressed 
in many of the same cancer types as EGFR, including approximately 70% of breast cancers, 
and is known to be co-over-expressed with EGFR in a subset of breast tumors (Maa et al., 
1995).  Additionally, EGFR and c-Src co-overexpression in mouse fibroblasts and human 
mammary epithelial cells results in synergistic increases in tumorigenesis (Maa et al., 1995; 
Belsches et al., 1997; Ware et al., 1997; Biscardi et al., 1999a; Biscardi et al., 1999b; Wilde 
et al., 1999; Dimri et al., 2007).  Furthermore, interaction between EGFR and c-Src results in 
EGFR kinase-independent signaling in breast cancer cell lines (Mueller et al., 2008).   
In addition to its interaction with EGFR, the Src family of tyrosine kinases is well known 
to localize within lipid rafts (Liu et al., 1997; Furuchi and Anderson, 1998; Davy et al., 
2000).  c-Src, the prototypical member of this family, interacts with lipid rafts through N-
terminal myristoylation and basic residues within the unique domain (Sigal et al., 1994).  
Localization of c-Src within lipid rafts has been described in neuronal, hematopoietic, and 
cervical and lung cancer cell lines (Shenoy-Scaria et al., 1993; Mukherjee et al., 2003; Kasai 
et al., 2005; Arcaro et al., 2007).  Lipid rafts mediate c-Src signaling as well, including c-Src-
dependent activation of PI3K/Akt signaling in human small cell lung cancer (SCLC) cell 
lines (Arcaro et al., 2007). 
The data herein shows that c-Src co-localizes and co-associates with EGFR in lipid rafts 
in SUM159 breast cancer cells.  Co-inhibition of c-Src and EGFR kinase activities resulted in 
a synergistic decrease in cell viability.  c-Src kinase inhibition abrogated EGFR-kinase 
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independent Akt phosphorylation, and was additive in combination with lovastatin, results 
that suggest that these inhibitors work on the same pathway.  Thus, c-Src is a portion of the 
mechanism by which lipid rafts mediate EGFR kinase-independent signaling in SUM159 
cells. 
4.2 Results 
A. c-Src localizes to lipid rafts in SUM159 cells 
In chapter 3, we show that in SUM159 cells, an EGFR TKI resistant breast cancer cell 
line, EGFR localized to lipid rafts .  Also, depletion of lipid rafts using cholesterol inhibitors 
sensitized SUM159 cells to the EGFR TKI gefitinib (chapter 3). To determine the 
mechanism by which EGFR localization to lipid rafts mediates EGFR TKI resistance, we 
wanted to identify other signaling components present in lipid rafts.  EGFR and c-Src have 
been shown to functionally interact and c-Src associates with lipid rafts (Maa et al., 1995; 
Furuchi and Anderson, 1998; Davy et al., 2000; Liu et al., 2007); therefore, we hypothesized 
that c-Src co-localized with EGFR in lipid rafts of SUM159 cells.  Using biochemical raft 
isolation techniques described previously, density fractions were collected from SUM159 
and SUM149 (a breast cancer cell line that does not express EGFR in lipid rafts) cell lines.  
Fractions 1-7 were determined to be lipid raft fractions due to absence of transferrin receptor, 
presence of flotillin protein (Fig. 4.1A), and the lipid raft specific ganglioside GM1 (data not 
shown) (Wolf et al., 1998).  Interestingly, in SUM159 cells, significantly more c-Src was 
present in fractions 1-7 than in SUM149 cells when quantified by densitometry (Fig. 4.1B; p-
value < 0.05).   
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Figure 4.1: c-Src localizes within lipid rafts in SUM159 breast cancer cells. (A) SUM159 or SUM149 
cells were plated, cultured for 72 h. Lipid rafts were separated by ultracentrifugation and immunoblotting 
was performed for c-Src, transferrin receptor and flotillin. Lanes numbered 1-7 indicate lipid raft fractions 
(Macdonald and Pike, 2005). (B) Densitometry was performed on c-Src immunoblots from A. Bars 
represent the percent of total c-Src in lipid raft fractions (1-7) compared to the total c-Src (fractions 1-14). 
Fractions 15 and 16 were excluded as pellet fractions. Experiments were repeated at least three times.  p-
value was calculated by comparing the percent of c-Src in lipid rafts in SUM159 cells compared to 
SUM159 cells using the student's t-test. (C) Two hundred thousand cells were plated onto coverslips and 
cultured under normal growth conditions for 48 h.  Coverslips containing cells were then incubated with 
Alexa-fluor 594 labeled cholera toxin subunit B (red) to stain lipid rafts, fixed, permeabilized, blocked, 
and then stained for c-Src utilizing 2-17 and an alexa-fluor 488 labeled secondary antibody (green).  DAPI 
was used to stain the nucleus (blue).  Imaging was performed using Zeiss Axioplan2 apotome microscope 
fitted with 63X 1.25 oil immersion lens at the Microscopy and Imaging Resources Laboratory (Wayne 
State University, Detroit, MI). Arrows represent lipid raft localized c-Src.
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To determine if c-Src localizes to plasma membrane lipid rafts, SUM159 cells were co-
immunostained with Alexafluor labeled cholera toxin subunit B (red) which binds to GM1, 
and with c-Src antibodies (green; Fig. 4.1C).  Co-localization between GM1 and c-Src 
occurred along the membrane of SUM159 cells (yellow, arrows), while staining of c-Src 
alone (green) was seen intracellularly.  No co-localization was observed between GM1 and c-
Src in SUM149 cells.  Taken together, these data further confirm the association of c-Src 
with lipid rafts and define the localization of this association to be at the plasma membrane.  
B. EGFR and c-Src co-localize in SUM159 cells 
Although EGFR and c-Src proteins both localize to lipid rafts in SUM159, it was 
unknown if the proteins co-associate within the same lipid raft domain.  Thus, to determine if 
c-Src and EGFR co-localize, SUM159 and SUM149 breast cancer cells were immunostained 
with Alexafluor labeled EGFR (green) and c-Src (red) antibodies (Fig. 4.2). The merged 
image shows co-localization of EGFR and c-Src (yellow) intracellularly in both cell lines, 
however; co-localization in patchy areas of the membrane (yellow, arrows) occurs solely in 
SUM159 cells.  These results suggest that c-Src and EGFR co-localize in both SUM159 and 
SUM149 cells, but only co-localize at the plasma membrane in SUM159 cells. 
Physical interaction between EGFR and c-Src has been shown in a number of cell types 
(Maa et al., 1995; Tice et al., 1999).  Activation of EGFR increases c-Src catalytic activity 
(Sato et al., 1995a; Sato et al., 1995b; Weernink and Rijksen, 1995), and c-Src can, in turn, 
phosphorylate EGFR, leading to increased activity of downstream pathways that promote  
mitogenesis (Maa et al., 1995; Biscardi et al., 1999a; Tice et al., 1999).  In order to determine 
if EGFR and c-Src physically interact in breast cancer cell lines, co-immunoprecipitation was  
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Figure 4.2: EGFR and c-Src co-localize in SUM159 and SUM149 cells. Two hundred thousand cells 
were plated onto coverslips and cultured under normal growth conditions for 48 h.  Coverslips containing 
cells were blocked, and then incubated with fluorphore-labelled antibodies (EGFR-488: green; Src-594: 
red).  The nucleus was stained with DAPI (blue). Imaging was performed using Zeiss Axioplan2 apotome 
microscope fitted with 63X 1.25 oil immersion lens at the Microscopy and Imaging Resources Laboratory 
(Wayne State University, Detroit, MI).  Arrows indicate areas of co-localization (yellow). 
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performed. Whole cell lysate (WCL) was utilized as a positive immunoblotting control (Fig. 
4.3A and B, lane 1), while mouse immunoglobulin immunoprecipitation was performed as a 
negative immunoprecipitation control (IgG, Fig. 4.3A and B lane 2).  We have previously 
shown that c-Src does not co-immunoprecipitate with EGFR from SUM149 cells (Mueller et 
al., 2010).  However, in SUM159 cells, when EGFR was pulled down from whole cell 
lysates, c-Src co-immunoprecipitated (Fig. 4.3A, lane 3).  When the reverse 
immunoprecipitation was performed, EGFR co-immunoprecipitated with c-Src (Fig. 4.3B, 
lane 3).  These data support the co-localization results demonstrating that EGFR and c-Src 
are localized to similar regions in SUM159 cells.  
The immunofluoresence data from the SUM159 cells suggests that EGFR and c-Src co-
associate at the plasma membrane, and even more specifically within lipid rafts, in the 
SUM159 cells.  Therefore, biochemical raft isolation was performed and equal sample 
volumes from fractions 1-7 were pooled and EGFR or c-Src was immunoprecipitated.  
Samples were then subjected to SDS-PAGE followed by immunoblotting for EGFR and c-
Src.  When EGFR was pulled down from lipid raft fractions of SUM159 cells, c-Src co-
associated (Fig. 4.3C, lane 3).  Low levels of EGFR were also precipitated from non-lipid 
raft fractions (Fig. 4.3C, lane 4).  When the reverse precipitation was performed, EGFR and 
c-Src were again both found immunoprecipitated from lipid raft fractions (Fig. 4.3C, lane 5).  
These data suggest that EGFR and c-Src physically interact within the lipid rafts of SUM159 
cells.   
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Figure 4.3: EGFR and c-Src co-associate within lipid rafts in SUM159 cells. (A and B) SUM159 cells 
were plated, allowed to grow for 48 h, and then lysed.  Five hundred micrograms of protein was 
immunoprecipitated with EGFR antibodies (A) or c-Src antibodies (B), then subjected to SDS-PAGE and 
immunoblotting for EGFR and c-Src.  Ten micrograms (2% input) of whole cell lysate (WCL) was 
utilized as a positive control and mouse IgG immunoprecipitation was performed as a negative control 
(IgG).  (C) Lipid rafts were isolated from SUM159 cells by biochemical raft isolation as described.  Two 
hundred microliters of each fraction (fractions 1-7 (LR), and fractions 8-14 (NR)) were pooled, and EGFR 
or c-Src was immunoprecipitated.  Immunoblotting was then performed for EGFR and c-Src.  Ten 
micrograms of whole cell lysate (WCL, 10% input) was utitilized as a positive control, while 
immunoprecipitation with IgG was utilized as a negative control. Immunoblots were performed at least 
three times. 
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C. EGFR and c-Src kinase inhibitors synergistically inhibit cell viability 
when both EGFR and c-Src are localized to lipid rafts 
Small molecule tyrosine kinase inhibitors of c-Src are currently approved and in use in 
cancer treatment.  Specifically, dasatinib, a c-Src TKI, was approved in 2006 for the 
treatment of leukemia (Brave et al., 2008), and is currently in clinical trials in a number of 
solid tumor types including breast cancer (Laird et al., 2003; Kim et al., 2010).  Tyrosine 
phosphorylation of c-Src on tyrosine 416 is required for activation of c-Src kinase (Sun et al., 
1998; Boerner et al., 2004).  Thus, to determine if dasatinib inhibits c-Src kinase activity in 
our model system, phosphorylation of c-Src on tyrosine 416 was measured.  Cells were 
treated with 0.5 µM dasatinib for 2 h and lysates were immunoblotted with phospho-tyrosine 
416 specific antibodies.  As shown in figure 4.4A, phosphorylation of c-Src on tyrosine 416 
was abrogated with dasatinib treatment.   
Preclinically, dasatinib treatment results in decreased cell growth in some breast cancer 
cell lines (Laird et al., 2003; Kim et al., 2010).  To determine if inhibition of c-Src kinase 
activity was sufficient to decrease SUM159 cell growth, cellular proliferation assays were 
performed.  SUM159 cells were treated with increasing doses of dasatinib and proliferation 
was measured by cell counting on days 1, 4, and 8.  As seen in figure 4.4B, SUM159 cells 
continued to proliferate in the presence of all doses of dasatinib tested. As mentioned 
previously, SUM159 cells also continue to proliferate in the presence of the EGFR TKI 
gefitinib.  Therefore, to determine if concomitant treatment with dasatinib and gefitinib could 
alter cell viability of SUM159 cells, MTS analyses were performed.  Cells were treated with 
dasatinib and gefitinib alone, or in combination for 72 h.  Cell viability was used to calculate  
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Figure 4.4: Dasatinib sensitizes SUM159 cells to gefitinib. (A) SUM159 cells were treated with the 
indicated dose of dasatinib and lysates were subjected to SDS-PAGE followed by immunoblotting for 
EGFR, c-Src and phospho-Y416 c-Src.  (B) Cells were plated in 35mm plates and grown for eight days.  
Treatment with the indicated doses of dasatinib occurred every other day and cell counts were performed 
on days 1, 4, and 8.  (C) Cells were plated in a 96-well plate and treated with variable doses of dasatinib 
and gefitinib for 72 h.  MTS analyses was then performed.  The IC50  of gefitinib at each dose of dasatinib 
was calculated and plotted on an isobologram.   IC50 values below the line denote a synergistic interaction 
between the two drugs, while on the line indicates an additive interaction. The combination index (CI-
value) was calculated as follows: (IC50  gefitinib at X dose of dasatinib)/(IC50  gefitinib alone) + (dose of 
dasatinib)/(IC50  dasatinib alone). CI-values below one denote a synergistic interaction between the two 
drugs, CI-values equal to one indicate an additive interaction, and CI-values above one designate an 
antagonistic interaction. All experiments were performed at least three times. p-values were calculated as 
a difference between CI-values and one utilizing the student's t-test.
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IC50 values and isobolograms were generated to determine drug synergy (Fig. 4.4C).  The 
IC50 of gefitinib alone was plotted on the y-axis and the IC50 of dasatinib alone was plotted on 
the x-axis.  A line was drawn between them.  This line represents the dose pairing that 
suggests an additive relationship between two drugs.  The IC50 of gefitinib was calculated at 
various doses of dasatinib and these data were plotted on the graph.  IC50 points that fall on 
the line are considered additive, while below the line is considered synergistic.  When these 
points were plotted, the IC50 of gefitinib at each dose of dasatinib fell below the line of 
additivity indicating that the effects of gefitinib and dasatinib are synergistic.  Combination 
index (CI) values were also determined for co-treatment of dasatinib and gefitinib. At all 
doses of dasatinib, the CI-value was significantly below 1 (p<0.05), which indicates that 
gefitinib and dasatinib have a synergistic interaction to reduce the viability of SUM159 
breast cancer cells. 
D. Inhibition of c-Src kinase activity and depletion of lipid rafts is additive 
Previous data have indicated that lovastatin, a cholesterol biosynthesis inhibitor, could 
synergize with gefitinib (chapter 3).  This is hypothesized to be due to depletion of lipid rafts 
after cholesterol inhibition.  The data presented so far indicate that c-Src localizes to these 
lipid raft microdomains in SUM159 cells, where it co-associates with EGFR (Figs. 4.1-4.3).  
Therefore, we hypothesized that localization of c-Src to lipid rafts is a mechanism by which 
lipid rafts mediate EGFR TKI resistance in SUM159 cells.  If this is the case, then treatment 
of SUM159 cells with dasatinib and lovastatin would not be synergistic, as they would 
inhibit the same pathway.  Thus, SUM159 cells were treated with dasatinib in combination 
with lovastatin and cell viability analyses were performed.  An isobologram was then created 
as previously described.  As shown in figure 4.5, the effect of dasatinib and lovastatin co- 
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Figure 4.5: Dasatinib and lovastatin are additive in SUM159 cells. Cells were placed in a 96-well plate 
and treated with variable doses of dasatinib and lovastatin for 72 h.  MTS analyses were then performed.  
The IC50  of dasatinib at each dose of lovastatin was calculated and plotted on an isobologram. IC50  values 
below the line denote a synergistic interaction between the two drugs, while on the line indicates an 
additive interaction. The combination index (CI-value) was calculated as follows: (IC50  dasatinib at X 
dose of lovasatin)/(IC50  dasatinib alone) + (dose of lovastatin)/(IC50  lovastatin alone). CI-values below 
one denote a synergistic interaction between the two drugs, CI-values equal to one indicate an additive 
interaction, and CI-values above one designate an antagonistic interaction. All experiments were 
performed at least three times. p-values were calculated as a difference between CI-values and one 
utilizing the student's t-test.
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treatment of SUM159 cells was additive, as the  IC50 of dasatinib at varying doses of 
lovastatin fell along the line of additivity.  When CI-values were calculated, the CI-values for 
the combination of dasatinib and lovastatin were not significantly different from one, 
indicating, again, that these two drugs act additively.  This additive interaction suggests that 
dasatinib and lovastatin act on the same pathway. 
E. c-Src kinase activity mediates EGFR kinase-independent Akt 
phosphorylation 
In 2007, Arcaro and colleagues found that lipid raft associated c-Src was critical for the 
activation of the PI3K/Akt signaling pathway in SCLC cell lines (Arcaro et al., 2007).  Their 
results suggested that lipid rafts provided a platform for interaction between c-Src and PI3K.  
To determine if lipid rafts may also provide such a platform in SUM159 breast cancer cells, 
biochemical raft isolation was performed followed by immunoblotting for p110α (Fig. 4.6A), 
the catalytic subunit of PI3K [reviewed in (Vanhaesebroeck et al., 2010)].  While the 
SUM149 cells contained little p110α in lipid rafts, there was a significant amount of p110α in 
the lipid raft fractions of SUM159 cells.  Thus, it is possible that PI3K signaling occurs 
downstream of the EGFR and c-Src co-association in lipid rafts within the SUM159 cells.  
We have previously shown that depletion of lipid rafts results in decreased EGFR-kinase 
independent Akt phosphorylation (chapter 3).  c-Src is known to be a downstream mediator 
of  EGFR signaling pathways, including Akt and MAPK (Stover et al., 1995; Biscardi et al., 
1999a; Tice et al., 1999).  Thus, to determine if c-Src mediates EGFR kinase-independent 
signaling in SUM159 cells, lysates were immunoblotted for phosphorylation of Akt and 
MAPK following treatment with gefitinib or dasatinib alone, or in combination (Fig. 4.6B). 
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Figure 4.6: Phosphorylation of Akt occurs through a c-Src/p110α co-localization to lipid rafts. (A) 
Biochemical raft isolation was performed as described on SUM159 and SUM149 cells.  Fractions were 
separated by SDS-PAGE and immunblotting for p110α, transferrin receptor, and flotillin was performed.  
(B) Whole cell lysates (right) were collected from SUM159 cells treated with 1.0 µM gefitinib (G) and 1.0 
µM dasatinib (D) alone or in combination (DG). Expression and phosphorylation of Akt and MAPK, as 
well as expression of EGFR was determined by immunoblotting. Immunoblots were repeated at least 
three times. 
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As shown previously, gefitinib effectively abrogates MAPK phosphorylation in SUM159 
cells, but Akt phosphorylation persists (Figure 4.6B, lane 2, and Irwin et Al., under review).  
c-Src kinase inhibition by dasatinib treatment resulted in a small decrease of MAPK 
phosphorylation, and was sufficient to decrease Akt phosphorylation in SUM159 cells (Fig. 
4.6B, lane 3).  Co-treatment with gefitinib and dasatinib resulted in no additional decrease in 
MAPK or Akt phosphorylation.  These data suggest that c-Src mediates EGFR kinase-
independent Akt phosphorylation in SUM159 cells. 
4.3 Discussion 
This study provides evidence that c-Src plays a role in lipid raft-dependent EGFR TKI 
resistance of SUM159 cells.  Specifically, we have shown that c-Src localizes to lipid rafts in 
the SUM159 cells, where it co-localizes and co-associates with EGFR.  The effects of 
inhibiting both EGFR and c-Src tyrosine kinase activities was synergistic in these cells.  
Also, we have demonstrated that dasatinib and lovastatin treatments were additive, 
suggesting that they inhibit members of the same biological pathway.  Lastly, we have shown 
that a catalytic subunit of PI3K (p110α) co-localizes with EGFR and c-Src to lipid rafts in 
SUM159 cells and that inhibition of both EGFR and c-Src kinase activities decreased both 
Akt and MAPK phosphorylation.  Taken together, these data have further characterized a 
mechanism for lipid rafts mediating EGFR TKI resistance by showing that c-Src is active and 
present in lipid rafts where it has the ability to regulate PI3K/Akt survival signals.  
Src family kinases have been described as being capable of localizing to lipid rafts (Liu et 
al., 1997; Furuchi and Anderson, 1998; Davy et al., 2000).  While other family members are 
likely to associate preferentially to lipid rafts through their double lipid modification, c-Src is 
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only singly lipid modified (Paige et al., 1993; Koegl et al., 1994; Shenoy-Scaria et al., 1994; 
Robbins et al., 1995; Yurchak and Sefton, 1995).    However, c-Src localization to lipid raft 
still occurs through interactions between the lipid environment and basic residues within the 
unique domain of c-Src (Sigal et al., 1994).  c-Src has been shown to localize to lipid rafts in 
neuronal (Mukherjee et al., 2003; Kasai et al., 2005), hematopoietic (Stoddart et al., 2002), 
and madin-darby canin kidney cells (Shenoy-Scaria et al., 1994), as well as skeletal 
myoblasts (Smythe et al., 2003), murine fibroblasts (Robbins et al., 1995), and cervical and 
lung cancer cell lines (Shenoy-Scaria et al., 1994; Arcaro et al., 2007).   Specifically, in 
breast cancer cells, Hitosugi and colleagues have shown that adhesion and growth is inhibited 
by lipid raft specific knockdown of c-Src (Hitosugi et al., 2007), suggesting that lipid rafts 
promote c-Src dependent cellular signaling to pathways of cellular adhesion and growth.  We 
have shown that c-Src localizes to lipid rafts in SUM159 breast cancer cells (Fig. 4.1).  Thus, 
it is possible that c-Src may mediate mitogenic signaling in these cells.   
We have identified an interaction between EGFR and c-Src within lipid raft membrane 
microdomains in breast cancer cells (Figs. 4.1-4.3).  Physical interaction between these two 
proteins has been noted previously.  Specifically, Maa and colleagues showed an initial 
physical interaction between EGFR and c-Src in a murine fibroblast model which was 
engineered to over-express both EGFR and c-Src (Maa et al., 1995).  In this model system, c-
Src potentiated EGFR-mediated transformation through direct physical interaction with 
EGFR.  c-Src was also co-immunoprecipitated as part of a complex between EGFR and c-
Met in SUM229 breast cancer cells (Mueller et al., 2008; Mueller et al., 2010).  This 
interaction was described to mediate EGFR TKI resistance of SUM229 cells.  We have 
shown that EGFR and c-Src physically associate in SUM159 breast cancer cells (Fig. 4.3A 
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and B).  More specifically, we have shown that a physical interaction occurs between these 
two proteins within lipid rafts (Fig. 4.3C).  While previous studies have revealed that these 
two proteins are both capable of localizing to lipid rafts in the same cell line (Hur et al., 
2004; Kasai et al., 2005; Jeon et al., 2010), the actual physical association within these lipid 
raft domains has not been previously shown. 
Our data indicate the concomitant inhibition of c-Src and EGFR kinase activities may 
result in decreased cell viability of breast cancer cell lines.  In particular, we have shown that 
while SUM159 cells are resistant to inhibition of either EGFR (chapter 3) and c-Src kinase 
activities (Fig. 4.4B), co-treatment with dasatinib and gefitinib resulted in synergistic 
decreases in cell viability (Fig. 4.4C).  It is not surprising that co-treatment resulted in 
decreased cellular viability in breast cancer cells.  First, c-Src is over-expressed in many of 
the same cancer types as EGFR, including approximately 70% of breast cancers, and is 
known to be co-over-expressed with EGFR in a subset of breast tumors (Maa et al., 1995).  
Additionally, EGFR and c-Src co-overexpression in mouse fibroblasts and human mammary 
epithelial cells results in synergistic increases in tumorigenesis (Maa et al., 1995; Belsches et 
al., 1997; Ware et al., 1997; Biscardi et al., 1999a; Biscardi et al., 1999b; Wilde et al., 1999; 
Dimri et al., 2007).  Thus, it stands to reason that these two proteins together may play an 
important role in mitogenic signaling in breast cancer cells.  Also, data shown in other cancer 
types suggest that dual inhibition of EGFR and c-Src kinase activities decreased cancer cell 
viability.  In particular, Johns and colleagues have demonstrated that down regulation of c-
Src expression improved the response of gliomas to EGFR monoclonal antibodies (Johns et 
al., 2007).  Also, decreased c-Src kinase activity results in increased sensitivity to EGFR 
inhibitors in head and neck cancer and epidermoid carcinoma cell lines (Koppikar et al., 
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2008; Andersen et al., 2009).  A recent Phase I/II study has also been published utilizing 
dasatinib in combination with the EGFR TKI erlotinib in non-small cell lung cancer (Haura 
et al., 2010).  Not only was this combination tolerable in patients, but disease control was 
observed as well.  Thus, our data suggest that combinatorial inhibition of EGFR and c-Src 
kinase activities may result in the decrease of the viability of breast cancer cells. 
It is thought that lipid rafts play a dual role in c-Src signaling.  Lipid rafts are also 
important in mediation of the c-Src dependent activation of PI3K/Akt signaling in human 
SCLC cell lines (Arcaro et al., 2007) and in the activation of FAK to promote early contact 
signaling in cells (Baillat et al., 2008).  Also, c-Src trafficking and co-localization with EGFR 
promotes EGFR-ligand independent MAPK signaling (Donepudi and Resh, 2008).  
However, lipid rafts also provide a platform for Csk binding protien (Cbp) to bring Csk, an 
endogenous inhibitor of c-Src, in close proximity to its substrate, which, in turn, results in 
down regulation of c-Src activity (Torgersen et al., 2001).  We have shown evidence that 
lipid rafts promote c-Src-dependent signaling in SUM159 breast cancer cells.  In particular, 
we suggest that lipid raft localized c-Src plays a role in EGFR-kinase independent signaling 
seen in these cells.  Inhibition of c-Src kinase activity with dasatinib results in abrogation of 
EGFR-kinase independent Akt phosphorylation (Fig. 4.6B).   
Previous studies have suggested that lipid rafts also mediate EGFR-kinase independent 
Akt phosphorylation in this cell line (chapter 3).  We have utilized synergy analyses to 
determine if lipid raft localized c-Src is responsible for Akt phosphorylation in these cells.  
Specifically, we hypothesized that if c-Src was mediating the effects seen downstream of 
lipid rafts in these cells, that concomitant inhibition of c-Src kinase activity and cholesterol 
biosynthesis (which results in reduction of lipid raft levels), would not be synergistic.  
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Indeed, co-treatment with dasatinib and lovastatin was additive in SUM159 cells (Fig. 4.5), 
suggesting that these two inhibitors are working together to down-regulate the same pathway.  
Thus, these data together suggest that lipid raft localized c-Src mediates EGFR-kinase 
independent Akt phosphorylation in SUM159 cells.  Furthermore, the co-localization of 
p110α, EGFR, and c-Src within lipid rafts in SUM159 cells (Fig. 4.6A) suggests that lipid 
rafts provide a platform for interaction between these molecules, leading to EGFR kinase-
independent activation of PI3K/Akt signaling. 
The results described here suggest a model for the activation of EGFR-dependent 
signaling pathways independent of EGFR-kinase activity.  Specifically, we have shown 
previously that lipid rafts play a role in such a pathway (Irwin et Al. under review).  Here, we 
have described a role for the non-receptor tyrosine kinase c-Src in the activation of EGFR-
kinase independent Akt signaling in the EGFR TKI resistant SUM159 breast cancer cell line.  
c-Src co-localized with EGFR in plasma membrane lipid rafts in SUM159 cells.  This co-
localization allowed the interaction between EGFR, c-Src, and PI3K, leading to EGFR-
kinase independent Akt phosphorylation.  The effects of dasatinib, a small molecule c-Src 
kinase inhibitor, and gefitinib, an EGFR TKI, were synergistic in these cells.  Dasatinib is 
currently in clinical trials in solid tumors (Laird et al., 2003; Kim et al., 2010), and therefore 
may be useful in combination with EGFR TKIs for breast cancers that are resistant to EGFR-
directed therapeutics alone. 
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Chapter 5 
5. Conclusions 
 The work herein provides evidence of a role for lipid rafts in EGFR TKI resistance.  We 
have found that EGFR localization to lipid rafts correlates with EGFR TKI resistance.  We 
have shown that depletion of cholesterol through the use of cholesterol biosynthesis 
inhibitors sensitizes breast cancer cells that are resistant to EGFR TKI-induced growth 
inhibition.  Our data suggest that lipid rafts provide a platform for the interaction of EGFR 
with other proteins, including c-Src and PI3K, to promote signaling in the absence of EGFR 
kinase activity (Fig. 5.1).  These findings provide rationale for the use of the cholesterol 
lowering drug lovastatin in combination with EGFR inhibitors in breast cancer. 
 As mentioned previously, breast cancer is one of the prevailing forms of cancer mortality 
in American women.  Specifically, basal-type breast cancers have the worst clinical 
prognosis.  The approval of targeted therapeutics for the treatment of basal-type breast 
cancers is of the utmost importance.  Unfortunately, there is no currently approved targeted 
therapeutic for this sub-type of breast cancer, due to the general lack of estrogen, 
progesterone, and HER2 receptors.  The epidermal growth factor receptor, a HER2 family 
member, is expressed in a large percentage of this sub-type of breast cancer, however; 
EGFR-targeted therapeutics have had limited success here.  Thus, our research provides 
insight that may allow the use of these targeted agents in breast cancer patients afflicted with 
basal-type breast cancer. 
 The work in this dissertation is not without its limitations.  Primarily, gefitinib is no 
longer approved for clinical use in the United States, which may limit the ability to translate 
Figure 5.1: Co-localization of EGFR and c-Src to lipid rafts promotes EGFR kinase-independent 
siganling. (A) Under normal growth conditions, EGFR and c-Src co-localize and co-associate within lipid 
rafts, and Akt and MAPK are phosphorylated leading to cell survival and proliferation. (B) When cholesterol 
is depleted (Statin), Akt phosphorylation is decreased, but MAPK remains phosphorylated. (C) When EGFR 
kinase acitivity is inhibited (gefitinib), EGFR-kinase dependent MAPK phosphorylation is abrogated, 
however, Akt phosphorylation is maintained  (D)  When there is cholesterol is depleted in combination with 
EGFR kinase inhibition, both of these signaling pathways are blocked correlating with an inhibition of 
cellular proliferation.
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this work into the clinical setting.  Further studies utilizing other EGFR inhibitors, such as 
erlotinib, lapatinib, and cetuximab may strengthen the clinical significance of this work.  In 
particular, combination studies looking at proliferation and viability of cells treated with the 
combination of these other EGFR inhibitors and cholesterol lowering drugs may provide 
further rationale for the use of these combinations in patients.  Also, in vivo studies are 
required to move these results towards the clinical arena.  For example, xenograft mouse 
models can be utilized to determine if the combination of EGFR inhibitors and cholesterol 
lowering drugs is a viable option to reduce tumor burden in vivo.  With these types of data, 
and the knowledge that both EGFR inhibitors and cholesterol lowering drugs are well 
tolerated in patients, this work can be translated forward into phase I studies to determine 
proper combinatorial dosing. 
 EGFR is not the only protein that is known to localize within lipid rafts.  Indeed, we have 
shown two other proteins, c-Src and p110α, that also localize to lipid rafts in basal breast 
cancers.  The EGFR family member HER2 also is capable of localizing within lipid raft 
membrane microdomains (Menendez et al., 2005).  HER2 positive breast cancers can 
currently be targeted by the monoclonal antibody trastuzumab, however, inevitably, 
resistance to trastuzumab occurs [reviewed in (Nahta and Esteva, 2006)].  Depletion of lipid 
rafts through inhibition of fatty acid synthase (FAS) has been found to overcome trastuzumab 
resistance in breast cancer (Menendez et al., 2005).  These results suggest that inhibition of 
lipid rafts, through a variety of mechanisms, may be important in the resistance to EGFR 
family member directed therapeutics. 
Recent data have implicated the EGFR family in resistance to estrogen receptor-directed 
therapeutics.  In particular, levels of EGFR and HER2 are elevated in MCF7 cell lines that 
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have acquired resistance to tamoxifen (McClelland et al., 2001; Knowlden et al., 2003).  
Thus, lapatinib, a dual EGFR/HER2 inhibitor (described earlier), has been used in preclinical 
studies in an effort to overcome such resistance (Chu et al., 2005).  However, our findings, 
and those of Menedez and colleagues, suggest that there may be resistance to this inhibitor 
due to elevated levels of lipid rafts in all breast cancer cells.  Preclinical studies regarding the 
localization of EGFR and/or HER2 to lipid rafts in these tamoxifen-resistant cell lines may 
therefore be useful to determine if cholesterol lowering drugs may be useful in such a setting. 
In general, while there is still more work to be done, the data in this dissertation moves 
the field forward towards a better understanding of the underlying mechanisms of resistance 
to EGFR tyrosine kinase inhibition in breast cancer.  The use of cholesterol lowering drugs in 
combination with EGFR inhibitors may provide the targeted clinical therapy needed in basal-
type breast cancers.  It is our hope that the research described here will set the stage for the 
further study of the localization of proteins to lipid rafts, and how this localization may affect 
resistance to well developed targeted therapeutics in breast cancer.    
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A ROLE FOR LIPID RAFTS IN EGFR TKI RESISTANCE IN BREAST 
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Breast cancer can be divided into genetic sub-types including luminal, HER2+, and basal-
type.  With the introduction of targeted therapies against estrogen receptor and HER2 
receptor mortality rates of American women with breast cancer have declined.  
Unfortunately, basal-type breast cancers, which have the worst clinical outcome, do not 
express estrogen receptor or HER2, and as such, have no targeted therapeutic option.  The 
epidermal growth factor receptor is an attractive target for therapeutics in basal-type breast 
cancer, as it is over-expressed in 60% of these cases.  Also, over-expression of EGFR 
correlates with poor patient prognosis.  Unfortunately, inhibitors of EGFR have shown little 
clinical efficacy in basal-type breast cancers.  We have utilized basal-type breast cancer cell 
lines to determine a potential mechanism of resistance to EGFR-targeted small molecule 
tyrosine kinase inhibitors (TKIs).  Specifically, we have shown that EGFR localizes to 
discrete membrane microdomains (lipid rafts) in cell lines that are resistant to EGFR TKI-
induced growth inhibition.  Depletion of lipid rafts via cholesterol reduction results in 
sensitivity of EGFR TKI resistant breast cancer cell lines to the EGFR TKI gefitinib.  
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Importantly, the effects of cholesterol lowering drugs and EGFR TKI in combination were 
synergistic.  We have shown that the non-receptor tyrosine kinase c-Src, which is co-over-
expressed with EGFR in a subset of breast tumors, also localizes to lipid rafts in the SUM159 
breast cancer cell line.  In this model system, c-Src kinase inhibition results in synergistically 
decreased cell viability in combination with EGFR tyrosine kinase inhibition.  c-Src kinase 
inhibition and cholesterol depletion are additive, results that suggest these two inhibitors 
work within the same pathway.  Indeed, treatment with either cholesterol lowering drugs or 
c-Src kinase inhibitors results in decreased EGFR-kinase independent Akt phosphorylation.  
Thus, lipid rafts may provide a platform whereby EGFR and c-Src interact to promote Akt 
signaling in the absence of EGFR kinase activity.  These results suggest, for the first time, 
that lipid rafts are involved in EGFR-kinase independent signaling, and that depletion of 
these rafts may work in combination with EGFR tyrosine kinase inhibition to decrease breast 
cancer cell growth.     
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